<PAGE> 1
================================================================================
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
[ ] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER 1-11343
---------------------
CORAM HEALTHCARE CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C>
DELAWARE 33-0615337
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
1125 SEVENTEENTH STREET 80202
SUITE 2100 (Zip Code)
DENVER, CO
(Address of principal executive offices)
</TABLE>
Registrant's telephone number, including area code: (303) 292-4973
---------------------
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] No [ ]
The number of shares outstanding of the Registrant's Common Stock, $.001
par value, as of May 12, 1998, was 48,809,749.
================================================================================
<PAGE> 2
PART I
FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
CORAM HEALTHCARE CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
ASSETS
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1998 1997
----------- ------------
(UNAUDITED)
<S> <C> <C>
Current assets:
Cash and cash equivalents................................. $ 15,240 $ 108,950
Cash limited as to use.................................... 2,528 1,029
Accounts receivable, net of allowance of $17,839 and
$24,047................................................ 88,496 86,142
Inventories............................................... 16,839 14,277
Other current assets...................................... 12,728 12,587
-------- ---------
Total current assets.............................. 135,831 222,985
Property and equipment, net................................. 19,447 20,050
Other assets................................................ 21,353 22,253
Other deferred costs........................................ 811 7,668
Goodwill, net of accumulated amortization of $60,702 and
$57,937................................................... 242,005 243,864
-------- ---------
Total assets...................................... $419,447 $ 516,820
======== =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable.......................................... $ 30,330 $ 39,084
Current maturities of long-term debt...................... 79,022 150,225
Other current liabilities................................. 42,928 45,296
-------- ---------
Total current liabilities......................... 152,280 234,605
Long-term debt, including revolving lines of credit......... 150,305 150,428
Minority interest in consolidated joint ventures............ 2,200 1,016
Other liabilities........................................... 2,419 1,588
Deferred income taxes, non-current.......................... 4,157 4,157
Stockholders' equity:
Preferred stock, par value $.001, authorized 10,000
shares, none issued.................................... -- --
Common stock, par value $.001, authorized 100,000 shares
at March 31, 1998 and December 31, 1997, issued and
outstanding 48,810 at March 31, 1998 and 48,069 at
December 31, 1997...................................... 49 48
Additional paid-in capital................................ 435,791 437,608
Accumulated deficit....................................... (327,754) (312,630)
-------- ---------
Total stockholders' equity........................ 108,086 125,026
-------- ---------
Total liabilities and stockholders' equity........ $419,447 $ 516,820
======== =========
</TABLE>
See accompanying notes.
2
<PAGE> 3
CORAM HEALTHCARE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
(IN THOUSANDS, EXCEPT PER COMMON SHARE DATA)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
--------------------
1998 1997
-------- --------
<S> <C> <C>
Net revenue................................................. $107,689 $123,915
Cost of service............................................. 80,500 83,925
-------- --------
Gross profit................................................ 27,189 39,990
Operating expenses:
Selling, general and administrative expenses.............. 21,073 23,652
Provision for estimated uncollectible accounts............ 3,666 4,288
Amortization of goodwill.................................. 2,765 3,612
-------- --------
Total operating expenses.......................... 27,504 31,552
-------- --------
Operating income (loss)..................................... (315) 8,438
Other income (expenses):
Interest expense.......................................... (14,175) (21,496)
Other income, net......................................... 777 647
-------- --------
Loss before income taxes and minority interests............. (13,713) (12,411)
Income tax expense........................................ 1,000 49
Minority interests in net income of consolidated joint
ventures............................................... 411 2,128
-------- --------
Net loss.................................................... $(15,124) $(14,588)
======== ========
Loss per common share....................................... $ (.31) $ (.31)
======== ========
Loss per common share -- assuming dilution.................. $ (.31) $ (.31)
======== ========
</TABLE>
See accompanying notes.
3
<PAGE> 4
CORAM HEALTHCARE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(IN THOUSANDS)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
--------------------
1998 1997
-------- -------
<S> <C> <C>
Net cash (used in) provided by operating activities......... $(10,585) $ 3,356
Cash flows from investing activities:
Purchases of property and equipment....................... (1,679) (1,332)
Other..................................................... (1,210) (686)
-------- -------
Net cash used in investing activities............. (2,889) (2,018)
-------- -------
Cash flows from financing activities:
Sales of stock, including exercise of stock options....... 9 384
Repayment of debt......................................... (80,245) (585)
-------- -------
Net cash used in financing activities............. (80,236) (201)
-------- -------
Net increase (decrease) in cash and cash equivalents...... $(93,710) $ 1,137
======== =======
</TABLE>
SUPPLEMENTAL INFORMATION:
Depreciation and amortization (including amortization of financing costs)
was $10,868 and $17,137 in the three month periods ended March 31, 1998 and
1997, respectively.
Interest expense for the three months ended March 31, 1998 and 1997
consisted of the following:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
MARCH 31,
-------------------
1998 1997
------- -------
<S> <C> <C>
Currently payable........................................... $ 383 $ 3,275
Deferred payment terms...................................... 8,919 8,882
Amortization of warrants and other debt costs............... 4,873 9,339
------- -------
Total interest expense............................ $14,175 $21,496
======= =======
</TABLE>
See accompanying notes.
4
<PAGE> 5
CORAM HEALTHCARE CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 1998
1. BASIS OF PRESENTATION
Business Activity. Coram Healthcare Corporation and its subsidiaries
("Coram" or the "Company") are primarily engaged in providing alternate site
(outside the hospital) infusion therapy and related services throughout the
United States. In addition, the Company provides services through one branch in
the province of Ontario, Canada. Other services offered by the Company include
mail-order pharmacy, pharmacy benefit management, ancillary network management
service and other non-intravenous infusion products and services.
Basis of Presentation. The accompanying unaudited condensed consolidated
financial statements have been prepared by the Company pursuant to the rules and
regulations of the Securities and Exchange Commission. Certain information and
footnote disclosures normally included in financial statements prepared in
accordance with generally accepted accounting principles have been condensed or
omitted pursuant to such regulations. The unaudited condensed consolidated
financial statements reflect all adjustments and disclosures that are, in the
opinion of management, necessary for a fair presentation. All such adjustments
are of a normal recurring nature. Certain amounts in the 1997 financial
statements have been reclassified to conform to the 1998 presentation.
Management does not believe the effect of such reclassifications are material.
The results of operations for the interim period ended March 31, 1998, are not
necessarily indicative of the results of the full fiscal year. For further
information, refer to the audited consolidated financial statements and notes
thereto included in the Company's Annual Report on Form 10-K, as amended, for
the year ended December 31, 1997.
Provision for Estimated Uncollectible Accounts. Management believes the net
carrying amount of accounts receivable is fairly stated and that the Company has
made adequate provision for uncollectible accounts based on all information
available. However, no assurance can be given as to the level of future
provisions for uncollectible accounts, or how they will compare to the levels
experienced in the past.
Earnings per Share. In 1997, the Financial Accounting Standards Board
issued Statement No. 128, Earnings per Share ("Statement 128"). Statement 128
replaced the calculation of primary and fully diluted earnings per share with
basic and diluted earnings per share. Unlike primary earnings per share, basic
earnings per share excludes any dilutive effects of options, warrants and
convertible securities. Diluted earnings per share is very similar to fully
diluted earnings per share under the previous earnings per share methodology.
All earnings per share amounts for all periods have been presented, and where
appropriate, restated to conform to the Statement 128 requirements.
5
<PAGE> 6
CORAM HEALTHCARE CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS -- (CONTINUED)
The following table sets forth the computation of basic and diluted
earnings per share for the three months ended March 31, 1998 and 1997:
<TABLE>
<CAPTION>
1998 1997
-------- --------
<S> <C> <C>
Numerator for basic and diluted earnings per share.......... $(15,124) $(14,588)
======== ========
Denominator:
Weighted average shares................................... 48,482 42,890
Contingently issuable shares................................ -- 3,372
-------- --------
Denominator for basic earnings per share.................. 48,482 46,262
Effect of other dilutive securities:
Stock options............................................. -- --
Warrants.................................................. -- --
-------- --------
Denominator for diluted earnings per share -- adjusted
weighted average shares and assumed conversion......... 48,482 46,262
======== ========
Loss per common share....................................... $ (0.31) $ (0.31)
======== ========
Loss per common share -- assuming dilution.................. $ (0.31) $ (0.31)
======== ========
</TABLE>
In the quarters ended March 31, 1998 and 1997, basic earnings per share
data was computed by dividing net loss by the weighted average number of common
shares and contingently issuable shares outstanding during the period. Diluted
earnings per share computations do not give effect to stock options or warrants
to purchase common stock as their effect would have been anti-dilutive.
Segment Reporting. Effective January 1, 1998, the Company adopted the
Financial Accounting Standards Board's Statement of Financial Accounting
Standards No. 131, Disclosures about Segments of an Enterprise and Related
Information ("Statement 131"). Statement 131 superseded FASB Statement No. 14,
Financial Reporting for Segments of a Business Enterprise. Statement 131
establishes standards for the way that public business enterprises report
information about operating segments in annual financial statements and requires
that those enterprises report selected information about operating segments in
interim financial reports. Statement 131 also establishes standards for related
disclosures about products and services, geographic areas and major customers.
Statement 131 does not require the disclosure of segment information in the
interim statements in the initial year of adoption. However, if applicable,
comparative information for 1998 interim periods shall be reported in financial
statements for interim periods in 1999.
2. ACQUISITIONS AND RESTRUCTURING
Certain agreements related to previously acquired businesses or interests
therein provide for additional contingent consideration to be paid by the
Company. The amount of additional consideration, if any, is generally based on
the financial performance of the acquired companies. The Company may be required
to pay approximately $2.4 million, subject to increase, based on the Company or
its subsidiaries exceeding certain revenue or income targets and changes in the
market value of the Company's stock. Subject to certain elections by the Company
or the sellers of such acquired entities, a maximum of approximately $1.4
million of these contingent obligations, subject to increase, may be paid in
cash with the remaining to be paid in common stock of the Company. If these
contingent payments are made, they will be recorded as additional goodwill in
the period in which the payment becomes probable. Payments made during the three
months ended March 31, 1998 and 1997 totaled $0.1 million and $0.2 million
respectively.
Merger and Restructuring. As a result of the formation of Coram and the
acquisition of substantially all of the assets of the alternate site infusion
business of Caremark, Inc. (the "Caremark Business") in 1994 and
6
<PAGE> 7
CORAM HEALTHCARE CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS -- (CONTINUED)
1995, respectively, the Company initiated the Coram Consolidation Plan and the
Caremark Business Consolidation Plan. These plans were initiated in order to
reduce operating costs, improve productivity and gain efficiencies through
consolidation of redundant infusion centers and corporate offices, reduction of
personnel, and elimination or discontinuance of investments in certain joint
ventures and other noninfusion facilities.
The Company continually evaluates the accruals and estimated costs to
complete the plans and may continue to adjust amounts recorded as contingencies
related to lease buyouts, contractual obligations and other facility reduction
costs are resolved. Under the two plans, the Company has made total payments and
asset disposals through March 31, 1998 as follows (in thousands):
<TABLE>
<CAPTION>
BALANCE AT
CHARGES THROUGH MARCH 31, 1998 MARCH 31, 1998
--------------------------------- ----------------------
CASH NON-CASH FUTURE CASH TOTAL
EXPENDITURES CHARGES TOTAL EXPENDITURES CHARGES
------------ -------- ------- ------------ -------
<S> <C> <C> <C> <C> <C>
Coram Consolidation Plan:
Merger Costs................. $27,500 $ 600 $28,100 $ 400 $28,500
======= ======= ======= ====== =======
Personnel Reduction Costs.... $20,300 $ 600 $20,900 $ 300 $21,200
Facility Reduction Costs..... 11,800 21,500 33,300 300 33,600
Discontinuance Costs......... 1,900 29,400 31,300 400 31,700
------- ------- ------- ------ -------
Total Restructuring
Costs.............. $34,000 $51,500 $85,500 $1,000 $86,500
======= ======= ======= ====== =======
Caremark Business Consolidation
Plan:
Personnel Reduction Costs.... $11,300 $ -- $11,300 $ -- $11,300
Facility Reduction Costs..... 8,950 3,900 12,850 3,850 16,700
------- ------- ------- ------ -------
Total Restructuring
Costs.............. $20,250 $ 3,900 $24,150 $3,850 $28,000
======= ======= ======= ====== =======
</TABLE>
The balance in the "Accrued Merger and Restructuring" liability at March
31, 1998 consists of future cash expenditures of $5.3 million referenced above
and $2.9 million of other accruals. The Company currently estimates that the
future cash expenditures related to both the Coram and Caremark Business
Consolidation Plans will be made in the following periods: 34% through March 31,
1999, 4% through March 31, 2000, 10% through March 31, 2001, and 52% through
March 31, 2002, and thereafter. Although subject to future adjustment and the
Company's ability to successfully implement its business strategy, the Company
believes it has adequate reserves and liquidity as of March 31, 1998, to meet
future expenditures related to the Coram Consolidation Plan and the Caremark
Business Consolidation Plan. However, there is no assurance that the reserves
will be adequate or that the Company will generate sufficient working capital to
meet future expenditures.
7
<PAGE> 8
CORAM HEALTHCARE CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS -- (CONTINUED)
3. LONG-TERM DEBT
Long-term debt is as follows (in thousands):
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1998 1997
--------- ------------
<S> <C> <C>
Senior Credit Facility...................................... $ -- $ 80,000
Rollover Note, including accrued interest................... 228,161 219,241
Other obligations, including capital leases, at interest
rates ranging from 6% to 16%, collateralized by certain
property and equipment.................................... 1,166 1,412
-------- ---------
229,327 300,653
Less current scheduled maturities........................... (79,022) (150,225)
-------- ---------
$150,305 $ 150,428
======== =========
</TABLE>
The Company's principal credit and debt agreements were entered into on
April 6, 1995 at the time of the acquisition of the Caremark Business. At
December 31, 1997, these agreements included (i) borrowings under a Credit
Agreement with Chase Manhattan Bank (formerly Chemical Bank) as Agent (the
"Senior Credit Facility") and (ii) a subordinated rollover note (the "Rollover
Note").
In January 1998, the Company repaid in full all principal, interest and
related fees totaling approximately $80.1 million due under the Senior Credit
Facility and terminated such facility. Interest on the Senior Credit Facility
was based on margins over certain domestic and foreign indices and was 8.94%
upon repayment. Additionally, in 1995 warrants were issued to the Company's
lenders under the Senior Credit Facility valued at approximately $8.0 million,
their value at the date of issuance, and were accounted for as interest expense
through March 1997. Accordingly, the Company charged approximately $1.6 million
to interest expense during the three months ended March 31, 1997 in relation to
these warrants.
The Rollover Note is outstanding at a principal amount of $150.0 million
and, as of March 31, 1998, deferred interest and fees totaling $78.2 million
were accrued thereon. The Rollover Note matures October 6, 2000 and carries an
interest rate which is based on various indices plus a margin which increases by
0.25% quarterly, but not to exceed 21.0% per annum. The rate as of March 31,
1998 was approximately 16.50%. For the three months ended March 31, 1998, an
additional $8.9 million was accrued on the Rollover Note for a total unsecured
obligation in the amount of $228.2 million. As long as the Rollover Note is
outstanding, the holders have the right to receive warrants to purchase up to
20% of the outstanding shares of the common stock of the Company (the
"Warrants") on a fully diluted basis. The Warrants are accounted for as interest
expense and additional paid-in capital. Through March 31,1998, Warrants for
approximately 8.4 million shares had been reserved in escrow with a value
recognized of approximately $28.7 million. The Company recorded interest expense
related to the Warrants of $3.2 million and $4.4 million during the quarters
ended March 31, 1998 and 1997, respectively. The agreement pursuant to which the
Rollover Note was issued contains customary covenants and events of default. At
March 31, 1998, the Company was in compliance with all of these covenants.
On May 6, 1998, the Company entered into a Securities Exchange Agreement
(the "Securities Exchange Agreement") with the holders of its Rollover Note,
Cerberus Partners, L.P., Goldman Sachs Credit Partners, L.P. and Foothill
Capital Corporation (the "Holders"). The Securities Exchange Agreement provides
for the cancellation of the Rollover Note (including deferred interest and fees)
and the Warrants in exchange (the "Exchange") for the payment of $4.3 million in
cash and the issuance by the Company to the Holders of (i) $150.0 million in
principal amount Series A Senior Subordinated Unsecured Notes (the "Series A
Notes") and (ii) $87.9 million in original principal amount of 8% Series B
Senior Subordinated Convertible Notes (the "Series B Notes"). In addition, under
the Securities Exchange Agreement, the Holders of the
8
<PAGE> 9
CORAM HEALTHCARE CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS -- (CONTINUED)
Series A and Series B Notes would have the right to name one director to the
Company's Board of Directors and the right to approve certain new debt including
a new senior credit facility.
Upon issuance, Series A Notes will mature on the later of October 2000 or
90 days after the maturity date of a new senior credit facility to be obtained
by the Company. The Series A Notes will bear interest at the rate of 9.875%
(subject to adjustment in certain circumstances to a maximum of 11.125%) per
annum, payable quarterly in arrears in cash or through the issuance of
additional Series A Notes at the election of the Company. The Holders can
require the Company to pay interest in cash if the Company exceeds a certain
interest coverage ratio.
Upon issuance, the term of the Series B Notes will be ten years from the
date of issuance and will bear interest at the rate of 8% per annum, payable
quarterly in arrears in cash or through the issuance of additional Series B
Notes at the election of the Company. The Series B Notes will be convertible
into shares of the Company's common stock at a conversion price (the "Conversion
Price") initially equal to $3.00 per share, subject to downward reset to the
prevailing market prices (calculated based on the average of the closing prices
for each of the preceding 20 days) on each of April 13, 1999 and October 13,
1999. The Conversion Price will also be subject to customary anti-dilution
adjustments, including adjustments for sale of common stock (other than pursuant
to existing obligations or employee benefit plans) at a price below the
Conversion Price prevailing at the time of such sale. Cash will be paid in lieu
of fractional shares upon conversion of the Series B Notes.
The Series A and Series B Notes will be redeemable, in whole or in part, at
the option of the Holders thereof in connection with any change of control of
the Company (as defined in the Securities Exchange Agreement), if the Company
ceases to hold and control certain interests in its significant subsidiaries, or
upon the acquisition of the Company or certain of its subsidiaries by a third
party. In such instances, the Series A and Series B Notes will be redeemable at
103% of the then outstanding principal amount plus accrued interest. The Series
B Notes will also be redeemable at the option of the Holders thereof upon
maturity of the Series A Notes at the outstanding principal amount thereof plus
accrued interest. In addition, the Series A Notes will be callable at 103% of
the then outstanding principal amount plus accrued interest at the option of the
Company.
The consummation of the Exchange, in addition to requiring shareholder
approval of the issuance of Series B Notes, is conditioned upon, among other
usual and customary conditions, (i) consummation of the transaction not later
than June 30, 1998, (ii) the execution by Donald J. Amaral, Chairman and CEO, of
an amendment to his employment contract extending the term of the employment
agreement and amending certain other terms thereof, and (iii) the execution of
an agreement for a new senior credit facility to be available to the Company for
acquisition and general corporate requirements and the immediate availability
for drawing thereunder. If the Securities Exchange Agreement is not consummated
on or prior to June 30, 1998, interest and deferred fees payable as of such date
on the Rollover Note will become immediately due. See "Management's Discussion
and Analysis of Financial Condition and Results of Operations -- Liquidity and
Capital Resources."
4. LITIGATION
The Company is a party to certain litigation that could, if their outcomes
were unfavorable, have a material adverse effect on the Company's financial
position, results of operations and liquidity. The Company intends to vigorously
defend itself in these matters. Nevertheless, due to the uncertainties inherent
in litigation, the ultimate disposition of these matters cannot be presently
determined. For a discussion of certain legal proceedings to which the Company
is a party, see Part I -- Item 3. "Legal Proceedings" contained in the Company's
Annual Report on Form 10-K, as amended, for the year ended December 31, 1997.
9
<PAGE> 10
CORAM HEALTHCARE CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS -- (CONTINUED)
The Company is also a party to various other legal actions arising out of
the normal course of its business. Management believes that the ultimate
resolution of such other actions will not have a material adverse effect on the
Company's financial position, results of operations and liquidity of the
Company. Nevertheless, due to the uncertainties inherent in litigation, the
ultimate disposition of these actions cannot presently be determined.
5. INCOME TAXES
During the three months ended March 31, 1998 and 1997, the Company recorded
an income tax expense of $1.0 million and $0.1 million, respectively. The
effective income tax rates for the three month periods ended March 31, 1998 and
1997 differ substantially from the expected combined federal and state income
tax rates calculated using applicable statutory rates as a result of fully
valuing the deferred tax assets.
As of March 31, 1998, deferred tax assets are net of a $117.4 million
valuation allowance. Realization of deferred tax assets is dependent upon the
ability of the Company to generate taxable income in the future. Deferred taxes
relate primarily to temporary differences consisting, in part, of accrued
restructuring costs, the charge for goodwill and other long-lived assets,
allowances for doubtful accounts that are not deductible for income tax purposes
until paid or realized and to net operating loss carryforwards that are
deductible against future taxable income.
10
<PAGE> 11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
This Quarterly Report on Form 10-Q contains certain forward-looking
statements (as such term is defined in the private Securities Litigation Reform
Act of 1995) and information relating to Coram that are based on the beliefs of
the management of Coram as well as assumptions made by and information currently
available to the management of Coram. When used in this Report, the words
"estimate," "project," "believe," "anticipate," "intend," "expect" and similar
expressions are intended to identify forward-looking statements. Such statements
reflect the current views of Coram with respect to future events and are subject
to risks and uncertainties that could cause actual results to differ materially
from those contemplated in such forward-looking statements. The risk factors set
forth in the Company's Annual Report on Form 10-K, as amended, constitute
important cautionary statements identifying important factors that could cause
actual results to differ from those in such forward-looking statements. Readers
are cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. Coram does not undertake any obligation
to release publicly any revisions to these forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
BACKGROUND
Business Strategy. The Company's business strategy is focused on the basic
factors that could lead to profitability: revenue generation programs, cost
reduction, quality improvement and cash collections. The Company continues to
focus on business relationships where it can provide high quality of care and
operate profitably. The Company is continuing to emphasize marketing efforts
aimed at improving its therapy mix and physician relationships and also has
continued the development of its specialty programs such as provider network
development and management for managed care payors, disease-state carve-outs
(i.e., vertical integration along disease-specific categories), transplant
programs, mail order prescription and pharmacy benefit management services and
women's health programs. Cost reduction efforts have focused on field
consolidation, reduction of corporate expenses, assessment of poorly performing
branches and a review of branch efficiencies. Delivery of quality service is
being monitored through an internal task force, more rigorous reporting and
independent patient satisfaction surveys gathered throughout the year. Further,
management continues to concentrate on reimbursement through an emphasis on
improving billing and cash collections and continued assessment of systems
support for reimbursement. While management believes the implementation of its
business strategy has improved operating performance, no assurances can be given
as to its ultimate success.
The settlement of the litigation with Caremark (the "Caremark Litigation"),
completion of the sale of the Company's interest in substantially all of its
lithotripsy partnerships, the stock of its equipment service company and certain
related assets (the "Lithotripsy Business") and the termination of the proposed
merger with Integrated Health Services, Inc. ("IHS"), permit management of the
Company to focus on operations and strategic alternatives to enable the Company
to realize its potential in the changing market for alternate site infusion
therapy services.
Five Year Capitated Agreement with Aetna U.S. Healthcare, Inc. In April
1998, the Company entered into a five year capitated agreement with Aetna U.S.
Healthcare, Inc. ("Aetna USHC") for the management and provision of certain home
health services, including home infusion, home nursing, respiratory therapy,
durable medical equipment, hospice care and home nursing support for several of
Aetna USHC's disease management programs. Effective July 1, 1998, the Company
will receive capitated payments on a monthly basis for covered members, assume
certain financial risk for certain home health services and manage a network of
home health providers through its Resource Network Division. The Company's
network of participating providers will include certain subsidiaries of the
Company, and the network will serve certain persons enrolled in Aetna USHC's
HMO-based plans in the eight state area covered under the agreement who are
presently not, or who will not be committed to other networks. As of the date
the agreement was executed, the membership covered totaled approximately 2.0
million lives. The Company expects the operation of this agreement to have an
impact on the Company beginning in the third quarter of 1998. See also
"Liquidity and Capital Resources."
11
<PAGE> 12
Debt Restructuring and Refinancing. At December 31, 1997, the Company had
two principal long term debt instruments, a Senior Credit Facility and the
Rollover Note and related Warrants, the combined outstanding balance of which
was approximately $300.7 million. In January 1998, the Company repaid in full
all amounts due under the Senior Credit Facility, and the Senior Credit Facility
was terminated. As a result, the Company experienced a reduction in interest
expense during the period ending March 31, 1998.
On May 6, 1998, the Company entered into the Securities Exchange Agreement
with the Holders of the Rollover Note under which the remainder of the Company's
long-term debt would be restructured. Under the terms of the Securities Exchange
Agreement, the Rollover Note and the Warrants would be cancelled in exchange for
the payment of $4.3 million in cash and the issuance by the Company to the
Holders of (i) $150.0 million in Series A Notes and (ii) $87.9 million in Series
B Notes. Even though consummation of the Securities Exchange Agreement is
subject to a number of conditions, including, among others, the approval of the
Company's stockholders of the issuance of the Series B Notes due to the stock
conversion feature included in the Series B Notes, completion of the debt
restructuring on the terms contemplated by the Securities Exchange Agreement
would put the Company in the position to reduce its annual interest expense
related to this debt by approximately $17.0 million based on Rollover Note
interest rates ranging from approximately 16.5% to 17.25%. There can be no
assurance that the Exchange will be consummated. See Note 3 of the Notes to
Unaudited Condensed Consolidated Financial Statements.
The terms of the Securities Exchange Agreement also contemplate the Company
obtaining a new senior credit facility of up to $65.0 million. The Company has
had preliminary discussions with several commercial banks about providing a
senior credit facility that could be used for a variety of corporate purposes,
including acquisitions, working capital and the other financing vehicles such as
letters of credit that could be used to support the operation of the Company's
business. However, there can be no assurance that the Company will be able to
secure a new senior credit facility or that it will be able to do so on
commercially acceptable terms.
Strategic Alternatives. Future strategic alternatives currently being
considered by the Company include, among others, the pursuit of opportunities in
its core alternate site infusion therapy business, including consolidation with
or acquisition of other companies in its core business or in businesses
complimentary to the Company's core business. From time to time, the Company
evaluates potential acquisitions in markets that permit the Company to grow its
local or regional business either through its core infusion therapy business or
through complimentary home health services such as respiratory therapy and
durable medical equipment. There can be no assurance that any acquisitions or
other strategic alternatives will be consummated or will be available to the
Company on commercially acceptable terms.
Factors Affecting Recent Operating Results. The most significant factors
affecting the Company's recent operating performance and financial condition are
as follows:
(i) settlement of the Caremark Litigation for $165.0 million in 1997.
Through 1995 and 1996, the Company suffered a loss of revenues from
under-performance of the Caremark Business compared to original
expectations, a negative impact on revenue referral sources and employee
morale throughout the Company. In addition, the Company incurred
substantial indebtedness to acquire the Caremark Business, which it
expected to service primarily through the operating income and cash flow of
the Caremark Business. With the settlement of the litigation, the Company
is now focused on its operations to realize its potential in the changing
market for alternate site infusion therapy services;
(ii) sale of the Lithotripsy Business in the third quarter of 1997
allowing the Company to substantially reduce its debt obligations and its
contingent liabilities associated with the Company's former commitments to
its partners in the Lithotripsy Business thereby further improving its
financial position;
(iii) distractions in its revenue generation programs in the first
half of 1997 during the pendency of the IHS Merger which was terminated
April 4, 1997;
(iv) ongoing pricing pressure in the Company's core infusion business
as a result of a continuing shift in payor mix from private indemnity
insurance to managed care and governmental payors and intense competition
among infusion providers;
12
<PAGE> 13
The following table sets forth the approximate percentages of the
Company's net revenue attributable to private indemnity insurance and other
payors, managed care organizations and Medicare and Medicaid programs
("governmental payors"), respectively, for the three months ended March 31,
1998, December 31, 1997 and March 31, 1997:
<TABLE>
<CAPTION>
THREE MONTHS ENDED
------------------------------------
MARCH 31, DECEMBER 31, MARCH 31,
1998 1997 1997
--------- ------------ ---------
<S> <C> <C> <C>
Private Indemnity Insurance and Other
Payors................................... 27% 28% 29%
Managed Care Organizations................. 47% 46% 43%
Medicare and Medicaid Programs............. 26% 26% 28%
--- --- ---
Total............................ 100% 100% 100%
--- --- ---
</TABLE>
(v) technological advances in the development of new medical
treatments for complex diseases that reduce the need for certain infusion
therapy services provided by the Company. For example, oral drugs such as
protease inhibitors have assisted persons living with HIV and AIDS to
remain healthier longer. Since the second quarter of 1996, the Company's
revenue has been negatively impacted by the transition of HIV multiple
therapy patients from intravenous therapy to oral medications; and
(vi) increased competition from hospitals and physicians who have
sought to increase the scope of services they offer through their
facilities and offices, including services similar to those offered by the
Company, or who have entered into risk bearing relationships with
third-party payors pursuant to which they have been delegated control over
the provision of a wide variety of healthcare services, including the
services offered by the Company.
Management believes that the Company's financial position and its standing
within the home healthcare industry improved in the year ended December 31,
1997, and continues to improve through the first quarter of 1998 primarily
through the stabilization of relationships with payors and referral sources.
Additionally, management believes that its focus on its operations and strategic
alternatives will further improve the financial position of the Company in
future periods. However, there can be no assurance that the improvement will
continue or that factors noted above would not have an adverse effect on the
financial position, results of operations and liquidity of the Company.
13
<PAGE> 14
RESULTS OF OPERATIONS
CERTAIN QUARTERLY COMPARISONS
Three Months Ended March 31, 1998 Compared With Three Months Ended December
31, 1997 (unaudited; in thousands except per share data):
<TABLE>
<CAPTION>
THREE MONTHS ENDED,
------------------------
MARCH 31, DECEMBER 31,
1998 1997
--------- ------------
<S> <C> <C>
Net revenue................................................. $107,689 $106,914
Cost of service............................................. 80,500 82,965
-------- --------
Gross profit................................................ 27,189 23,949
Operating expenses:
Selling, general and administrative expenses.............. 21,073 22,960
Provision for estimated uncollectible accounts............ 3,666 3,682
Amortization of goodwill.................................. 2,765 2,766
-------- --------
Total operating expenses.......................... 27,504 29,408
-------- --------
Operating loss.............................................. (315) (5,459)
Other income (expenses):
Interest expense.......................................... (14,175) (19,503)
Gain on sale of business.................................. -- 8,772
Other income, net......................................... 777 1,365
-------- --------
Loss before income taxes and minority interests............. (13,713) (14,825)
Income tax expense........................................ 1,000 4,175
Minority interests in net income of consolidated joint
ventures............................................... 411 226
-------- --------
Net loss.................................................... $(15,124) $(19,226)
======== ========
Loss per common share....................................... $ (.31) $ (.39)
======== ========
Loss per common share -- assuming dilution.................. $ (.31) $ (.39)
======== ========
</TABLE>
Gross Profit. Gross profit increased $3.2 million from $24.0 million or a
gross margin of 22.4% in the quarter ended December 31, 1997 to $27.2 million or
a gross margin of 25.2% in the quarter ended March 31, 1998. The improvement is
due primarily to the increase of $0.8 million in net revenue and a decrease in
cost of service of $2.5 million. See "Factors Affecting Recent Operating
Results."
Selling, General and Administrative Expenses. SG&A decreased $1.9 million
or 8.2%, from $23.0 million in the quarter ended December 31, 1997 to $21.1
million in the quarter ended March 31, 1998. The improvement is due primarily to
the Company's continuing strategy to reduce corporate and field administrative
costs. See "Business Strategy."
Operating Loss. The Company recorded operating losses of $0.3 million
during the three months ended March 31, 1998 compared to an operating loss of
$5.5 million during the three months ended December 31, 1997. The improvement is
due primarily to the increase in gross profit of $3.2 million as well as the
decrease in SG&A costs of $1.9 million described above.
Interest Expense. Interest expense decreased by $5.3 million or 27.3%, from
$19.5 million in the quarter ended December 31, 1997 to $14.2 million in the
quarter ended March 31, 1998. The decline is due primarily to a decrease of $1.7
million in interest related to the Senior Credit Facility which was paid in full
and terminated in January 1998 and a decrease of $3.4 million in interest
relating to the Warrants issued under the Rollover Note.
Gain On Sale of Business. During the quarter ended December 31, 1997, the
Company recorded a gain, net of related costs, of $8.8 million in connection
with the sale of its Lithotripsy Business. See "Factors Affecting Recent
Operating Results."
14
<PAGE> 15
Income Tax Expense. During the three months ended March 31, 1998, the
Company recorded income tax expense of $1.0 million compared to $4.2 million in
the three months ended December 31, 1997. The 1997 income tax expense is related
primarily to the gain on the sale of the Lithotripsy Business.
Net Loss. Net loss for the quarter ended March 31, 1998 was $15.1 million
compared to a net loss of $19.2 million for the quarter ended December 31, 1997.
Eliminating the effect of the non-recurring gain on sale of business recorded in
the fourth quarter of 1997, net loss improved by $12.9 million. As discussed
above, the improvement can be attributed to the increase in gross profit, the
decrease in SG&A and the decrease in interest expense.
Three Months Ended March 31, 1998 Compared With Three Months Ended March 31,
1997
As previously discussed in "Factors Affecting Recent Operating Results,"
the Company sold substantially all its Lithotripsy Business in 1997, while
retaining its interest in one Lithotripsy Partnership. During the quarters ended
March 31, 1998 and 1997, the Lithotripsy Business provided the following to the
Company's operations (in millions):
<TABLE>
<CAPTION>
THREE MONTHS
ENDED MARCH 31,
---------------
1998 1997
---- -----
<S> <C> <C>
Net revenue................................................. $0.4 $11.9
Gross profit................................................ 0.2 7.4
Operating income............................................ 0.2 5.4
</TABLE>
Net Revenue. Net revenue decreased $16.2 million or 13.1%, from $123.9
million in the quarter ended March 31, 1997 to $107.7 million in the quarter
ended March 31, 1998. The decrease can be attributed primarily to the $11.5
million decrease in net revenue provided by the Company's Lithotripsy Business.
Additionally, the decrease is due to a decline in patient census of 4.9% within
the Company's ongoing base business, as well as, the continued unfavorable shift
in payor mix. See"Factors Affecting Recent Operating Results."
Gross Profit. Gross profit decreased $12.8 million from $40.0 million or a
gross margin of 32.2% in the quarter ended March 31, 1997 to $27.2 million or a
gross margin of 25.2% in the quarter ended March 31, 1998. The decline results
primarily from the decrease in net revenue discussed above. See "Factors
Affecting Recent Operating Results."
Selling, General and Administrative Expenses. SG&A decreased $2.6 million
or 10.9%, from $23.7 million in the quarter ended March 31, 1997 to $21.1
million in the quarter ended March 31, 1998. The improvement is due primarily to
a decrease in SG&A of $1.1 million due to the sale of the Company's Lithotripsy
Business and the Company's continuing strategy to reduce corporate and field
administrative costs. See "Business Strategy."
Operating Income (Loss). The Company recorded an operating loss of $0.3
million during the three months ended March 31, 1998 compared to operating
income of $8.4 million during the three months ended March 31, 1997. The decline
is due primarily to the decrease in net revenue of $16.2 million offset by the
decrease in SG&A of $2.6 million described above.
Interest Expense. Interest expense decreased by $7.3 million or 34.1%, from
$21.5 million in the quarter ended March 31, 1997 to $14.2 million in the
quarter ended March 31, 1998. The improvement is due primarily to a decrease of
$3.3 million in interest related to the Senior Credit Facility which was paid in
full and terminated in January 1998, a decrease of $2.4 million in interest
related to Junior Subordinated PIK notes cancelled in connection with the
settlement of the Caremark Litigation and a decrease of $1.2 million in interest
relating to the Warrants issued under the Rollover Note.
Minority Interest in Net Income of Consolidated Joint Ventures. Minority
interest expense decreased $1.7 million, from $2.1 million in the three months
ended March 31, 1997 to $0.4 million in three months ended March 31, 1998. The
decrease is due primarily to the sale of substantially all of the Lithotripsy
Business in 1997.
15
<PAGE> 16
LIQUIDITY AND CAPITAL RESOURCES
The Company's cash and cash equivalents decreased $93.7 million from $108.9
million at December 31, 1997 to $15.2 million at March 31, 1998. The decrease
was primarily due to the repayment of the Senior Credit Facility for $80.0
million and a decrease in cash from operations due primarily to a reduction of
accounts payable.
Deferred interest and fees on the Rollover Note were to become due and
payable March 31, 1998. However, the Company received an extension until
September 30, 1998 for the payment of the deferred interest and fees, provided
that the Company and the Holders could reach an agreement in principle by April
13, 1998 for its restructuring . The Company and the Holders reached an
agreement in principle on April 13, 1998 on the Rollover Note restructuring and
entered into the Securities Exchange Agreement on May 6, 1998.
The Securities Exchange Agreement provides for a restructuring of the debt
represented by the Rollover Note and the related Warrants pursuant to which the
Rollover Note and the Warrants would be cancelled and exchanged for the Series A
Notes and Series B Notes. The Exchange, in addition to requiring shareholder
approval of the issuance of Series B Notes, is conditioned upon, among other
usual and customary conditions, (i) consummation of the transaction not later
than June 30, 1998, (ii) the execution by Donald J. Amaral, Chairman and CEO, of
an amendment to his employment contract extending the term of the employment
agreement and amending certain other terms thereof, and (iii) the execution of
an agreement for senior loans to be used by the Company for acquisition and
general corporate requirements and the immediate availability for drawing
thereunder. There can be no assurance that the Exchange will be consummated, or
that future cash flow from operations will be sufficient to cover the Company's
current or future debt obligations. If the Exchange is not consummated on or
prior to June 30, 1998, interest and deferred fees payable as of such date on
the Rollover Note in the approximate amount of $87.7 million will become
immediately due. As of May 15, 1998, the Company does not have and does not
anticipate having by June 30 the financial resources needed to satisfy its
obligations under the Rollover Note, that would become due on June 30 if the
Exchange is not consummated.
The terms of the Company's agreement with Aetna USHC require the Company to
obtain and maintain a series of letters of credit that increase incrementally to
an aggregate of $14.5 million. The Company obtained the initial $3.0 million
letter of credit by pledging a like amount of cash with the bank that issued the
required letter of credit. The Company would anticipate obtaining the subsequent
letters of credit required under the agreement with Aetna USHC through its new
senior credit facility if it is able to obtain a new senior credit facility. If
no new credit facility is obtained, the Company would be forced to continue
posting cash collateral for its letters of credit. Consequently, the Company's
access to up to $14.5 million of its cash would be limited, thereby reducing the
amount of cash available for the payment of the Company's debts and liabilities
and the pursuit of the Company's strategic alternatives such as acquisitions.
FUTURE HEALTH CARE PROPOSALS AND LEGISLATION
In recent years, an increasing number of legislative initiatives have been
introduced or proposed in Congress and in state legislatures that would effect
major changes in the health care system, either nationally or at the state
level. Among the proposals under consideration are various insurance market
reforms, forms of price control, expanded fraud and abuse and antireferral
legislation and further reductions in Medicare and Medicaid reimbursement. Most
recently, on August 5, 1997, President Clinton signed into law the Budget
Reconciliation Act of 1997, which provides for reductions in Medicare and
Medicaid of over $115 billion and $13 billion, respectively, over five years.
The impact of these reductions on the health care industry in general and the
Company specifically cannot be determined at this time. Further, the Company
cannot predict whether any of the above proposals or any other proposals will be
adopted. No assurance can be given that the implementation of the Budget
Reconciliation Act or any other reforms will not have a material adverse effect
on the business of the Company.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
16
<PAGE> 17
PART II
OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
The Company is party to various legal actions arising out of the normal
course of its business. Management believes that the ultimate resolution of such
actions, except as previously disclosed, will not have a material adverse effect
on the Company's financial position, results of operations and liquidity of the
Company. For a discussion of certain legal proceedings to which the Company is
party, see Part I -- Item 3. "Legal Proceedings" in the Company's Annual Report
on Form 10-K, as amended for the year ended December 31, 1997.
ITEM 2. CHANGE IN SECURITIES
Not applicable.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS
Not applicable.
ITEM 5. OTHER INFORMATION
Not applicable.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(A) Exhibits
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
------- -----------
<C> <S>
10.01 -- Securities Exchange Agreement among the Company, Cerberus
Partners, L.P., Goldman Sachs Credit Partners, L.P., and
Foothill Capital Corporation. Certain attachments and
schedules to the Securities Exchange Agreement are
omitted from this Exhibit. The Registrant agrees to
furnish supplementally any omitted exhibit or schedule to
the Securities Exchange Commission.
10.02 -- Form of Letter of Credit required by the Master Agreement
by and between the Registrant and its applicable
affiliates and Aetna U.S. Healthcare, Inc. and its
applicable affiliates.
27 -- Financial Data Schedule
</TABLE>
17
<PAGE> 18
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
CORAM HEALTHCARE CORPORATION
By: /s/ WENDY L. SIMPSON
----------------------------------
Wendy L. Simpson
Executive Vice President and
Chief Financial Officer
May 15, 1998
18
<PAGE> 19
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
------- -----------
<C> <S>
10.01 -- Securities Exchange Agreement among the Company, Cerberus
Partners, L.P., Goldman Sachs Credit Partners, L.P., and
Foothill Capital Corporation. Certain attachments and
schedules to the Securities Exchange Agreement are
omitted from this Exhibit. The Registrant agrees to
furnish supplementally any omitted exhibit or schedule to
the Securities Exchange Commission.
10.02 -- Form of Letter of Credit required by the Master Agreement
by and between the Registrant and its applicable
affiliates and Aetna U.S. Healthcare, Inc. and its
applicable affiliates.
27 -- Financial Data Schedule
</TABLE>
<PAGE> 1
EXHIBIT 10.1
SECURITIES EXCHANGE AGREEMENT
dated as of May 6, 1998
by and between
CORAM, INC.
CORAM HEALTHCARE CORPORATION
and
CERBERUS PARTNERS, L.P.
GOLDMAN SACHS CREDIT PARTNERS L.P.
FOOTHILL CAPITAL CORPORATION
Exchange of Subordinated Rollover Notes
and Warrants
for
$150,000,000 Series A
Subordinated Notes due 2000
$87,922,213 Series B
Convertible Subordinated Notes due 2008
<PAGE> 2
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Section Page
- ------- ----
<S> <C>
1. DEFINITIONS........................................................................................ 2
2. EXCHANGE OF SUBORDINATED ROLLOVER NOTES AND WARRANTS FOR NEW NOTES................................. 19
2.1 Exchange of Subordinated Rollover Notes and Warrants..................................... 19
2.2 Closing.................................................................................. 19
2.3 Deliveries at Closing.................................................................... 19
2.4 The Series A Notes....................................................................... 20
2.5 The Series B Notes....................................................................... 21
2.6 Prepayment of the Notes.................................................................. 21
2.7 Receipt of Payments...................................................................... 24
2.8 Application of Payments.................................................................. 24
2.9 Sharing of Payments...................................................................... 24
2.10 Indemnity............................................................................... 25
2.11 Access.................................................................................. 25
2.12 Taxes................................................................................... 26
2.13 Conversion of Series B Notes............................................................ 27
2.14 Registration Rights..................................................................... 33
2.15 Legend............................................................................. 33
3. NOTEHOLDERS' REPRESENTATIONS....................................................................... 34
3.1 Investment Intention..................................................................... 34
3.2 Accredited Investor...................................................................... 34
3.3 Existence................................................................................ 34
3.4 Power; Authorization; Enforceable Obligations............................................ 34
3.5 Ownership of Notes and Warrants.......................................................... 35
4. REPRESENTATIONS AND WARRANTIES..................................................................... 35
4.1 Securities Laws.......................................................................... 35
4.2 Organization; Powers..................................................................... 35
4.3 Authorization............................................................................ 36
4.4 Enforceability........................................................................... 36
4.5 Governmental Approvals................................................................... 37
4.6 Financial Statements..................................................................... 37
4.7 No Material Adverse Change............................................................... 37
</TABLE>
1
<PAGE> 3
<TABLE>
<CAPTION>
Section Page
- ------- ----
<S> <C>
4.8 Title to Properties; Possession Under Leases............................................. 37
4.9 Subsidiaries and Joint Ventures.......................................................... 38
4.10 Litigation; Compliance with Laws........................................................ 38
4.11 Agreements.............................................................................. 39
4.12 Federal Reserve Regulation.............................................................. 39
4.13 Investment Company Act; Public Utility Holding Company Act.............................. 39
4.14 Tax Returns............................................................................. 39
4.15 No Material Misstatements............................................................... 39
4.16 Employee Benefit Plans.................................................................. 40
4.17 Environmental Matters................................................................... 40
4.18 Insurance............................................................................... 41
4.19 Solvency................................................................................ 41
4.20 Labor Matters........................................................................... 42
4.21 Year 2000 Systems....................................................................... 42
5. AFFIRMATIVE COVENANTS.............................................................................. 43
5.1 Existence; Businesses and Properties..................................................... 43
5.2 Insurance................................................................................ 43
5.3 Obligations and Taxes.................................................................... 44
5.4 Financial Statements, Reports, Etc....................................................... 44
5.5 Litigation and Other Notices............................................................. 46
5.6 Employee Benefits........................................................................ 46
5.7 Maintaining Records; Access to Properties and Inspections................................ 47
5.8 Compliance with Environmental Laws....................................................... 47
5.9 Preparation of Environmental Reports..................................................... 47
5.10 Further Assurances...................................................................... 47
5.11 Compliance Procedures................................................................... 48
5.12 New Amaral Employment Agreement......................................................... 48
6. NEGATIVE COVENANTS................................................................................. 48
6.1 Indebtedness............................................................................. 48
6.2 Liens.................................................................................... 50
6.3 Sale and Lease-Back Transactions......................................................... 52
6.4 Investments, Loans and Advances.......................................................... 52
6.5 Mergers, Consolidations, Sales of Assets and Acquisitions................................ 54
6.6 Dividends and Distribution............................................................... 55
6.7 Transactions with Affiliates............................................................. 56
6.8 Business of Company and Subsidiaries..................................................... 56
</TABLE>
2
<PAGE> 4
<TABLE>
<CAPTION>
Section Page
- ------- ----
<S> <C>
6.9 Fiscal Year.............................................................................. 56
6.10 Other Agreements........................................................................ 56
7. CONDITIONS PRECEDENT............................................................................... 57
7.1 Conditions Precedent..................................................................... 57
7.2 Additional Conditions.................................................................... 59
8. EVENTS OF DEFAULT; RIGHTS AND REMEDIES............................................................. 59
8.1 Events of Default........................................................................ 59
8.2 Waivers by the Company................................................................... 63
8.3 Right of Set-Off......................................................................... 63
9. SUBORDINATION...................................................................................... 64
9.1 Notes Subordinated to Senior Debt........................................................ 64
9.2 Priority and Payment Over of Proceeds in Certain Events.................................. 64
9.3 Rights of Holders of Senior Debt Not to Be Impaired...................................... 66
9.4 Subrogation.............................................................................. 67
9.5 Obligations of the Company Unconditional................................................. 67
9.6 Notice to Holders........................................................................ 68
9.7 Right of Any Holder as Holder of Senior Debt............................................. 68
9.8 Reinstatement............................................................................ 68
10. BOARD OF DIRECTORS............................................................................ 68
11. MISCELLANEOUS..................................................................................... 69
11.1 Complete Agreement; Modification of Agreement; Sale of Interests........................ 69
11.2 Fees and Expenses....................................................................... 71
11.3 No Waiver by Noteholders................................................................ 72
11.4 Remedies................................................................................ 73
11.5 Waiver of Jury Trial.................................................................... 73
11.6 Severability............................................................................ 73
11.7 Parties................................................................................. 73
11.8 Conflict of Terms....................................................................... 73
11.9 Governing Law........................................................................... 73
11.10 Notices................................................................................ 74
11.11 Survival............................................................................... 76
11.12 Section Titles......................................................................... 76
11.13 Counterparts........................................................................... 76
11.14 Publicity.............................................................................. 76
</TABLE>
3
<PAGE> 5
<TABLE>
<CAPTION>
Section Page
- ------- ----
<S> <C>
SCHEDULES
I New Notes; Initial Account Details
4.3 Authorization
4.5 Governmental Approvals
4.9 Subsidiaries, Designated Subsidiaries and Joint Ventures
4.10 Litigation; Compliance with Laws
4.20 Labor Matters
6.1 Indebtedness
6.1(xii) Indebtedness of Joint Ventures or Subsidiaries
6.2 Liens
6.4(i)(c) Investments in Joint Ventures on or Prior to Closing Date
6.4(i)(d) Investments in Joint Ventures After Closing Date
6.4(i)(e) Joint Ventures in Formation Process
6.4(v) Loans to Subsidiaries
6.7 Transactions with Affiliates
EXHIBITS
A-1 Form of Series A Note
A-2 Form of Series B Note
B-1 Form of Holdings Guarantee
B-2 Form of Subsidiary Guarantee
C Registration Rights
D Opinion of Paul, Hastings, Janofsky
& Walker LLP
</TABLE>
4
<PAGE> 6
SECURITIES EXCHANGE AGREEMENT
Securities Exchange Agreement, dated as of May 6, 1998, by and
between CORAM, INC., a Delaware corporation (the "Company"), CORAM HEALTHCARE
CORPORATION, a Delaware corporation ("Holdings"), CERBERUS PARTNERS, L.P.
("Cerberus"), GOLDMAN SACHS CREDIT PARTNERS L.P. ("GSCP") and FOOTHILL CAPITAL
CORPORATION ("Foothill"), as holders of interests in the Subordinated Rollover
Notes and Warrants issued pursuant to the Existing Securities Purchase Agreement
referred to below (each a "Noteholder" and, together with any other holders from
time to time of interests in the Series A Notes or Series B Notes (as
hereinafter defined), collectively, the "Noteholders").
W I T N E S S E T H :
WHEREAS, pursuant to (i) a Securities Purchase Agreement dated
as of April 6, 1995, among the Company, Holdings and Coram Funding, Inc., as
amended and supplemented by letter agreements dated October 13, 1995, March 31,
1996, March 28, 1997 and March 29, 1998 (as so amended and supplemented, the
"Existing Securities Purchase Agreement"), (ii) a Warrant Agreement dated as of
April 6, 1995 between Holdings and Coram Funding, Inc. (the "Warrant
Agreement"), (iii) those other documents defined in the Existing Securities
Purchase Agreement as "Bridge Documents", (iv) an assignment agreement, dated as
of April 22, 1997, between Coram Funding, Inc. as assignor and Cerberus as
assignee, and (v) separate assignment agreements dated as of April 22, 1997
between Cerberus as assignor and GSCP and Foothill, respectively, as assignees,
the Company is indebted to the Noteholders as at April 13, 1998 in the amount of
$229,522,213 (including all principal, interest and fees thereon) and each
Noteholder is entitled to Warrants issued or issuable by Holdings exercisable
for the number of shares of Common Stock calculated in accordance with the
provisions set forth in the Existing Securities Purchase Agreement and the
Warrant Agreement;
WHEREAS, the Company and Holdings have agreed to issue
$8,400,000 in original principal amount of Series B Notes in addition to the
Deferred Warrant Consideration in consideration of the cancellation of the
Warrants; and
WHEREAS, the Company and Holdings have requested the
Noteholders to exchange all of their interests in the Subordinated Rollover
Notes and the Warrants for their pro rata share of the Series A Notes, the
Series B Notes and the Deferred Warrant Consideration referred to herein, and
the Noteholders have agreed to such exchange on and subject to the terms and
conditions of this Agreement;
1
<PAGE> 7
NOW, THEREFORE, in consideration of the premises and the
covenants hereinafter contained, it is agreed as follows:
1. DEFINITIONS
"Additional Series A Notes" shall mean Series A Notes issued
in satisfaction of the Company's obligation to pay interest on the Series A
Notes in accordance with the terms of this Agreement and the Series A Notes.
"Additional Series B Notes" shall mean Series B Notes issued
in satisfaction of the Company's obligation to pay interest on the Series B
Notes in accordance with the terms of this Agreement and the Series B Notes.
"Affiliate" shall mean, when used with respect to a specified
Person, another Person that directly, or indirectly through one or more
intermediaries, Controls or is Controlled by or is under common Control with the
Person specified.
"Agreement" shall mean this Securities Exchange Agreement
including all amendments, modifications and supplements hereto and any
appendices, exhibits and schedules hereto or thereto, and shall refer to the
Agreement as the same may be in effect at the time such reference becomes
operative.
"Applicable Series A Rate" shall have the meaning set forth in
Section 2.4.
"Bank Warrants" shall mean the warrants issued to the lenders
under the credit agreement dated as of April 6, 1995 among the Company,
Holdings, the lenders named therein and Chemical Bank as Agent, to purchase 2.5
million shares of Common Stock of Holdings or, at the option of such lenders, 6%
of the shares of the Company, exercisable at a nominal price over five years.
"Business Day" shall mean any day other than a Saturday,
Sunday or day on which banks in New York City or Denver, Colorado, are
authorized or required by law to close.
"Capital Expenditures" shall mean, for any Person in respect
of any period, the sum of (a) the aggregate of all expenditures incurred by such
Person during such period that, in accordance with GAAP, are or should be
included in "additions to property, plant or equipment" or similar items
reflected in the statement of cash flows of such Person and (b) to the extent
not covered by clause (a) above, the aggregate of
2
<PAGE> 8
all expenditures by such Person to acquire by purchase or otherwise the
business, property or fixed assets of, or stock or other evidence of beneficial
ownership of, any other Person; provided, however, that Capital Expenditures
shall not include (a) expenditures of proceeds of insurance settlements in
respect of lost, destroyed or damaged assets, equipment or other property to the
extent such expenditures are made to replace or repair all or any part of such
lost, destroyed or damaged assets, equipment or other property within 12 months
of the receipt of such proceeds, or (b) expenditures by such Person to acquire
by purchase or otherwise the business, property or fixed assets, or stock or
other evidence of beneficial ownership of any other Person as to which no
consent of the Required Holders is required under Section 6.4 hereof.
"Capital Lease Obligations" of any Person shall mean the
obligations of such Person to pay rent or other amounts under any lease of (or
other arrangement conveying the right to use) real or personal property, or a
combination thereof, which obligations are required to be classified and
accounted for as capital leases on a balance sheet of such Person under GAAP,
and the amount of such obligations shall be the capitalized amount thereof
determined in accordance with GAAP.
A "Change of Control" shall be deemed to have occurred if:
(a) any Person or group (within the meaning of Rule 13d-5 of
the SEC as in effect on the date hereof) other than the Noteholders or a group
composed principally thereof shall own directly or indirectly, beneficially or
of record, shares representing 30% or more of the aggregate ordinary voting
power represented by the issued and outstanding capital stock of Holdings;
(b) during any period of two consecutive calendar years,
individuals who at the beginning of such period constituted Holdings' Board of
Directors (together with any new directors whose election to Holdings' Board of
Directors or whose nomination for election to Holdings' Board of Directors by
Holdings' shareholders was approved by a vote of at least two-thirds of
Holdings' directors then still in office who either were directors at the
beginning of such period or whose election or nomination for election was
previously so approved) together with any individual serving during such period
as a member of Holdings' Board of Directors designated pursuant to Section 10
hereof cease for any reason to constitute a majority of Holdings' directors then
in office;
(c) any change in control with respect to Holdings, the
Company or any Subsidiary (or similar event, however denominated) shall occur
under and as defined in any agreement in respect of Indebtedness (other than
Capital Lease Obligations) to
3
<PAGE> 9
which Holdings, the Company or any Subsidiary is party;
(d) Holdings shall cease to own and control directly, of
record and beneficially, 100% of each class of outstanding capital stock of the
Company free and clear of all Liens other than as a result of the exercise of
the Bank Warrants; or
(e) The Company shall cease to own and control directly, of
record and beneficially, 100% of each class of outstanding capital stock of each
of the Significant Subsidiaries other than Curaflex.
"Closing" shall have the meaning set forth in Section 2.2
hereof.
"Closing Date" shall have the meaning set forth in Section 2.2
hereof.
"Code" shall mean the Internal Revenue Code of 1986, as
amended, and any successor thereto.
"Common Stock" shall mean the common stock, $.001 par value
per share, of Holdings.
"Company" shall have the meaning set forth in the first
paragraph of this Agreement.
"Compensation" shall mean, with respect to any Person, all
payments and accruals commonly considered to be compensation, including, without
limitation, all wages, salary, deferred payment arrangements, bonus payments and
accruals, profit sharing arrangements, payments in respect of stock option or
phantom stock option or similar arrangements, stock appreciation rights or
similar rights, incentive payments, pension or employment benefit contributions
or similar payments, made to or accrued for the account of such Person or
otherwise for the direct or indirect benefit of such Person.
"Consolidated Interest Expense" shall mean, with respect to
Holdings, the Company and the Subsidiaries on a consolidated basis for any
period, interest accrued or paid by Holdings, the Company and the Subsidiaries
during such period in respect of Total Debt determined on a consolidated basis
in accordance with GAAP; provided that Consolidated Interest Expense shall not
include interest accrued or paid on the Series B Notes.
"Control" shall mean the possession, directly or indirectly,
of the power
4
<PAGE> 10
to direct or cause the direction of the management or policies of a Person,
whether through the ownership of voting securities, by contract or otherwise,
and the terms "Controlling" and "Controlled" shall have meanings correlative
thereto.
"Coram Parties" shall mean Holdings, the Company and the
Subsidiary Guarantors.
"Curaflex" shall mean Curaflex Health Services, Inc., a
Delaware corporation.
"Current Market Price" shall mean the average of the daily
closing prices for Holdings' Common Stock for the 20 consecutive trading days
prior to the date on which it is to be determined.
"Default" shall mean any event which, with the passage of time
or notice or both, would, unless cured or waived, become an Event of Default.
"Deferred Warrant Consideration" shall mean $4,300,000,
payable by the Company in cash in the manner and at the time set forth in
Section 2.3(c).
"Designated Subsidiary" shall mean at any time any Subsidiary
that has assets with a total market value not in excess of $10,000 at such time
and either (a) has not conducted any business or other operations during the
12-month period prior to such time or (b) has, as a result of a group
restructuring or asset disposition involving one or more Subsidiaries, in each
case permitted by this Agreement, become inactive at such time and will after
such time no longer conduct any business or other operations. The Designated
Subsidiaries in existence on the date hereof are set forth on Schedule 4.9.
"Dollars" or "$" shall mean lawful money of the United States
of America.
"Earn-out Obligations" shall mean any obligations whether
contingent or matured, to pay additional consideration in connection with the
acquisition by Holdings, the Company or any Subsidiary of any capital stock or
assets.
"EBITDA" shall mean, with respect to Holdings, the Company and
the Subsidiaries on a consolidated basis for any period, the consolidated net
income of such corporation and its subsidiaries on a consolidated basis for such
period plus, to the extent deducted in computing such consolidated net income,
the sum of (a) income tax
5
<PAGE> 11
expense, (b) interest expense, (c) depreciation and amortization expense, (d)
any extraordinary losses and (e) any restructuring charges (whether cash or
noncash) in such period minus to the extent added in computing such consolidated
net income, any extraordinary gains, all as determined on a consolidated basis
with respect to such corporation and its subsidiaries in accordance with GAAP.
"Effective Date" shall have the meaning set forth in Section
2.2.
"Employee Loan" means a loan by Holdings, the Company or any
of their Subsidiaries (a) to one of its employees who has moved more than 50
miles to take or continue employment with Holdings, the Company or any such
Subsidiary, as the case may be, and who has not sold his or her residence prior
to such move, where the proceeds of such loan are used by such employee for the
purpose of purchasing or leasing a residence and such loan becomes due or
payable upon the sale by such employee of his or her residence prior to such
move or (b) to one of its employees representing payment for any capital stock
of Holdings or representing payment of the exercise price of options or other
rights to acquire capital stock of Holdings.
"Employment Agreement Condition" shall have the meaning set
forth in Section 7.1(f).
"Environment" shall mean ambient air, surface water and
groundwater (including potable water, navigable water and wetlands), the land
surface or subsurface strata, the workplace or as otherwise defined in any
Environmental Law.
"Environmental Claim" shall mean any written accusation,
allegation, notice of violation, claim, demand, order, directive, cost recovery
action or other cause of action by, or on behalf of, any Governmental Authority
or any Person for damages, injunctive or equitable relief, personal injury
(including sickness, disease or death), Remedial Action costs, tangible or
intangible property damage, natural resource damages, nuisance, pollution or any
adverse effect on the environment, in each case caused by any Hazardous
Material, or for fines, penalties or restrictions, resulting from or based upon:
(a) the existence, or the continuation of the existence, of a Release (including
sudden or non-sudden, accidental or non-accidental Releases); (b) exposure to
any Hazardous Material; (c) the presence, use, handling, transportation,
storage, treatment or disposal of any Hazardous Material; or (d) the violation
or alleged violation of any Environmental Law or Environmental Permit.
"Environmental Law" shall mean any and all applicable current
and future treaties, laws, rules, regulations, codes, ordinances, orders,
decrees, judgments,
6
<PAGE> 12
injunctions, notices or binding agreements issued, promulgated or entered into
by any Governmental Authority, relating in any way to the environment,
preservation or reclamation of natural resources or human exposure to or the
management or Release or threatened Release of any Hazardous Material.
"Environmental Permit" shall mean any permit, approval,
authorization, certificate, license, variance, filing or permission required by
or from any Governmental Authority pursuant to any Environmental Law.
"ERISA" shall mean the Employee Retirement Income Security Act
of 1974, as the same may be amended from time to time.
"ERISA Affiliate" shall mean any trade or business (whether or
not incorporated) that, together with the Company, is treated as a single
employer under Section 414 (b) or (c) of the Code or, with respect to any
matters that relate to Section 302 of ERISA and Section 412 of the Code, under
Section 414 (b), (c), (m) or (o) of the Code.
"Escrow Agent" shall have the meaning set forth in the
Existing Securities Purchase Agreement.
"Escrow Agreement" shall have the meaning set forth in the
Existing Securities Purchase Agreement.
"Escrow Securities" shall mean the Subordinated Rollover Notes
and the Warrants.
"Event of Default" shall have the meaning set forth in Section
8.1 hereof.
"Exchange Act" shall mean the Securities Exchange Act of 1934,
as amended, and all rules and regulations promulgated thereunder.
"Existing Securities Purchase Agreement" shall have the
meaning set forth in the recitals to this Agreement.
"Financial Officer" of any corporation shall mean the chief
financial officer, principal accounting officer, treasurer or controller of such
corporation.
"First Adjustment Date" shall mean September 30, 1998.
7
<PAGE> 13
"Fiscal Year" shall mean the twelve month period ending
December 31. Subsequent changes of the fiscal year of the Company shall not
change the term "Fiscal Year," unless the Required Holders shall consent in
writing to such changes.
"GAAP" shall mean generally accepted accounting principles in
the United States of America as in effect from time to time.
"Governmental Authority" shall mean any nation or government,
any state or other political subdivision thereof, and any agency, department or
other entity exercising executive, legislative, judicial, regulatory or
administrative functions of or pertaining to government.
"Guarantee" shall mean, as to any Person, any obligation of
such Person guaranteeing any Indebtedness, lease, dividend, or other obligation
("primary obligations") of any other Person (the "primary obligor") in any
manner including, without limitation, any obligation or arrangement of such
Person (a) to purchase or repurchase any such primary obligation, (b) to advance
or supply funds (i) for the purchase or payment of any such primary obligation
or (ii) to maintain working capital or equity capital of the primary obligor or
otherwise to maintain the net worth or solvency or any balance sheet condition
of the primary obligor, (c) to purchase property, securities or services
primarily for the purpose of assuring the owner of any such primary obligation
of the ability of the primary obligor to make payment of such primary
obligation, or (d) to indemnify the owner of such primary obligation against
loss in respect thereof; provided, however, that the term "Guarantee" shall not
include endorsements for collection or deposits in the ordinary course of
business.
"Guarantee Agreements" shall mean the Holdings Guarantee and
the Subsidiary Guarantees.
"Guarantors" shall mean, collectively, Holdings and the
Subsidiary Guarantors.
"Hazardous Materials" shall mean all explosive or radioactive
substances or wastes, hazardous or toxic substances or wastes, pollutants,
solid, liquid or gaseous wastes, including petroleum or petroleum distillates,
asbestos or asbestos-containing materials, polychlorinated biphenyls ("PCBs") or
PCB-containing materials or equipment, radon gas, infectious or medical wastes
and all other substances or wastes of any nature regulated pursuant to any
Environmental Law.
8
<PAGE> 14
"Health Care Law" shall mean any and all applicable current
and future treaties, laws, rules, regulations, codes, ordinances, orders,
decrees, judgments, injunctions, notices or binding agreements issued,
promulgated or entered into by the Food and Drug Administration, the Health Care
Financing Administration, the Department of Health and Human Services ("HHS"),
the Office of Inspector General of HHS, the Drug Enforcement Administration, any
other Governmental Authority or the Health Industry Manufacturers Association or
any other industry organization, including any state and/or local professional
licensing laws, certificate of need laws and state reimbursement laws, the
Physician Self-Referral Laws, relating in any way to the manufacture,
distribution, marketing, sale or other disposition of any product or service of
Holdings, the Company or any Subsidiary, the conduct of the business of
Holdings, the Company or any Subsidiary, the provision of health care services
generally, or to any relationship among Holdings, the Company and its
Subsidiaries, on the one hand, and their suppliers and customers and patients
and other end-users of their products and services, on the other hand.
"Holdings" shall have the meaning set forth in the first
paragraph of this Agreement.
"Holdings Guarantee" shall mean the guarantee entered by
Holdings substantially in the form of Exhibit B-1 hereto.
"Home Healthcare Non Compete Agreement" shall mean the non
compete agreement to be entered into by Donald Amaral with the Company and/or
Holdings, covering the home healthcare industry, with a term of not less than
two years commencing no later than May 31, 1998, in a form approved by the
Original Noteholders.
"Indebtedness" of any Person shall mean, without duplication,
(a) all obligations of such Person for borrowed money or with respect to
deposits or advances in respect thereof of any kind, (b) all obligations of such
Person evidenced by bonds, debentures, notes or similar instruments, (c) all
obligations of such Person upon which interest charges are customarily paid
(excluding operating leases and trade accounts payable and accrued obligations
incurred in the ordinary course of business), (d) all obligations of such Person
under conditional sale or other title retention agreements relating to property
or assets purchased by such Person, (e) all obligations of such Person issued or
assumed as the deferred purchase price of property or services (excluding trade
accounts payable and accrued obligations incurred in the ordinary course of
business but including any Earn-out Obligations), (f) all Indebtedness of others
secured by (or for which the holder of such Indebtedness has an existing right,
9
<PAGE> 15
contingent or otherwise, to be secured by) any Lien on property owned or
acquired by such Person, whether or not the obligations secured thereby have
been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h)
all Capital Lease Obligations of such Person, (i) all net obligations of such
Person in respect of interest rate protection agreements, foreign currency
exchange agreements or other interest or exchange rate hedging arrangements, (j)
all obligations of such Person as an account party in respect of letters of
credit and bankers' acceptances and (k) all obligations in respect of Reverse
Repurchase Agreements. The Indebtedness of any Person shall include the
Indebtedness of any partnership consolidated with such Person for financial
reporting purposes.
"Initial Healthcare Non-Compete Agreement" shall mean the
non-compete agreement to be entered into by Donald Amaral with the Company or
Holdings, as the case may be, covering the entire healthcare industry, with a
term expiring on the earlier date of expiration or termination of the employment
agreement dated as of October 13, 1995 between Holdings and Donald J. Amaral and
the date on which the New Amaral Employment Agreement becomes effective, in a
form approved by the Original Noteholders.
"Interest Payment Date" shall have the meaning assigned to
such term in Section 2.4 hereof.
"Interest Rate Protection Agreement" shall mean any interest
rate cap, swap, collar or floor agreement or other agreement or arrangement
satisfactory to the Required Holders entered into by the Company designed to
protect the Company against fluctuations in interest rates.
"IRS" shall mean the U.S. Internal Revenue Service, or any
successor thereto.
"Joint Venture" shall mean the partnerships listed in Schedule
4.9 and any other Person that is not a Wholly Owned Subsidiary and in which
Holdings, the Company or any of the Subsidiaries directly or indirectly holds an
ownership interest pursuant to a partnership agreement or other joint venture
documents.
"Lien" shall mean any mortgage or deed of trust, pledge,
hypothecation, lien, charge, claim, security interest, easement or encumbrance,
or preference, priority or other security agreement of any kind or nature
whatsoever (including, without limitation, any title retention agreement, any
financing lease having substantially the same economic effect as any of the
foregoing, and the filing of, or agreement to give,
10
<PAGE> 16
any financing statement perfecting a security interest as to assets owned by the
relevant Person under the UCC or comparable law of any jurisdiction).
"Material Adverse Effect" shall mean a materially adverse
effect on (a) the business, assets, operations, properties, financial condition
or prospects of Holdings and its Subsidiaries taken as a whole, (b) the ability
of Holdings or the Company or the collective ability of the other Coram Parties
to perform its or their obligations under the Note Documents and (c) the
validity or enforceability of any of the Note Documents.
"Merger Event" shall mean, with respect to Holdings, the
Company or any Significant Subsidiary, any consolidation with, sale, lease or
other transfer of all or substantially all of its assets to, or merger with or
into, any other corporation, and, in the case of any such consolidation or
merger, Holdings, the Company or such Significant Subsidiary, as the case may
be, is not the surviving entity.
"Multiemployer Plan" shall mean a multiemployer plan as
defined in Section 4001(a)(3) of ERISA to which the Company or any ERISA
Affiliate is making or accruing an obligation to make contributions, or has
within any of the preceding five plan years made or accrued an obligation to
make contributions.
"New Amaral Employment Agreement" shall mean an employment
agreement between Don Amaral and the Company and/or Holdings, providing for
Donald Amaral's employment with the Company for a term of not less than two
years commencing on or prior to the Closing Date, in a form approved by the
Original Noteholders.
"New Healthcare Non-Compete Agreement" shall mean a
non-compete agreement to be entered into by Donald Amaral with the Company
and/or Holdings, covering the entire healthcare industry, with a term identical
to that of the New Amaral Employment Agreement in a form approved by the
Original Noteholders.
"Non-Compete Agreements" shall mean the Home Healthcare
Non-Compete Agreement, the Initial Healthcare Non-Compete Agreement and the New
Healthcare Non-Compete Agreement.
"Note Documents" shall mean this Agreement, the Notes, the
Registration Rights, and the Subsidiary Guarantees.
"Noteholder" shall have the meaning set forth in the first
paragraph of this Agreement.
11
<PAGE> 17
"Notes" or "New Notes" shall mean the Series A Notes and the
Series B Notes.
"Obligations" shall mean all amounts owing by the Company to
the Noteholders and any of their representative assignees pursuant hereto or the
Notes, including, without limitation, all principal, interest, fees, expenses,
attorneys' fees and any other sum chargeable to any Coram Party under any of the
Note Documents.
"Organic Change" shall have the meaning set forth in Section
2.13(g) of this Agreement.
"Original Noteholders" shall mean Cerberus, GSCP and Foothill.
"PBGC" shall mean the Pension Benefit Guaranty Corporation or
any successor thereto.
"Permitted Investments" shall mean:
(a) direct obligations of, or obligations the principal of and
interest on which are unconditionally guaranteed by, the United States of
America (or by any agency thereof to the extent such obligations are backed by
the full faith and credit of the United States of America), in each case
maturing within 90 days from the date of acquisition thereof;
(b) investments in commercial paper maturing within 90 days
from the date of acquisition thereof and having, at such date of acquisition,
the highest credit rating obtainable from Standard & Poor's Ratings Group or
from Moody's Investors Service, Inc.;
(c) investments in certificates of deposit, banker's
acceptances and time deposits maturing within 90 days from the date of
acquisition thereof issued or guaranteed by or placed with, and money market
deposit accounts issued or offered by, any domestic office of any commercial
bank organized under the laws of the United States of America or any State
thereof that (i) has a combined capital and surplus and undivided profits of not
less than $250,000,000 and (ii) is rated (or the senior debt securities of the
holding company of such commercial bank are rated) in one of the three highest
grades by Standard & Poor's Ratings Group or Moody's Investors Service, Inc., or
another nationally recognized rating agency if neither of such two named rating
agencies shall rate such bank; and
12
<PAGE> 18
(d) other investment instruments approved in writing by the
Required Holders (whether on an individual basis or pursuant to an approval of
any investment policy of the Company).
"Permitted Liens" shall have the meaning set forth in Section
4.8.
"Plan" shall mean any employee pension benefit plan (other
than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or
Section 412 of the Code that is maintained for current or former employees, or
any beneficiary thereof, of Holdings, the Company or any ERISA Affiliate.
"Person" shall mean any individual, sole proprietorship,
partnership, limited liability company, joint venture, trust, unincorporated
organization, association, corporation, institution, public benefit corporation,
entity or government (whether federal, state, county, city, municipal or
otherwise, including, without limitation, any instrumentality, division, agency,
body or department thereof).
"Physician Self-Referral Laws" shall mean 42 U.S.C. ss.
1320a-7b and ss. 1395nn, as from time to time amended, modified or supplemented,
and any successor or similar law, rule, regulation, code, ordinance, order,
decree, judgment, injunction, notice or binding agreement of any Governmental
Authority that imposes restrictions on the right of Holdings, the Company or any
of the Subsidiaries to bill any Governmental Authority if the physician ordering
the applicable service has an ownership, investment or other financial interest
in Holdings, the Company or any of the Subsidiaries or receives compensation
from Holdings, the Company or any of the Subsidiaries, including, by way of
example, California Labor Code ss. 139 and California Business & Professions
Code ss.ss. 650.01 and 650.02, in each case as from time to time amended,
modified or supplemented.
"Registration Rights" shall mean the registration rights
applicable to the Notes and the shares issuable upon conversion of the Series B
Notes, attached as Exhibit C.
"Release" shall mean any spilling, leaking, pumping, pouring,
emitting, emptying, discharging, injecting, escaping, leaching, dumping,
disposing, depositing, dispersing, emanating or migrating of any Hazardous
Material in, into, onto or through the environment.
"Remedial Action" shall mean (a) "remedial action" as such
term is
13
<PAGE> 19
defined in CERCLA, 42 U.S.C. Section 9601(24), and (b) all other actions
required by any Governmental Authority or voluntarily undertaken to: (i)
cleanup, remove, treat, abate or in any other way address any Hazardous Material
in the environment; (ii) prevent the Release or threat of Release, or minimize
the further Release of any Hazardous Material so it does not migrate or endanger
or threaten to endanger public health, welfare or the environment; or (iii)
perform studies and investigations in connection with, or as a precondition to,
(i) or (ii) above.
"Reportable Event" shall mean any reportable event as defined
in Section 4043 of ERISA or the regulations issued thereunder with respect to a
Plan.
"Required Holders" shall mean those Noteholders who hold at
least a majority of the outstanding principal amount of the Notes.
"Responsible Officer" of any corporation shall mean any
executive officer or Financial Officer of such corporation and any other officer
or similar official thereof responsible for the administration of the
obligations of such corporation in respect of this Agreement.
"Retiree Welfare Plan" shall refer to any Welfare Plan
providing for continuing coverage or benefits for any participant or any
beneficiary of a participant after such participant's termination of employment,
other than continuation coverage provided pursuant to Section 4980B of the IRC
and at the sole expense of the participant or the beneficiary of the
participant.
"Reverse Repurchase Agreements" shall mean sales by the
Company of its assets consisting of marketable securities with a concurrent
agreement by the Company to repurchase the same assets at a later date at a
fixed price.
"SEC" shall mean the U.S. Securities and Exchange Commission,
or any successor thereto.
"Second Adjustment Date" shall mean March 31, 1999.
"Securities Act" shall mean the Securities Act of 1933, as
amended, and all rules and regulations promulgated thereunder.
"Senior Agent" shall mean the "Administrative Agent" or Person
performing comparable functions under the Senior Loan Agreement.
14
<PAGE> 20
"Senior Debt" shall mean all principal of and premium, if any,
and interest on, and all other amounts owing in respect of any Indebtedness of
the Company now or hereafter outstanding under the Senior Loan Agreement which
is permitted to be outstanding hereunder, and any extensions, renewals,
amendments or modifications thereof, provided that (i) no such extension,
renewal, amendment or modification shall increase the principal amount thereof,
and (ii) any such extension, renewal, amendment or modification shall be
approved by the Required Holders. The phrase "terms of the Senior Debt" shall
mean the terms and conditions of all documents, instruments and agreements
evidencing or executed in connection with the Senior Debt.
"Senior Lender" shall mean the Lenders from time to time under
the Senior Loan Agreement.
"Senior Loan Agreement" shall mean the agreement to be entered
into among the Company as borrower, the Subsidiaries named therein as guarantors
and the financial institutions named therein as lenders or to which the credit
provided for thereby may be syndicated, providing for senior secured loans to be
used by the Company for acquisitions, working capital letters of credit, and
general corporate requirements in a form approved by the Original Noteholders.
"Series A Maturity Date" shall mean the later of October 15,
2000 and the date which is 90 days after the original maturity date under the
Senior Loan Agreement.
"Series B Maturity Date shall April 15, 2008.
"Series A Notes" shall mean the $150,000,000 Series A Senior
Subordinated Notes of the Company issued to the Noteholders hereunder,
substantially in the form of Exhibit A-1 hereto, and includes any Additional
Series A Notes.
"Series B Notes" shall mean the $87,922,213 Series B Senior
Subordinated Convertible Notes of the Company issued to the Noteholders
hereunder, substantially in the form of Exhibit A-2 hereto, and includes any
Additional Series B Notes.
"Significant Noteholder" shall have the meaning set forth in
Section 2.11.
"Significant Subsidiaries" shall mean T2 Medical, Inc., a
Delaware corporation, Coram Resource Network, Inc., a Delaware corporation and
Curaflex.
15
<PAGE> 21
"Stockholder Approval" and "Stockholder Approval Condition"
shall have the respective meanings set forth in Section 7.1(g).
"Stock" shall mean all shares, options, warrants, general or
limited partnership interests, limited liability company membership interest,
participations or other equivalents (regardless of how designated) of or in a
corporation, partnership, limited liability company or equivalent entity whether
voting or nonvoting, including, without limitation, common stock, preferred
stock, or any other "equity security" (as such term is defined in Rule 3a11-1 of
the General Rules and Regulations promulgated by the SEC under the Exchange
Act).
"Subordinated Debt" shall have the meaning set forth in
Section 9.1 hereof.
"Subordinated Rollover Notes" shall mean the senior
subordinated increasing rate notes of the Company issued pursuant to the
Existing Securities Purchase Agreement.
"Subsidiary" shall mean, with respect to any Person, (a) any
corporation of which an aggregate of more than 50% of the outstanding Stock
having ordinary voting power to elect a majority of the board of directors of
such corporation (irrespective of whether, at the time, Stock of any other class
or classes of such corporation shall have or might have voting power by reason
of the happening of any contingency) is at the time, directly or indirectly,
owned legally or beneficially by such Person and/or one or more Subsidiaries of
such Person, and (b) any partnership or other entity in which such Person and/or
one or more Subsidiaries of such Person shall have an interest (whether in the
form of voting or participation in profits or capital contribution) of more than
50% of all such interests in such partnership or other entity. When such term is
used in the context of Holdings or the Company, it shall mean a Subsidiary of
Holdings or the Company.
"Subsidiary Guarantors" shall mean, collectively, (a) each
Subsidiary of the Company, other than the Designated Subsidiaries, which is or
becomes a guarantor of the Obligations under this Agreement and (b) each
Subsidiary which is or becomes a guarantor of the obligations under the Senior
Loan Agreement, and "Subsidiary Guarantees" shall mean each guarantee executed
by such Subsidiary Guarantor, substantially in the form of Exhibit B-2 hereto.
"Taxes" shall have the meaning set forth in Section 2.12
hereof.
16
<PAGE> 22
"Title IV Plan" shall mean a Pension Plan, other than a
Multiemployer Plan, which is covered by Title IV of ERISA.
"Total Debt" shall mean, with respect to Holdings, the Company
and the Subsidiaries on a consolidated basis at any time, all Indebtedness of
Holdings, the Company and the Subsidiaries as determined on a consolidated basis
in accordance with GAAP.
"Transactions" shall have the meaning assigned to such term in
Section 4.3.
"UCC" shall mean the Uniform Commercial Code of the
jurisdiction with respect to which such term is used, as in effect from time to
time.
"Unfunded Pension Liability" shall mean, at any time, the
aggregate amount, if any, of the sum of (i) the amount by which the present
value of all accrued benefits under each Title IV Plan exceeds the fair market
value of all assets of such Title IV Plan allocable to such benefits in
accordance with Title IV of ERISA, all determined as of the most recent
valuation date for each such Title IV Plan using the actuarial assumptions in
effect under such Title IV Plan, and (ii) for a period of five (5) years
following a transaction reasonably likely to be covered by Section 4069 of
ERISA, the liabilities (whether or not accrued) that could be avoided by the
Company, any of its Subsidiaries or any ERISA Affiliate as a result of such
transaction.
"Warrant Agreement" shall have the meaning set forth in the
recitals to this Agreement.
"Warrants" shall mean all the warrants issued or issuable by
Holdings to the Noteholders pursuant to the Warrant Agreement.
"Welfare Plan" shall mean any welfare plan, as defined in
Section 3(1) of ERISA, which is maintained or contributed to by the Company, any
of its Subsidiaries or any ERISA Affiliate.
"Withdrawal Liability" shall mean liability to a Multiemployer
Plan as a result of a complete or partial withdrawal from such Multiemployer
Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA.
"Wholly Owned Subsidiary" shall mean any Subsidiary in which
any
17
<PAGE> 23
combination of the Company and the other Wholly Owned Subsidiaries shall own
100% of the outstanding Stock.
Any accounting term used in this Agreement shall have, unless
otherwise specifically provided herein, the meaning customarily given such term
in accordance with GAAP as constituted on the date hereof, and all financial
computations hereunder shall be computed, unless otherwise specifically provided
herein, in accordance with GAAP consistently applied. That certain terms or
computations are explicitly modified by the phrase "in accordance with GAAP"
shall in no way be construed to limit the foregoing. The words "herein,"
"hereof" and "hereunder" and other words of similar import refer to this
Agreement as a whole, including the Annexes, Exhibits and Schedules hereto, as
the same may from time to time be amended, modified or supplemented, and not to
any particular section, subsection or clause contained in this Agreement.
Wherever from the context it appears appropriate, each term stated in either the
singular or plural shall include the singular and the plural, and pronouns
stated in the masculine, feminine or neuter gender shall include the masculine,
the feminine and the neuter.
2. EXCHANGE OF SUBORDINATED ROLLOVER NOTES AND WARRANTS FOR NEW NOTES
2.1 Exchange of Subordinated Rollover Notes and Warrants.
Subject to the terms and conditions set forth in this Agreement, each Noteholder
agrees to exchange its pro rata share of the Subordinated Rollover Notes and the
Warrants held by it or issuable to it (whether beneficially or of record) at the
Closing Date for its pro rata share of the Series A Notes, the Series B Notes
and the Deferred Warrant Consideration, on the terms and subject to the
conditions set forth herein.
2.2 Closing. (a) The closing of the exchange of the
Subordinated Rollover Notes and Warrants (the "Closing") shall take place within
five Business Days after the satisfaction or waiver of the conditions (the
"Closing Conditions") set forth in Article 7 hereof or such date and time as
shall be mutually agreed to by the parties hereto (the "Closing Date"), but in
any event no later than June 30, 1998, at the offices of Weil, Gotshal & Manges
LLP, 767 Fifth Avenue, New York, New York, or such other place as shall be
mutually agreed to by the parties hereto.
(b) The effective date of the Closing (the "Effective Date")
shall be April 13, 1998, provided that (i) the condition precedent set forth in
Section 7.1(g) is satisfied on or before May 31, 1998 and (ii) the Closing
occurs on or before June 30, 1998. If the condition precedent set forth in
Section 7.1(g) is not satisfied by May 31,
18
<PAGE> 24
1998, then the Effective Date shall be the Closing Date. The parties agree that
once all Closing Conditions (other than the Stockholder Approval Condition and
the Employment Agreement Condition) have been satisfied or waived, they will be
legally and irrevocably bound to close the transactions contemplated hereby upon
the earlier of satisfaction by the Company or waiver by the Noteholders of the
Closing Conditions, provided, however, that (i) the Noteholders may not
unilaterally waive the Stockholder Approval Condition, and (ii) satisfaction or
waiver of all Closing Conditions must occur on or prior to June 30, 1998. The
Company and Holdings hereby agree to use their best efforts to satisfy all
Closing Conditions as soon as reasonably practicable after the date hereof.
2.3 Deliveries at Closing. (a) On the Closing Date, the
Noteholders will deliver to the Company (i) the Subordinated Rollover Notes or
other instrument evidencing such indebtedness marked "cancelled" or similarly
annotated, (ii) the Warrants or other documentary evidence (if any) evidencing
the Noteholders' entitlement to the Warrants and (iii) a letter signed by the
Noteholders terminating the Escrow Agreement.
(b) On the Closing Date, the Company will deliver to the
Noteholders the New Notes payable to and registered in the name of each
Noteholder in the amount set forth on Schedule I hereto; and
(c) On the earlier of (i) the closing date of the Senior Loan
Agreement and (ii) 90 days after the Closing Date, the Company will pay to each
Noteholder in cash its pro rata share of the Deferred Warrant Consideration in
the amounts set forth on Schedule I hereto.
2.4 The Series A Notes. (a) The Company has authorized the
issuance of $150,000,000 in aggregate principal amount of its Series A Notes due
on the later of October 15, 2000 and the date which is 90 days after the
original maturity date under the Senior Loan Agreement, which shall be in the
form of Exhibit A-1 hereto and shall have the terms as herein and therein
provided.
(b) The Company will pay interest, accruing from and after the
Effective Date, on the Series A Notes to each Noteholder quarterly in arrears on
January 15, April 15, July 15 and October 15 of each year, commencing July 15,
1998 (each an "Interest Payment Date") at the Applicable Series A Rate. The
"Applicable Series A Rate" shall mean (i) 9 7/8% per annum from the date of
issuance to the First Adjustment Date, (ii) 10 1/2% per annum thereafter until
the Second Adjustment Date if EBITDA for the nine months ending September 30,
1998 is less than $22,500,000,
19
<PAGE> 25
otherwise at the rate set forth in clause (i) above, and (iii) from the Second
Adjustment Date until maturity (or redemption), the rate per annum in effect
after the First Adjustment Date plus 5/8% if EBITDA for the 12 months ending
March 31, 1999 is less than $32,500,000, otherwise at such rate without the 5/8%
increase.
(c) The Series A Notes will be payable in full on the Series A
Maturity Date.
(d) The Company shall have the right, in lieu of payment of
interest on the Series A Notes in cash, to pay interest on each Interest Payment
Date through the issuance of Additional Series A Notes in principal amount equal
to the amount of interest then due and owing. Such Additional Series A Notes
shall otherwise be identical to outstanding Series A Notes and will be issued to
each Noteholder pro rata; provided, however, that interest due on any Interest
Payment Date shall be payable in cash if, on such Interest Payment Date, (A)
EBITDA less Capital Expenditures for the period of the four preceding
consecutive fiscal quarters divided by four, divided by (B) Consolidated
Interest Expense for the immediately preceding fiscal quarter, is equal to or
greater than 2.0.
(e) Interest in the Series A Notes shall be computed on the
basis of a 360 day year of twelve 30 day months.
2.5 The Series B Notes. (a) The Company has authorized the
issuance of $87,922,213 in aggregate principal amount of its Series B Notes due
April 15, 2008, which shall be in the form of Exhibit A-2 hereto and shall have
the terms as herein and therein provided.
(b) The Company will pay interest, accruing from and after the
Effective Date, on the Series B Notes to each Noteholder quarterly in arrears on
January 15, April 15, July 15 and October 15 of each quarter, commencing July
15, 1998 (each an "Interest Payment Date") at the rate of 8.00% per annum.
(c) The Series B Notes will be payable in full on the Series B
Maturity Date.
(d) The Company shall have the right, in lieu of payment of
interest in cash, to pay interest on each Interest Payment Date through the
issuance of Additional Series B Notes in principal amount equal to the amount of
interest then due and owing. Such Additional Series B Notes shall otherwise be
identical to outstanding Series B Notes and will be issued to each Noteholder
pro rata.
20
<PAGE> 26
(e) The Series B Notes shall be convertible into shares of
Common Stock on the terms set forth in Section 2.13.
(f) Interest on the Series B Notes shall be computed on the
basis of a 360 day year of twelve 30 day months.
2.6 Prepayment of the Notes. In addition to the payment of the
entire unpaid principal amount of the Notes of each series at the final maturity
thereof, the Company will make prepayments in respect of the Notes as
hereinafter provided.
(a) The Company may, without any other penalty or premium, at
its option and upon notice as provided below, prepay at any time all, or from
time to time any part of, the Series A Notes (in a minimum amount of $1,000,000
and otherwise in multiples of $100,000) at 103% of the principal amount so
prepaid, together with interest accrued thereon to the date of such prepayment.
The Company will give each holder of Series A Notes written notice of each
optional prepayment under this Section 2.6 (a) not less than 10 days and not
more than 30 days prior to the date fixed for such prepayment. Each such notice
shall specify the date fixed for such prepayment (which shall be a Business
Day), the aggregate principal amount of the Series A Notes to be prepaid on such
date, the principal amount held by each Noteholder to be prepaid (determined in
accordance with Section 2.6(e)) and the interest to be paid on the prepayment
date with respect to such principal amount being prepaid. Except as otherwise
agreed to by the Holders of the outstanding Series A Notes, each prepayment
pursuant to this Section 2.6(a) shall be applied to all outstanding Series A
Notes, ratably in proportion to the principal amount thereof held by the
Holders.
(b) The Series B Notes shall not be redeemable at the option
of the Company.
(c) Within 30 days after the occurrence of a Change of Control
or Merger Event, the Company will give written notice thereof to the holders of
all outstanding Notes, which notice shall (i) refer specifically to this Section
2.6(c), (ii) describe the Change of Control or Merger Event in reasonable detail
and specify the Change of Control Prepayment Date and the Response Date (as
respectively defined below) in respect thereof and (iii) offer to prepay all
Notes at the price specified below on the date therein specified (the "Change of
Control Prepayment Date"), which shall be a Business Day not less than 45 nor
more than 60 days after the date of such notice. Each holder of a Note will
notify the Company of such holder's acceptance or rejection of the opportunity
to redeem by giving written notice of such acceptance or rejection to
21
<PAGE> 27
the Company at least five days prior to the Change of Control Prepayment Date
(the "Response Date"), except that the failure by any such holder to respond in
writing to such offer on or before the Response Date shall be deemed to be a
rejection of such offer by such holder in respect of such Change of Control or
Merger Event, as the case may be. Each holder may accept the offer to prepay the
Notes as to all or part of the Notes held by it.
On the Change of Control Prepayment Date the Company will
prepay all of the Notes held by the holders as to which such offer has been
accepted, at the principal amount of each such Note, together with interest
accrued thereon to the Change in Control Prepayment Date, plus a premium equal
to 3% of such principal amount.
If any holder shall reject such offer with respect to any
Notes held by it, such holder shall be deemed to have waived its rights under
this Section 2.6(c) to require prepayment of all such Notes held by such holder
in respect of such Change of Control or Merger Event, but not in respect of any
subsequent Change of Control or Merger Event.
(d) Not less than 30 days nor more than 60 days prior to the
maturity date of the Series A Notes, the Company will give written notice
thereof to the holders of all outstanding Series B Notes, which notice shall (i)
refer specifically to this Section 2.6(d), (ii) specify the Series B Prepayment
Date and the Response Date (as respectively defined below) in respect thereof
and (iii) offer to prepay all Series B Notes at the price specified below on the
date on which the Series A Notes are to be repaid in full (the "Series B
Prepayment Date"). Each holder of a Series B Note will notify the Company of
such holder's acceptance or rejection of such offer by giving written notice of
such acceptance or rejection to the Company at least five days prior to the
Series B Prepayment Date (the "Response Date"), except that the failure by any
such holder to respond in writing to such offer on or before the Response Date
shall be deemed to be a rejection of such offer by such holder in respect of
such Series B Prepayment Date.
On the Series B Prepayment Date, the Company will prepay all
of the Series B Notes held by the holders as to which such offer has been
accepted, at the principal amount of each such Series B Note, together with
interest accrued thereon to the Series B Prepayment Date.
If any holder shall reject such offer, such holder shall be
deemed to have waived its rights under this Section 2.6(d) to require prepayment
of all Series B Notes
22
<PAGE> 28
held by such holder.
(e) In the case of each prepayment of Notes pursuant to this
Section 2.6, the principal amount of each Note to be prepaid shall mature and
become due and payable on the date fixed for such prepayment, together with
interest on such principal amount accrued to such date and the applicable
premium, if any. From and after such date, unless the Company shall fail to pay
such principal amount when so due and payable, together with the interest and
premium, if any, as aforesaid, interest on such principal amount shall cease to
accrue. Any Note paid or prepaid in full shall be surrendered to the Company and
cancelled and shall not be reissued.
(f) The Company will not and will not permit any Affiliate to
purchase, redeem, prepay or otherwise acquire, directly or indirectly, any of
the outstanding Notes except upon the payment or prepayment of the Notes in
accordance with the terms of this Agreement and the Notes.
2.7 Receipt of Payments. The Company shall make each payment
under the Notes not later than 11:00 A.M. (New York City time) on the day when
due in lawful money of the United States of America in immediately available
funds to the account of each Noteholder in the United States as designated by
such Noteholder from time to time. The initial accounts designated by the
Original Noteholders shall be as set forth on Schedule I. For purposes only of
computing interest under the Notes, all payments shall be applied by each
Noteholder to the Notes on the day payment has been credited by such
Noteholder's bank to such Noteholder's account in immediately available funds.
2.8 Application of Payments. The Company irrevocably waives
the right to direct the application of any and all payments at any time or times
hereafter received by the Noteholders from or on behalf of the Company pursuant
to the terms of this Agreement, and the Company irrevocably agrees that the
Noteholders shall have the continuing exclusive right to apply any and all such
payments against the then due and payable Obligations of the Company and in
repayment of the Notes as each Noteholder may deem advisable. In the absence of
a specific determination by a Noteholder with respect thereto, the same shall be
applied in the following order: (i) then due and payable fees and expenses for
which the Company has received an invoice; (ii) then due and payable interest
payments on the Notes; and (iii) then due and payable principal payments on the
Notes.
2.9 Sharing of Payments. If any holder of a Note or a portion
thereof shall obtain any payment (whether voluntary, involuntary, through the
exercise of any
23
<PAGE> 29
right of set-off, or otherwise) on account of the Note held by it in excess of
its ratable share of payments on account of the Notes held by all holders
thereof, such Noteholder shall forthwith purchase from each other holder such
participations in the Notes held by it as shall be necessary to cause such
purchasing holder to share the excess payment ratably with each other
Noteholder; provided, however, that if all or any portion of such excess payment
is thereafter recovered from such purchasing Noteholder, such purchase shall be
rescinded and such Noteholder shall repay to the purchasing holder the purchase
price to the extent of such recovery together with an amount equal to such
Noteholder's ratable share (according to the proportion of (i) the amount of
such Noteholder's required repayment to (ii) the total amount so recovered from
the purchasing Noteholder) of any interest or other amount paid or payable by
the purchasing holder in respect of the total amount so recovered. The Company
agrees to make all payments on the Notes to all holders thereof (other than any
payments made pursuant to Section 2.6(c) and (d)) on a pro rata basis, based on
the principal amount of the Series A Notes and Series B Notes held by each.
2.10 Indemnity. Each of Holdings and the Company shall
indemnify and hold each Noteholder and each of its respective officers,
directors, employees and Affiliates harmless from and against any and all suits,
actions, proceedings, claims, damages, losses, liabilities and expenses
(including, without limitation, reasonable attorneys' fees and disbursements,
including those incurred upon any appeal) (collectively, the "Indemnified
Liabilities") which may be instituted or asserted against or incurred by such
Noteholder or such other indemnified Person as the result of (i) its having
entered into this Agreement or any of the other Note Documents or having
exchanged its interest in the Subordinated Rollover Notes and the Warrants
hereunder in respect of any Indemnified Liabilities arising out of any suit,
action, proceeding or claim instituted by or on behalf of any third party
alleging tortious interference or by or on behalf of Holdings, the Company or
their Subsidiaries, any securityholder, officer or director of any of the
foregoing acting in such capacity, or any person claiming by, through or on
behalf of, derivately or otherwise, any such person or entity, or (ii) relating
to or arising out of any untrue representation, breach of warranty or failure to
perform any covenants or agreement by Holdings or the Company contained herein
or in any Note Document or (iii) arising out of any Environmental Law applicable
to Holdings, the Company or any Subsidiaries; provided, however, that neither
Holdings nor the Company shall be liable for such indemnification to such
indemnified Person to the extent that any such suit, action, proceeding, claim,
damage, loss, liability or expense results from (i) a breach or default by any
Noteholder or any holder in performing its obligations under any of the Note
Documents or (ii) such indemnified Person's gross negligence or willful
misconduct or (iii) any action by any Noteholder against another Noteholder or
(iv) any action by equity holders of any Noteholder against such Noteholder
24
<PAGE> 30
relating to or arising out of such Noteholder's entering into this Agreement or
any of the other Note Documents.
2.11 Access. The Noteholders and any of their respective
officers, employees and/or agents shall have the right, exercisable as
frequently as it reasonably determines to be appropriate but in any event not
more than once in any 30 day period, upon a reasonable advance notice during
normal business hours, to inspect the properties and facilities of Holdings, the
Company and its Subsidiaries and to inspect, audit and make extracts from all of
Holdings, the Company's and such Subsidiaries' records, files and books of
account, unless the disclosure of any such information is prohibited by law. The
Company or Holdings, as the case may be, shall deliver any document or
instrument reasonably necessary for any Noteholder, as such Noteholder may
request, to obtain access to records of Holdings, the Company or any
Subsidiaries from any service bureau for the purposes described in the preceding
sentence. Holdings and the Company shall instruct its and its Subsidiaries'
banking and other financial institutions to make available to each Noteholder
which individually or through its Affiliates holds 10% or more of the principal
amount of the Notes issued on the Closing Date (or 10% or more of the principal
amount of either Series of Notes issued on the Closing Date) (a "Significant
Noteholder"), such information and records as such Noteholders may reasonably
request. Nothing in this Agreement shall require Holdings, the Company or any of
their Subsidiaries to provide or permit access to or for any person who is or
could reasonably be expected to become in the foreseeable future a competitor of
Holdings, the Company or any of their Subsidiaries other than any information
that is generally available to the public.
2.12 Taxes. (a) The Company agrees to pay any present or
future stamp or documentary taxes or any other sales, transfer, excise, mortgage
recording or property taxes, charges or similar levies that arise from any
payment made hereunder or under the Notes or from the execution, sale, transfer,
delivery or registration of, or otherwise with respect to, this Agreement, the
Notes, the shares of Common Stock issuable upon conversion of the Series B
Notes, or the other Note Documents (hereinafter referred to as "Taxes").
(b) The Company shall indemnify each Noteholder for the full
amount of Taxes paid by such Noteholder and any liability (including penalties,
interest and expenses) arising therefrom or with respect thereto not resulting
from such Noteholder's delay, gross negligence or wilful misconduct. This
indemnification shall be made within 30 days from the date any Noteholder makes
written demand therefor.
(c) Within 30 days after the date of any payment of Taxes, the
Company
25
<PAGE> 31
shall furnish to each Noteholder the original or a certified copy of a receipt
evidencing payment thereof.
(d) Without prejudice to the survival of any other agreement
of the Company hereunder, the agreements and obligations of the Company
contained in this Section 2.12 shall survive the payment in full of the Notes.
(e) Notwithstanding anything herein to the contrary, nothing
in any Note Document shall obligate Holdings, the Company or any Subsidiary to
make any payment to any Person in respect of or relating to any tax of any
nature whatsoever based upon income of any such Person.
2.13 Conversion of Series B Notes. (a) Subject to the
provisions for adjustment hereinafter set forth, the Series B Notes shall be
convertible, in whole or in part, at any time and from time to time, at the
option of the holder thereof (a "Conversion"), up to the outstanding principal
amount of Series B Notes held by such holder thereof at the time of such
conversion into a number of fully paid and nonassessable shares of Common Stock
equal to the quotient obtained by dividing (A) the principal amount of the
Series B Notes to be converted by (B) the Conversion Price (as hereinafter
defined). The Conversion Price shall initially be $3.00 per share of Common
Stock and shall be adjusted on the First Conversion Price Adjustment Date and
Second Conversion Adjustment Date as hereinafter provided. On April 13, 1999
(the "First Conversion Price Adjustment Date"), the Conversion Price shall be
adjusted to equal the lesser of (A) the then current Conversion Price and (B)
the Current Market Price on the First Conversion Price Adjustment Date; and on
October 13, 1999 (the "Second Conversion Price Adjustment Date"), the Conversion
Price shall be adjusted to equal to the lesser of (A) the then current
Conversion Price and (B) the Current Market Price on the Second Conversion Price
Adjustment Date. The Conversion Price shall be subject to further adjustments
from time to time pursuant to Section 2.13(f) below.
No fractional shares shall be issued upon the conversion of
any Series B Notes. All shares of Common Stock (including fractions thereof)
issuable upon conversion of Series B Notes by a holder thereof shall be
aggregated for purposes of determining whether conversion would result in the
issuance of any fractional share. If, after the aforementioned aggregation, the
conversion would result in the issuance of a fraction of a share of Common
Stock, Holdings shall, in lieu of issuing any fractional share, pay the holder
otherwise entitled to such fraction a sum in cash equal to the Current Market
Price of such fraction on the date of conversion.
(b)(_)(_) A conversion of the Series B Notes may be effected
by any
26
<PAGE> 32
Noteholder upon the surrender to Holdings at the principal office of Holdings of
the certificate for such Series B Notes to be converted accompanied by a written
notice stating that such Noteholder elects to convert all or a specified amount
of its Series B Notes in accordance with the provisions of this Section 2.13 and
specifying the name or names in which such Noteholder wishes the certificate or
certificates for shares of Common Stock to be issued.
(c) In case the written notice specifying the name or names in
which any Noteholder wishes the certificate or certificates for shares of Common
Stock to be issued shall specify a name or names other than that of such
Noteholder, such notice shall be accompanied by payment of all transfer taxes
payable upon the issuance of shares of Common Stock in such name or names. Other
than such taxes, Holdings will pay any and all issue and other taxes (other than
taxes based on income) that may be payable in respect of any issue or delivery
of shares of Common Stock on conversion of Series B Notes pursuant hereto. As
promptly as practicable, and in any event within five Business Days after the
surrender of such certificate or certificates and the receipt of such notice
relating thereto and, if applicable, payment of all transfer taxes (or the
demonstration to the satisfaction of Holdings that such taxes have been paid),
Holdings shall deliver or cause to be delivered (1) certificates representing
the number of validly issued, fully paid and nonassessable full shares of Common
Stock to which the holder of Series B Notes being converted shall be entitled
and (2) if less than all the Series B Notes evidenced by the surrendered
certificate or certificates is being converted, a new certificate or
certificates, of like tenor, for the Series B Notes evidenced by such
surrendered certificate or certificates less the number of Series B Notes being
converted.
(d) A conversion shall be deemed to have been made at the
close of business on the date of giving the written notice referred to in the
first sentence of (b) above and of such surrender of the certificate or
certificates representing the Series B Notes to be converted so that the rights
of the holder thereof as to the Series B Notes being converted shall cease
except for the right to receive shares of Common Stock in accordance herewith,
and the Person entitled to receive the shares of Common Stock shall be treated
for all purposes as having become the record holder of such shares of Common
Stock at such time.
(e) Holdings shall at all times reserve, and keep available
for issuance upon the conversion of the Series B Notes, such number of its
authorized but unissued shares of Common Stock as will from time to time be
sufficient to permit the conversion of all outstanding Series B Notes, and shall
take all action required to increase the authorized number of shares of Common
Stock if necessary to permit the
27
<PAGE> 33
conversion of all outstanding Series B Notes.
(f) The Conversion Price will be subject to adjustment from
time to time as follows:
(i) In case Holdings shall at any time or from time to
time after the Closing Date (A) pay a dividend, or make a distribution, on the
outstanding shares of Common Stock in shares of Common Stock, (B) subdivide the
outstanding shares of Common Stock, (C) combine the outstanding shares of Common
Stock into a smaller number of shares or (D) issue by reclassification of the
shares of Common Stock any shares of capital stock of Holdings, then, and in
each such case, the Conversion Price in effect immediately prior to such event
or the record date therefor, whichever is earlier, shall be adjusted so that the
holder of any Series B Notes thereafter surrendered for conversion shall be
entitled to receive the number of shares of Common Stock or other securities of
Holdings which Noteholder would have owned or have been entitled to receive
after the happening of any of the events described above, had such Series B
Notes been surrendered for conversion immediately prior to the happening of such
event or the record date therefor, whichever is earlier. An adjustment made
pursuant to this clause (i) shall become effective (x) in the case of any such
dividend or distribution, immediately after the close of business on the record
date for the determination of holders of shares of Common Stock entitled to
receive such dividend or distribution, or (y) in the case of such subdivision,
reclassification or combination, at the close of business on the day upon which
such corporate action becomes effective. No adjustment shall be made pursuant to
this clause (i) in connection with any transaction to which Section 2.13(g)
applies.
(ii) In case Holdings shall issue shares of Common
Stock (or rights, warrants or other securities convertible into or exchangeable
for shares of Common Stock), other than pursuant to existing obligations or
pursuant to any existing employee benefit plan after the Closing Date, other
than issuances covered by clause (i) above, at a price per share (or having an
exercise, conversion or exchange price per share) less than the Conversion Price
as of the date of issuance of such shares or of such rights, warrants or other
convertible or exchangeable securities, then, and in each such case, the
Conversion Price shall be reduced (but not increased) to a price determined by
dividing (A) an amount equal to the sum of (x) the number of shares of Common
Stock outstanding immediately prior to such issue multiplied by the then
existing Conversion Price, plus (y) the aggregate number of shares of Common
Stock the aggregate consideration, if any, received by Company upon such issue
would purchase at the Conversion Price then in effect, by (B) the total number
of shares of Common Stock outstanding immediately after such issue or sale (in
the case of warrants
28
<PAGE> 34
or convertible securities, on an as exercised or as converted basis, as the case
may be). For the purpose of determining the consideration received by Holdings
upon any such issue pursuant to clause (y) above, if the consideration received
by Holdings is other than cash, its value will be deemed its fair market value,
as determined in good faith by the Board of Directors of Holdings.
(iii) An adjustment made pursuant to clause (ii)
above shall be made on the next Business Day following the
date on which any such issuance is made and shall be effective
retroactively immediately after the close of business on such
date. No adjustment shall be made pursuant to clause (ii) in
respect of any issuance of shares of Common Stock on or prior
to the Closing Date. For purposes of clause (ii), the
aggregate consideration received by Holdings in connection
with the issuance of shares of Common Stock or of rights,
warrants or other securities exchangeable or convertible into
shares of Common Stock shall be deemed to be equal to the sum
of the aggregate offering price of all such Common Stock and
such rights, warrants, or other exchangeable or convertible
securities plus the aggregate amount, if any, receivable upon
exchange or conversion of any such exchangeable or convertible
securities into shares of Common Stock.
(iv) In case Holdings shall at any time or from time
to time after the Closing Date declare, order, pay or make a
dividend or other distribution (including, without limitation,
any distribution of stock or other securities or property or
rights or warrants to subscribe for securities of Holdings or
any of its Subsidiaries by way of dividend or spinoff), on its
Common Stock, other than dividends or distributions of shares
of Common Stock which are referred to in clause (i) above and
cash dividends paid out of retained earnings, than the
Conversion Price shall be adjusted so that the holder of
Series B Notes shall be entitled to receive, upon the
conversion thereof, the number of shares of Common Stock
determined by multiplying (A) the applicable Conversion Price
on the day immediately prior to the record date fixed for the
determination of stockholders entitled to receive such
dividend or distribution by (B) a fraction, the numerator of
which shall be the Current Market Price per share of Common
Stock at such record date, and the denominator of which shall
be such Current Market Price per share of Common Stock less
the Fair Market Value of such dividend or distribution per
share of Common Stock. No adjustment shall be made pursuant to
this clause (iv) in connection with any transaction to which
Section 2.13(g) applies.
29
<PAGE> 35
(v) For purposes of this Section 2.13(f), the number
of shares of Common Stock at any time outstanding shall not
include any shares of Common Stock then owned or held by or
for the account of Holdings or any of its Subsidiaries.
(vi) If Holdings shall take a record of the holders
of its Common Stock for the purpose of entitling them to
receive a dividend or other distribution, and shall thereafter
and before the distribution to stockholders thereof legally
abandon its plan to pay or deliver such dividend or
distribution, then thereafter no adjustment in the number of
shares of Common Stock issuable upon exercise of the right of
conversion granted by this Section 2.13(f) or in the
Conversion Price then in effect shall be required by reason of
the taking of such record.
(vii) Anything in this Section 2.13(f) to the
contrary notwithstanding, Holdings shall not be required to
give effect to any adjustment in the Conversion Price unless
and until the net effect of one or more adjustments (each of
which shall be carried forward), determined as above provided,
shall have resulted in a change of the Conversion Price by at
least one cent, and when the cumulative net effect of more
than one adjustment so determined shall be to change the
Conversion Price by at least one cent, such change in
Conversion Price shall thereupon be given effect.
(viii) If any option or warrant expires or is
cancelled without having been exercised, then, for the
purposes of the adjustments set forth above, such option or
warrant shall have been deemed not to have been issued and the
Conversion Price shall be adjusted accordingly. No holder of
Common Stock which was previously issued upon conversion of
Series B Notes shall have any obligation to redeem or cancel
any such shares of Common Stock as a result of the operation
of this clause (viii).
(g) In case of any reorganization of capital, reclassification
of capital stock (other than a reclassification of capital subject to
2.13(f)(i)), consolidation or merger with or into another corporation (where
Holdings is not the surviving corporation), or sale, transfer or disposition of
all or substantially all the property, assets or business of Holdings to another
corporation (any one or more of such events being an "Organic Change"), the
Series B Notes then outstanding, shall thereafter be convertible into, in lieu
of the Common Stock issuable upon such conversion prior to
30
<PAGE> 36
consummation of such Organic Change, the kind and amount of shares of stock and
other securities and property receivable (including cash) upon the consummation
of such Organic Change by a holder of that number of shares of Common Stock into
which the Series B Notes was convertible immediately prior to such Organic
Change (including, on a pro rata basis, the cash, securities or property
received by holders of Common Stock in any tender or exchange offer that is a
step in such Organic Change). In case securities or property other than Common
Stock shall be issuable or deliverable upon conversion as aforesaid, then all
references in this Section 2.13(g) shall be deemed to apply, so far as
appropriate and nearly as may be, to such other securities or property.
(h) In case at any time or from time to time Holdings shall
pay any stock dividend or make any other non-cash distribution to the holders of
its Common Stock, or shall offer for subscription pro rata to the holders of its
Common Stock any additional shares of stock of any class or any other right, or
there shall be any capital reorganization or reclassification of the Common
Stock of Holdings or consolidation or merger of Holdings with or into another
corporation, or any sale or conveyance to another corporation of the property of
Holdings as an entirety or substantially as an entirety, or there shall be a
voluntary or involuntary dissolution, liquidation or winding up of Holdings,
then, in any one or more of said cases, Holdings shall give at least 20 days'
prior written notice to the registered holders of the Series B Notes at the
addresses of each as shown on the books of Holdings as of the date on which (i)
the books of Holdings shall close or a record shall be taken for such stock
dividend, distribution or subscription rights or (ii) such non-bankruptcy
reorganization, reclassification, consolidation, merger, sale or conveyance,
dissolution, liquidation or winding up shall take place, as the case may be,
provided that in the case of any Organic Change to which Section 2.13(g) applies
Holdings shall give at least 30 days' prior written notice as aforesaid. Such
notice shall also specify the date as of which the holders of the Common Stock
of record shall participate in said dividend, distribution or subscription
rights or shall be entitled to exchange their Common Stock for securities or
other property deliverable upon such non-bankruptcy reorganization,
reclassification, consolidation, merger, sale or conveyance or participate in
such dissolution, liquidation or winding up, as the case may be. Failure to give
such notice shall not invalidate any action so taken.
(i) Reports as to Adjustments. Upon any adjustment of the
Conversion Price then in effect and any increase or decrease in the number of
shares of Common Stock issuable upon the operation of the conversion set forth
in this Section 2.13, then, and in each such case, Holdings shall promptly
deliver to each holder of the Series B Notes, a certificate signed by the
President or a Vice President and by the Treasurer or
31
<PAGE> 37
an Assistant Secretary of Holdings setting forth in reasonable detail the event
requiring the adjustment and the method by which such adjustment was calculated
and specifying the Conversion Price then in effect following such adjustment and
the increased or decreased number of shares issuable upon the conversion granted
by this Section 2.13, and shall set forth in reasonable detail the method of
calculation of each and a brief statement of the facts requiring such
adjustment. Where appropriate, such notice to holders of the Series B Notes may
be given in advance and included as part of the notice required under the
provisions of Section 11.10.
2.14 Registration Rights. The Notes and the shares of Common
Stock issuable upon conversion of the Series B Notes shall have the benefit of
the registration rights set forth on Exhibit C to this Agreement.
2.15 Legend. Each certificate representing the Notes shall
bear a legend substantially in the following form:
THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS AND MAY NOT
BE, OFFERED OR SOLD UNLESS IT HAS BEEN REGISTERED UNDER SUCH
ACT AND APPLICABLE STATE SECURITIES LAWS OR UNLESS AN
EXEMPTION FROM REGISTRATION IS AVAILABLE.
3. NOTEHOLDERS' REPRESENTATIONS
Each Noteholder severally makes the following representations
and warranties as to itself only to Holdings and the Company, each and all of
which shall survive the execution and delivery of this Agreement and the Closing
hereunder:
3.1 Investment Intention. Each Noteholder is holding the Notes
for its own account, for investment purposes and not with a view to the
distribution thereof. Each Noteholder will not, directly or indirectly, offer,
transfer, sell, assign, pledge, hypothecate or otherwise dispose of the Notes
(or solicit any offers to buy, purchase, or otherwise acquire the Notes), except
in compliance with the Securities Act.
3.2 Accredited Investor. Each Noteholder is an "accredited
investor" (as that term is defined in Rule 501 of Regulation D under the
Securities Act) and by reason of its business and financial experience, it has
such knowledge, sophistication and experience in business and financial matters
as to be capable of evaluating the
32
<PAGE> 38
merits and risks of the prospective investment, is able to bear the economic
risk of such investment and is able to afford a complete loss of such
investment.
3.3 Existence. Each Noteholder is a corporation or limited
partnership, as the case may be, duly organized, validly existing and in good
standing under the laws of its jurisdiction of organization.
3.4 Power; Authorization; Enforceable Obligations. The
execution, delivery and performance by such Noteholder of this Agreement and the
other Note Documents to be executed by it: (i) are within such Noteholder's
corporate or partnership power, as applicable; (ii) have been duly authorized by
all necessary corporate or partnership action, as applicable; (iii) are not in
contra-vention of any provision of such Noteholder's certificate of
incorporation or by-laws, or partnership agreement, or certificate of limited
partnership, as applicable; and (iv) will not violate any law or regulation, or
any order or decree of any Governmental Authority binding on such Noteholder.
This Agreement and the other Note Documents to which such Noteholder is a party
have each been duly executed and delivered by Noteholder and constitute the
legal, valid and binding obligations of such Noteholder, enforceable against it
in accordance with their respective terms, subject to applicable bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and similar laws
affecting creditors' rights and remedies generally, and subject, as to
enforceability, to general principles of equity, including principles of
commercial reasonableness, good faith and fair dealing (regardless of whether
enforcement is sought in a proceeding at law or in equity).
3.5 Ownership of Notes and Warrants. The Noteholders are the
beneficial owners of, and have good and marketable title to, the Subordinated
Rollover Notes and the Warrants and, on the Closing Date will deliver for
exchange their interests in the Subordinated Rollover Notes and the Warrants,
free and clear of all Liens, options, purchase rights, contracts, commitments,
equities, claims and demands. No Noteholder is a party to any option, warrant,
purchase right or other contract or commitment that could require such
Noteholder to sell, transfer or dispose of any of the Subordinated Rollover
Notes, Warrants, or any Common Stock or other property issuable upon exercise of
the Warrants (other than this Agreement). No Noteholder is a party to any voting
trust, proxy or other agreement or understanding with respect to voting of any
capital stock of Holdings.
33
<PAGE> 39
4. REPRESENTATIONS AND WARRANTIES
Each of Holdings and the Company makes the following
representations and warranties to the Noteholders on the date hereof and on the
Closing Date, each and all of which shall survive the execution and delivery of
this Agreement and the Closing hereunder:
4.1 Securities Laws. The exchange of the Subordinated Rollover
Notes and Warrants for New Notes and the Deferred Warrant Consideration, as
provided in this Agreement, are exempt from the registration requirements of the
Securities Act by virtue of Section 3(a)(9) thereof, and all applicable state
securities laws, and are otherwise in compliance with such laws. Neither the
Company nor any Person acting on its behalf has taken or will take any action
(including, without limitation, any offering of any securities of the Company
under circumstances which would require the integration of such offering with
the offering of the New Notes under the Securities Act and the rules and
regulations of the SEC thereunder) which might subject the offering, issuance or
exchange of the New Notes to the registration requirements of Section 5 of the
Securities Act.
4.2 Organization; Powers. Each of Holdings, the Company and
the Subsidiaries (a) is a corporation or partnership duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
organization, (b) has all requisite power and authority, and has in effect all
the requisite permits, approvals and other authorizations from all applicable
Governmental Authorities, to own its property and assets and to carry on its
business as now conducted and as proposed to be conducted, except where the
failure to have any such power or authority could not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect, (c) is
qualified to do business in every jurisdiction where such qualification is
required, except where the failure so to qualify could not reasonably be
expected to, individually or in the aggregate, result in a Material Adverse
Effect, and (d) in the case of the Coram Parties, has the corporate power and
authority to execute, deliver and perform its obligations under each of the Note
Documents and each other agreement or instrument contemplated thereby to which
it is or will be a party and, in the case of the Company, to issue the Notes
hereunder.
4.3 Authorization. The execution, delivery and performance by
each of Holdings, the Company and the other Coram Parties of each of the Note
Documents to which it is party and the issuance of the Notes hereunder (the
"Transactions") (a) have been duly authorized by all requisite corporate and, if
required, stockholder action and (b) will not (i) violate (A) any provision of
law, statute, rule or regulation, or of the certificate or articles of
incorporation or other constitutive documents or by-laws of Holdings, the
Company or any Coram Party, (B) any order of any Governmental Authority or (C)
except as set forth on Schedule 4.3, any provision of any indenture,
34
<PAGE> 40
agreement or other instrument to which Holdings, the Company or any Subsidiary
is a party or by which any of them or any of their property is or may be bound,
except, in the case of this clause (C), to the extent any such violations could
not reasonably be expected, individually or in the aggregate, to result in a
Material Adverse Effect or to adversely affect the Noteholders in any material
respect, (ii) be in conflict with, result in a breach of or constitute (alone or
with notice or lapse of time or both) a default under any such indenture,
agreement or other instrument that is material to any Coram Party or (iii)
result in the creation or imposition of any Lien upon or with respect to any
property or assets now owned or hereafter acquired by Holdings, the Company or
any Subsidiary.
4.4 Enforceability. This Agreement has been duly executed and
delivered by Holdings and the Company and constitutes, and each other Note
Document when executed and delivered by the Company and each other Coram Party
thereto will constitute, a legal, valid and binding obligation of the Company
and such Coram Party enforceable against the Company and such Coram Party in
accordance with its terms, subject to applicable bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and similar laws affecting
creditors' rights and remedies generally, and subject, as to enforceability, to
general principles of equity, including principles of commercial reasonableness,
good faith and fair dealing (regardless of whether enforcement is sought in a
proceeding at law or in equity).
4.5 Governmental Approvals. No action, consent or approval of,
registration or filing with or any other action by any Governmental Authority is
or will be required in connection with the Transactions, except for those set
forth on Schedule 4.5 which have been or will be made or obtained on or prior to
the Closing Date and are or will on the Closing Date be in full force and
effect.
4.6 Financial Statements. The Company has heretofore furnished
to the Noteholders (a) the consolidated balance sheets and statements of income
and cashflows of Holdings as of and for each of the fiscal years ended December
31, 1995, 1996 and 1997, respectively, audited by and accompanied by the opinion
of Ernst & Young LLP, independent public accountants. Such financial statements
present fairly the financial condition and results of operations and cashflows
of Holdings and its consolidated subsidiaries, as of such dates and for such
periods. Such balance sheets and the notes thereto disclose all material
liabilities, direct or contingent, of Holdings and its consolidated subsidiaries
as of the dates thereof. Such financial statements were prepared in accordance
with GAAP applied on a consistent basis, except as otherwise indicated in the
notes thereto.
35
<PAGE> 41
4.7 No Material Adverse Change. There has been no material
adverse change in the business, assets, operations, properties, financial
condition or prospects of Holdings, the Company and the Subsidiaries, taken as a
whole, in each case since December 31, 1997.
4.8 Title to Properties; Possession Under Leases. (a) Each of
Holdings, the Company and their Subsidiaries has good and marketable title to,
or valid leasehold interests in, all its material properties and assets, except
for minor defects in title that do not interfere with its ability to conduct its
business as currently conducted or to utilize such properties and assets for
their intended purposes. All such material properties and assets are free and
clear of Liens, other than Liens expressly permitted by Section 6.2 ("Permitted
Liens").
(b) Each of Holdings, the Company and the Subsidiaries has
complied with all obligations under all leases to which it is a party and all
such leases are in full force and effect, except for any instances of
noncompliance and such failures of such leases to be in full force and effect
that, individually or in the aggregate, could not reasonably be expected to
result in a Material Adverse Effect. Each of Holdings, the Company and the
Subsidiaries enjoys peaceful and undisturbed possession under all such leases
except to the extent that the failure to enjoy such peaceful and undisturbed
possession could not reasonably be expected to result in a Material Adverse
Effect.
4.9 Subsidiaries and Joint Ventures. (a) Except as may result
from the exercise of the Bank Warrants by the holders thereof for shares of the
Company, Holdings directly owns 100% of the capital stock of the Company and
does not and shall not own directly any equity interest in any other Person and
(b) Schedule 4.9 sets forth as of the Closing Date a list of all the
Subsidiaries, Designated Subsidiaries and Joint Ventures and the direct or
indirect percentage ownership interest of the Company therein.
4.10 Litigation; Compliance with Laws. (a) Except as set forth
on Schedule 4.10, there are not any actions, suits or proceedings at law or in
equity or by or before any Governmental Authority now pending or, to the
knowledge of Holdings or the Company, threatened against or affecting Holdings,
the Company or any Subsidiary or any business, property or rights of any such
Person (i) that involve any Note Document or the Transactions or (ii) as to
which there is a reasonable possibility of an adverse determination and which,
if adversely determined, could reasonably be expected, individually or in the
aggregate, to result in a Material Adverse Effect.
(b) None of Holdings, the Company or any of the Subsidiaries
nor any
36
<PAGE> 42
of their respective properties or assets is in violation of, nor is the
continued operation of their material properties and assets as currently
conducted reasonably expected to violate, any law, rule or regulation (including
any Health Care Law, any zoning, building, Environmental Law, ordinance, code or
approval or any building permits), or is in default with respect to any
judgment, writ, injunction or decree of any Governmental Authority, where such
violation or default could reasonably be expected individually or in the
aggregate, to result in a Material Adverse Effect.
(c) Except as set forth on Schedule 4.10, there currently
exists (i) no assertion of any claim of material violation by Holdings, the
Company or any of the Subsidiaries of the Physician Self-Referral Laws, and (ii)
no active inquiry, investigation or audit with respect to the compliance of
Holdings, the Company or any of the Subsidiaries with the Physician
Self-Referral Laws, in either case that could reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Effect.
4.11 Agreements. (a) None of Holdings, the Company or any of
the Subsidiaries is a party to any agreement or instrument or subject to any
corporate restriction that has resulted or could reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Effect or to
materially adversely affect the rights, remedies and benefits available to the
Noteholders under any Note Document.
(b) None of Holdings, the Company or any of the Subsidiaries
is in default in any manner under any provision of any indenture or other
agreement or instrument evidencing Indebtedness, or any other material agreement
or instrument to which it is a party or by which it or any of its properties or
assets are or may be bound, where such default could reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Effect or to
materially adversely affect the rights, remedies and benefits available to the
Noteholders under any Note Document.
4.12 Federal Reserve Regulation. None of Holdings, the Company
or any of the Subsidiaries is engaged principally, or as one of its important
activities, in the business of extending credit for the purpose of purchasing or
carrying margin stock.
4.13 Investment Company Act; Public Utility Holding Company
Act. Neither the Company nor any Subsidiary is (a) an "investment company" as
defined in, or subject to regulation under, the Investment Company Act of 1940
or (b) a "holding company" as defined in, or subject to regulation under, the
Public Utility Holding Company Act of 1935.
37
<PAGE> 43
4.14 Tax Returns. Each of Holdings, the Company and the
Subsidiaries has filed or caused to be filed all federal, state and local tax
returns required to have been filed by it and has paid or caused to be paid all
taxes due and payable by it and all assessments received by it, except for (a)
state and local taxes, fees and assessments that could not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect or
to materially adversely affect the rights, remedies and benefits available to
the Noteholders under any Note Document and (b) taxes that are being contested
in good faith by appropriate proceedings and for which the Company shall have
set aside on its books adequate reserves.
4.15 No Material Misstatements. The written information,
reports, financial statements, exhibits and schedules furnished by or on behalf
of the Company to the Noteholders in connection with the negotiation of any Note
Document or included therein or delivered pursuant thereto, taken as a whole,
did and do not contain any material misstatement of fact or did and do not omit
to state any material fact necessary to make the statements therein, in the
light of the circumstances under which they were, are or will be made, not
misleading, provided that to the extent any such information, report, financial
statement, exhibit or schedule was based upon or constitutes a forecast,
projection or other forward-looking statements, the Company represents only that
it acted in good faith and utilized reasonable assumptions based on information
available to it at the time of preparation thereof and due care in the
preparation of such information, report, financial statement, exhibit or
schedule (it being understood that forecasts, projections and other
forward-looking statements by their nature involve approximations and
uncertainties).
4.16 Employee Benefit Plans. Each of Holdings, the Company and
its ERISA Affiliates is in compliance in all material respects with the
applicable provisions of ERISA and the Code and the regulations and published
interpretations thereunder. No Reportable Event has occurred in respect of any
Plan of Holdings, the Company or any ERISA Affiliate that could reasonably be
expected to have a Material Adverse Effect. The present value of all benefit
liabilities under each Plan (based on those assumptions used to fund such Plan)
did not, as of the last annual valuation date applicable thereto, materially
exceed the value of the assets of such Plan. Neither Holdings, the Company nor
any ERISA Affiliate has incurred any Withdrawal Liability that could reasonably
be expected to have a Material Adverse Effect. Neither Holdings, the Company nor
any ERISA Affiliate has received any notification that any Multiemployer Plan is
in reorganization or has been terminated, within the meaning of Title IV of
ERISA, and no Multiemployer Plan is reasonably expected to be in reorganization
or to be terminated, where such reorganization or termination has resulted or
can reasonably be expected to result in an increase in the contributions
38
<PAGE> 44
required to be made to such Plan that could reasonably be expected to have a
Material Adverse Effect.
4.17 Environmental Matters. (a) The properties owned or
operated by Holdings, the Company and the Subsidiaries (the "Properties") do not
contain any Hazardous Materials in amounts or concentrations that (i)
constitute, or constituted a violation of, or (ii) could give rise to liability
under, Environmental Laws, which violations and liabilities, in the aggregate,
could reasonably be expected to result in a liability to Holdings, the Company
and the Subsidiaries in excess of $5,000,000.
(b) The Properties and all operations of Holdings, the Company
and the Subsidiaries are in compliance, and in all prior periods have been in
compliance, with all Environmental Laws and all necessary Environmental Permits
have been obtained and are in effect, except to the extent that such
non-compliance or failure to obtain any necessary permits, in the aggregate,
could not reasonably be expected to result in a liability to Holdings, the
Company and the Subsidiaries in excess of $5,000,000.
(c) There have been no Releases or threatened Releases at,
from, under or proximate to the Properties or otherwise in connection with the
operations of Holdings, the Company or the Subsidiaries, which Releases or
threatened Releases, in the aggregate, could reasonably be expected to result in
a liability to Holdings, the Company and the Subsidiaries in excess of
$5,000,000.
(d) None of Holdings, the Company or any of the Subsidiaries
has received any notice of an Environmental Claim in connection with the
Properties or the operations of the Company or the Subsidiaries or with regard
to any Person whose liabilities for environmental matters Holdings, the Company
or the Subsidiaries has retained or assumed, in whole or in part, contractually,
by operation of law or otherwise, that, in the aggregate, could reasonably be
expected to result in a liability to Holdings, the Company and the Subsidiaries
in excess of $5,000,000, nor do Holdings, the Company or the Subsidiaries have
reason to believe that any such notice will be received or is being threatened.
(e) Hazardous Materials have not been transported from the
Properties, nor have Hazardous Materials been generated, treated, stored or
disposed of at, on or under any of the Properties in a manner that could
reasonably be expected to give rise to liability under any Environmental Law
that could reasonably be expected to result in a liability to Holdings, the
Company and the Subsidiaries in excess of $5,000,000, nor have any of Holdings,
the Company or the Subsidiaries retained or assumed any liability,
contractually, by operation of law or otherwise, with respect to the generation,
39
<PAGE> 45
treatment, storage or disposal of Hazardous Materials, which transportation,
generation, treatment, storage or disposal, or retained or assumed liabilities,
in the aggregate, could reasonably be expected to result in a liability to
Holdings, the Company and the Subsidiaries in excess of $5,000,000.
4.18 Insurance. Holdings, the Company and the Subsidiaries
have insurance in such amounts and covering such risks and liabilities as are in
accordance with normal industry practice.
4.19 Solvency. The Company does not intend to, and will not
permit any Subsidiary to, and does not believe that it or any Subsidiary will,
incur debts beyond its ability to pay such debts as they mature, taking into
account the timing of and amounts of cash to be received by it or any such
Subsidiary and the timing of the amounts of cash to be payable on or in respect
of its Indebtedness or the Indebtedness of any such Subsidiary.
4.20 Labor Matters. Except as set forth in Schedule 4.20,
there are no strikes pending or, to the best knowledge of Holdings and the
Company, threatened against the Company or any Subsidiary that could reasonably
be expected, individually or in the aggregate, to result in a Material Adverse
Effect. The hours worked and payment made to employees and the Subsidiaries have
not been in violation of the Fair Labor Standards Act or any other applicable
law dealing with such matters, and all payments due from the Company or any
Subsidiary or for which any claim may be made against the Company or any
Subsidiary, on account of wages and employee health and welfare insurance and
other benefits have been paid or accrued as a liability on the books of the
Company or such Subsidiary, except to the extent that any such violation or any
failure to make such payment or accrual, could not reasonably be expected,
individually or in the aggregate, to result in a Material Adverse Effect.
4.21 Year 2000 Systems. The Company is using its best efforts
to implement the necessary changes to make all material Date Data and
Date-Sensitive Systems Year 2000 Compliant. "Date Data" means any data of any
type that includes date information or which is otherwise derived from,
dependent on or related to date information. "Date-Sensitive System" means any
software, microcode or hardware system or component, including any electronic or
electronically controlled system or component, that processes any Date Data and
that is installed, in development or on order by the Coram Parties for their
internal use, or which the Coram Parties sell, lease, license, assign or
otherwise provide, or the provision or operation of which the Coram Parties
provides the benefit, to its customer, vendors, suppliers, affiliates or any
other third party. "Year 2000 Compliant" means (i) with respect to Date Data,
that such
40
<PAGE> 46
data is in proper format and accurate for all dates in the twentieth and
twenty-first centuries, and (ii) with respect to Date-Sensitive Systems, that
each such system accurately processes all Date Data, including for the twentieth
and twenty-first centuries, without loss of any functionality or performance,
including but not limited to calculating, comparing, sequencing, storing and
displaying such Date Data (including all leap year considerations), when used as
a stand-alone system or in combination with other software or hardware.
5. AFFIRMATIVE COVENANTS
Each of Holdings and the Company covenants and agrees with
each Noteholder that, so long as any Notes are outstanding, unless the Required
Holders shall otherwise consent in writing, Holdings and the Company will, and
will cause each of its Subsidiaries to:
5.1 Existence; Businesses and Properties. (i) Do or cause to
be done all things necessary to preserve, renew and keep in full force and
effect its legal existence, except as otherwise expressly permitted under
Section 6.5.
(ii)(a) Do or cause to be done all things necessary to obtain,
preserve, renew, extend and keep in full force and effect the rights, licenses,
permits, franchises, authorizations, patents, copyrights, trademarks and trade
names necessary for the conduct of its business; (b) maintain and operate such
business prudently in accordance with applicable industry practice; (c) comply
with all applicable laws, rules, regulations (including any Health Care Law, any
zoning or building law, any Environmental Law and any ordinance, code or
approval) and orders of any Governmental Authority, whether now in effect or
hereafter enacted; and (d) at all times maintain and preserve all property
necessary for the conduct of its business and keep such property in good repair,
working order and condition and from time to time make, or cause to be made, all
needful and proper repairs, renewals, additions, improvements and replacements
thereto necessary in order that the business carried on in connection therewith
may be properly conducted at all times, except, in the case of clauses (a), (c)
and (d), to the extent that the failure to comply with such covenants could not
reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect.
5.2 Insurance. With respect to itself and each of its
Subsidiaries (other than the Designated Subsidiaries), keep its insurable
properties adequately insured at all times by financially sound and reputable
insurers; maintain such other insurance, to such extent and against such risks,
including fire and other risks insured against by extended coverage, as is
customary with companies in the same or similar businesses operating in the same
or similar locations, including (i) public liability insurance against
41
<PAGE> 47
claims for personal injury or death or property damage occurring upon, in, about
or in connection with the use of any properties owned, occupied or controlled by
it and (ii) business interruption insurance; and maintain such other insurance
as may be required by law, provided, however, that in no event shall any bonding
requirements that have been or may in the future be imposed under Medicare by
the Healthcare Financing Administration be deemed to be requirements in respect
of insurance for any purpose hereunder.
5.3 Obligations and Taxes. Pay and discharge promptly when due
(i) all taxes, assessments and governmental charges or levies imposed upon it or
upon its income or profits or in respect of its property, before the same shall
become delinquent or in default and (ii) all lawful claims for labor, materials
and supplies or otherwise that, if unpaid, could reasonably be expected to give
rise to a Lien upon such properties or any part thereof that would not
constitute a Permitted Lien hereunder; provided, however, that such payment and
discharge shall not be required with respect to any such tax, assessment,
charge, levy or claim so long as the validity or amount thereof shall be
contested in good faith by appropriate proceedings and the Company shall have
set aside on its books adequate reserves with respect thereto and such contest
operates to suspend collection of the contested obligation, tax, assessment or
charge and enforcement of a Lien.
5.4 Financial Statements, Reports, Etc. In the case of
Holdings, furnish to each Significant Noteholder:
(i) within 90 days after the end of each fiscal year, (a)
its consolidated and consolidating balance sheets and related
statements of operations and stockholders' equity and consolidated
statement of cash flows showing the financial condition of Holdings and
its consolidated subsidiaries as of the close of such fiscal year and
the results of its operations and the operations of such subsidiaries
during such year, all audited by Ernst & Young LLP or other independent
public accountants of recognized national standing and accompanied by
an opinion of such accountants (which shall not be qualified in any
material respect) to the effect that such consolidated financial
statements fairly present the financial condition, results of
operations and cashflows of Holdings on a consolidated basis in
accordance with GAAP consistently applied and (b) a comparison of such
annual results to the budget prepared by the Company with respect to
such fiscal year;
(ii) within 45 days after the end of each of the first
three fiscal quarters of each fiscal year, the Company's quarterly
report on Form 10-Q for
42
<PAGE> 48
each such period;
(iii) concurrently with any delivery of financial
statements under (i) or (ii) above, a certificate of the accounting
firm or Financial Officer opining on or certifying such statements
(which certificate, when furnished by an accounting firm, may be
limited to accounting matters and disclaim responsibility for legal
interpretations) (a) certifying that no Event of Default or Default has
occurred or, if such an Event of Default or Default has occurred,
specifying the nature and extent thereof and any corrective action
taken or proposed to be taken with respect thereto and (b) setting
forth computations in reasonable detail satisfactory to the Noteholders
setting forth the calculations required by Sections 2.4(b) and 2.4(d)
of this Agreement on the relevant dates and for the relevant periods
under such Sections;
(iv) not later than thirty days after approval by
Holdings' Board of Directors, (a) the budget for such fiscal year
prepared by the Company and (b) financial projections of Holdings and
its consolidated subsidiaries through the greater of three years and
those that are actually prepared and available, containing
substantially the same information as is required to be provided under
the Senior Loan Agreement, all certified by the chief financial officer
of Holdings to be a good faith estimate of the forecasted financial
performance of Holdings and its consolidated subsidiaries for such
period based on the information available to Holdings at the time of
preparation;
(v) not later than 60 days after the end of each fiscal
quarter, a certificate of a Financial Officer of Holdings setting forth
(a) a list of all Designated Subsidiaries added or terminated during
such fiscal quarter, and (b) a list of all Joint Ventures created,
acquired, terminated or otherwise disposed of during such fiscal
quarter;
(vi) promptly after the same become publicly available,
copies of all periodic and other reports, proxy statements and other
materials filed by it with the SEC, or with any national securities
exchange, or distributed to its shareholders generally, as the case may
be (with the exhibits relating thereto to be provided, at the Company's
expense, upon the request of any Noteholder); and
(vii) (a) at the time the same is provided to the Senior
Agent or any Senior Lender under the Senior Loan Agreement, any
information provided to such Persons pursuant to the provisions thereof
and (b) promptly, from time
43
<PAGE> 49
to time, such other information regarding the operations, business
affairs and financial condition of the Company or any Subsidiary, or
compliance with the terms of any Note Document, as the Noteholders may
reasonably request.
Copies of all reports delivered as provided in subsection (vi) above that
include the information required in subsections (i) and (ii) above shall to that
extent be deemed to satisfy the requirements of such subsections (i) and (ii).
5.5 Litigation and Other Notices. Furnish to the Noteholders
prompt (but in any event within five Business Days thereof) written notice of
the following:
(i) any Event of Default or Default, specifying the
nature and extent thereof and the corrective action (if any) proposed
to be taken with respect thereto;
(ii) the filing or commencement of, or any threat or
notice of intention of any Person to file or commence, any action, suit
or proceeding, whether at law or in equity or by or before any
Governmental Authority, against the Company or any Affiliate thereof
that could reasonably be expected to result in a Material Adverse
Effect; and
(iii) any other development that has resulted in, or could
reasonably be expected to result in, a Material Adverse Effect.
5.6 Employee Benefits. (i) Comply in all material respects
with the applicable provisions of ERISA and the Code and (ii) furnish to the
Noteholders (a) as soon as possible after, and in any event within 30 days after
any Responsible Officer of Holdings, the Company or any ERISA Affiliate knows or
has reason to know that, any Reportable Event has occurred that alone or
together with any other Reportable Event could reasonably be expected to result
in liability of Holdings, the Company or any ERISA Affiliate to the PBGC in an
aggregate amount exceeding $1,000,000, a statement of a Financial Officer
setting forth details as to such Reportable Event and the action that the
Company proposes to take with respect thereto, together with a copy of the
notice, if any, of such Reportable Event given to the PBGC, (b) promptly after
receipt thereof, a copy of any notice that Holdings, the Company or any ERISA
Affiliate may receive from the PBGC relating to the intention of the PBGC to
terminate any Plan or Plans (other than a Plan maintained by an ERISA Affiliate
that is considered an ERISA Affiliate only pursuant to subsection (m) or (o) of
Code Section 414) or to appoint a trustee to administer any such Plan, (c)
within 10 days after the due date for filing with the PBGC pursuant to Section
412(n) of the Code a notice of failure
44
<PAGE> 50
to make a required installment or other payment with respect to a Plan, a
statement of a Financial Officer setting forth details as to such failure and
the action that the Company proposes to take with respect thereto, together with
a copy of any such notice given to the PBGC and (d) promptly and in any event
within 30 days after receipt thereof by Holdings, the Company or any ERISA
Affiliate from the sponsor of a Multiemployer Plan, a copy of each notice
received by Holdings, the Company or any ERISA Affiliate concerning (A) the
imposition of Withdrawal Liability or (B) a determination that a Multiemployer
Plan is, or is expected to be, terminated or in reorganization, both within the
meaning of Title IV of ERISA.
5.7 Maintaining Records; Access to Properties and Inspections.
Maintain all financial records in accordance with GAAP and permit any
representatives designated by any Noteholder to visit and inspect the financial
records and the properties of Holdings, the Company or any Subsidiary at
reasonable times and intervals and as often as reasonably requested, but, except
where a Default or Event of Default has occurred and is continuing, in no event
more than once in any 30 day period and to make extracts from and copies of such
financial records. and permit any representatives designated by any Noteholder
to discuss the affairs, finances and condition of Holdings, the Company or any
Subsidiary with the officers thereof and independent accountants therefor.
5.8 Compliance with Environmental Laws. Comply, and cause all
lessees and other Persons occupying its Properties to comply, in all material
respects with all Environmental Laws and Environmental Permits applicable to its
operations and Properties; obtain and renew all material Environmental Permits
necessary for its operations and Properties; and conduct any Remedial Action in
accordance with Environmental Laws, except to the extent that any failure to
comply with the foregoing could not reasonably be expected, individually or in
the aggregate, to result in a liability to Holdings, the Company and the
Subsidiaries in excess of $5,000,000.
5.9 Preparation of Environmental Reports. If a default caused
by reason of a breach of Section 4.17 or 5.8 shall have occurred and be
continuing, at the request of the Required Holders, provide to Noteholders
within 45 days (or such longer period as shall reasonably be required, so long
as the Required Holders do not object thereto) after such request, at the
expense of the Company, an environmental site assessment report for the
Properties that are the subject of such default prepared by an environmental
consulting firm acceptable to the Noteholders, indicating the presence or
absence of Hazardous Materials and a good faith estimate of the cost of any
compliance or Remedial Action in connection with such Properties.
45
<PAGE> 51
5.10 Further Assurances. Execute any and all further
documents, agreements and instruments, and take all further action that may be
required under applicable law, or which the Noteholders may reasonably request,
in order to effectuate the transactions contemplated by the Note Documents.
5.11 Compliance Procedures. At all times comply in all
material respects with applicable Physician Self-Referral Laws and maintain
adequate internal audit procedures to assure substantial compliance with
applicable Physician Self-Referral Laws.
5.12 New Amaral Employment Agreement. Use its best efforts to
enter into the New Amaral Employment Agreement by not later than May 31, 1998.
6. NEGATIVE COVENANTS
Each of Holdings and the Company covenants and agrees with
each Noteholder that, so long as any Notes are outstanding, unless the Required
Holders shall otherwise consent in writing, Holdings and the Company will not,
and will not cause or permit any of the Subsidiaries to:
6.1 Indebtedness. Incur, create, assume or permit to exist any
Indebtedness, except:
(i) in the case of Holdings, the Company, each Wholly
Owned Subsidiary and each Subsidiary that is not a Joint Venture,
Indebtedness for borrowed money existing on the date hereof and set
forth in Schedule 6.1 and any extensions, renewals or replacements of
such Indebtedness to the extent that (i) the aggregate principal amount
of such Indebtedness is not at any time increased, (ii) no material
terms applicable to such Indebtedness shall be more favorable to the
extending, renewing or replacement lenders than the terms that are
applicable to the holders of such Indebtedness on the date hereof and
(iii) the interest rate applicable to such Indebtedness shall be a
market interest rate as of the time of such extension, renewal or
replacement;
(ii) in the case of the Company, Senior Debt in an
aggregate principal amount not to exceed $65,000,000 at any time
outstanding;
(iii) in the case of the Guarantors, the guarantees under
the Guarantee Agreements;
46
<PAGE> 52
(iv) in the case of the Company, Interest Rate
Protection Agreements, entered into in order to hedge the interest
payable on up to 100% of the aggregate principal amount of the Senior
Debt outstanding as of the date on which the most recent such Interest
Rate Protection Agreement is entered into, in the form approved by the
Required Holders;
(v) in the case of the Company, Indebtedness created
hereunder;
(vi) intercompany Indebtedness between (a) the Company
and any of the Wholly Owned Subsidiaries, (b) any Wholly Owned
Subsidiaries of the Company and (c) between Holdings and the Company or
any Wholly Owned Subsidiary, in an aggregate amount not exceeding at
any time $2,000,000;
(vii) Indebtedness consisting of Earn-out Obligations not
in excess of $5,000,000 at any time outstanding;
(viii) in the case of the Company, Guarantees issued for
the benefit of any Wholly Owned Subsidiary in respect of obligations
under operating leases and other obligations in the ordinary course of
business;
(ix) Reverse Repurchase Agreements permitted under
Section 6.4(vi);
(x) Indebtedness owing by a Subsidiary existing at the
time such Subsidiary was acquired (or assumed by the Company or such
Subsidiary at the time assets of such Subsidiary were acquired) (and
any extensions, renewals or replacements of such Indebtedness to the
extent that (i) the aggregate principal amount of such Indebtedness is
not at any time increased, (ii) no material terms applicable to such
Indebtedness shall be more favorable to the extending, renewing or
replacement lenders than the terms that are applicable to the holders
of such Indebtedness on the date hereof and (iii) the interest rate
applicable to such Indebtedness shall be a market interest rate as of
the time of such extension, renewal or replacement), provided such
Indebtedness was not incurred or created in connection with or in
contemplation of such acquisition;
(xi) Indebtedness of any Joint Venture owing to
Holdings, the Company or any other Subsidiary to the extent permitted
by Section 6.4(v);
47
<PAGE> 53
(xii) in the case of any Joint Venture or any Subsidiary
that is not a Wholly Owned Subsidiary, Indebtedness for borrowed money
and Capital Lease Obligations existing on the date hereof and set forth
in Schedule 6.1(xii) (and any extensions, renewals or replacements of
such Indebtedness to the extent that (A) the aggregate principal amount
of such Indebtedness is not at any time increased, (B) no material
terms applicable to such Indebtedness shall be more favorable to the
extending, renewing or replacement lenders than the terms that are
applicable to the holders of such Indebtedness on the date hereof and
(C) the interest rate applicable to such Indebtedness shall be a market
interest rate as of the time of such extension, renewal or
replacement);
(xiii) Capital Lease Obligations entered into in the ordinary
course of business not exceeding in the aggregate $5,000,000 at any
time (exclusive of any sale and leaseback transactions permitted by
Section 6.3).
6.2 Liens. Create, incur, assume or permit to exist any Lien
on any property or assets (including stock or other securities of any Person,
including any Subsidiary) now owned or hereafter acquired by it, on any income
or revenues or rights in respect of any thereof, except:
(i) Liens on property or assets of the Company and its
Subsidiaries existing on the date of the Senior Loan Agreement as set
forth in Schedule 6.2 thereto, provided that (subject to the provisions
of subsection (xii) below) such Liens shall secure only those
obligations that they secure on the date hereof;
(ii) any Lien securing the Senior Debt;
(iii) any Lien existing on any property or asset prior to
the acquisition thereof by the Company or any Subsidiary provided that
(i) such Lien is not created in contemplation of or in connection with
such acquisition and (ii) such Lien does not apply to any other
property or assets of the Company or any Subsidiary;
(iv) Liens for taxes not yet due or that are being
contested in compliance with Section 5.3;
(v) carriers', warehousemen's, mechanic's,
materialmen's, repairmen's or other like Liens arising in the ordinary
course of business and
48
<PAGE> 54
securing obligations that are not due and payable or that are being
contested in compliance with Section 5.3;
(vi) pledges and deposits made in the ordinary course of
business in compliance with workmen's compensation, unemployment
insurance and other social security laws or regulations;
(vii) deposits to secure the performance of bids, trade
contracts (other than for Indebtedness), leases (other than Capital
Lease Obligations), statutory obligations, surety and appeal bonds,
performance bonds and other obligations of a like nature incurred in
the ordinary course of business;
(viii) zoning restrictions, easements, rights-of-way,
restrictions on use of real property and other similar encumbrances
incurred in the ordinary course of business that, in the aggregate, are
not substantial in amount and do not materially detract from the value
of the property subject thereto or interfere with the ordinary conduct
of the business of the Company or any of its Subsidiaries;
(ix) any Lien existing or arising by operation of law in
the ordinary course of business of Holdings, the Company and its
Subsidiaries, such as banker's Liens or similar rights of offset;
(x) (a) Liens placed upon real or personal property
acquired or held in the ordinary course of business at the time of
acquisition or improvement of such property to secure the purchase
price thereof or incurred solely to finance the acquisition or
improvement of such property, provided that (A) such Liens do not cover
property other than the property acquired or improved and (B) the
Indebtedness secured by such Liens does not in any case exceed the
lesser of the cost or fair market value of such property at the time of
such acquisition, and (b) liens incurred in connection with Capital
Lease Obligations, so long as the aggregate principal amount of
Indebtedness secured by the Liens permitted pursuant to this paragraph
(x) is permitted pursuant to Section 6.1(xiii);
(xi) attachment or judgment Liens not in excess of
$2,500,000 in the aggregate and any other immaterial attachment or
judgment Lien discharged within 30 days of the entry of judgment or the
expiry of stay (provided that no foreclosure action has been commenced
with respect to such Liens that has not been stayed or discharged
within thirty (30) days); and
49
<PAGE> 55
(xii) Liens incurred in connection with the extension,
renewal or refinancing of the Indebtedness secured by the Liens
described in paragraphs (i), (iii) and (x) above, provided that (a) any
extension, renewal or replacement Lien is limited to the property
encumbered by the existing Lien and the principal amount of the
Indebtedness being extended, renewed or refinanced is not increased and
(ii) the extension, renewal or refinancing of such Indebtedness is
permitted pursuant to Section 6.1.
6.3 Sale and Lease-Back Transactions. Enter into any
arrangement, directly or indirectly, with any Person whereby it shall sell or
transfer any property, real or personal, used or useful in its business, whether
now owned or hereafter acquired, and thereafter rent or lease such property or
other property that it intends to use for substantially the same purpose or
purposes as the property being sold or transferred, except for the sale and
lease-back of the Sabratek pumps or any similar arrangements entered into
amending or in replacement of such arrangement and except that the Company or
any Subsidiary may enter into any such arrangement with respect to computer
equipment and motor vehicles so long as the aggregate amount of Indebtedness
incurred in connection with such arrangements does not exceed $5,000,000 at any
time outstanding.
6.4 Investments, Loans and Advances. Purchase, hold or acquire
any capital stock, evidences of Indebtedness or other securities of, make or
permit to exist any loans or advances to, or make or permit to exist any
investment or any other interest in, any other Person (each, an "Investment"),
except:
(i) (a) Investments by the Company or any Subsidiary
Guarantor permitted by Section 6.4(iv) in any Subsidiary Guarantor or
in any Person that, immediately after the making of such Investment, is
a Subsidiary Guarantor, (b) Investments by Holdings in the capital
stock of the Company, (c) Investments by the Company or any Subsidiary
Guarantor made on or prior to the Closing Date in any Joint Venture
that is in existence as of the Closing Date and described on Schedule
6.4(i)(c), (d) Investments by the Company or any Subsidiary Guarantor
made after the Closing Date in any Joint Venture that is in existence
as of the Closing Date and described on Schedule 6.4(i)(d) to purchase
any portion of or all the ownership interest of any partner or co-owner
in such Joint Venture in an aggregate amount not in excess of
$5,000,000 for the period following the date hereof and (e) Investments
by the Company or any Subsidiary Guarantor (A) made after the Closing
Date in any Joint Venture that is described on Schedule 6.4(i)(e)
(other than Investments made pursuant to clause (d)
50
<PAGE> 56
above), (B) in any Joint Venture acquired after the Closing Date in
connection with any acquisition or (C) in any Joint Venture created or
entered into after the Closing Date, provided that the aggregate amount
of additional investments in Joint Ventures pursuant to this clause (e)
shall not exceed $5,000,000 for the period following the date hereof;
(ii) Permitted Investments;
(iii) in the case of the Company, Interest Rate
Protection Agreements permitted pursuant to Section 6.1(iv);
(iv) Acquisitions involving in each case a total
purchase price (either individually or for a series of related
transactions) of not more than $10,000,000;
(v) Investments by Holdings, the Company or any of the
Subsidiaries consisting of loans at arms' length terms to any Person in
which Holdings, directly or indirectly, owns more than a 20% equity
interest (but that is not a Wholly Owned Subsidiary) existing on the
Closing Date and set forth in Schedule 6.4(v), and any extensions,
renewals or replacements of the same, provided that the aggregate
principal amount of such loans are not at any time increased;
(vi) Reverse Repurchase Agreements maturing within 30
days of the date of purchase, provided that the aggregate amount of
such Reverse Repurchase Agreements at any time shall not exceed 75% of
all short-term Investments of Holdings, the Company and the
Subsidiaries;
(vii) other Investments not exceeding $5,000,000 in the
aggregate at any time outstanding;
(viii) Investments arising from transactions by the
Company or any of the Subsidiaries with customers or suppliers in the
ordinary course of business, including debt obligations and other
investments received in connection with the bankruptcy or
reorganization of customers and suppliers and in settlement of
delinquent obligations of, and other disputes with, customers or
suppliers, arising in the ordinary course of business and in the
exercise of the reasonable business judgment of the Company or any
Subsidiary.
(ix) Employee Loans not exceeding $2,000,000 in
aggregate
51
<PAGE> 57
principal amount at any time outstanding; and
(x) acquisitions constituting a transaction permitted by
Section 6.5(iv) or 6.5(vi).
6.5 Mergers, Consolidations, Sales of Assets and Acquisitions.
Merge into or consolidate with any other Person, or permit any other Person to
merge into or consolidate with it, or sell, transfer, lease or otherwise dispose
of (in one transaction or in a series of transactions) all or any substantial
part of its assets (whether now owned or hereafter acquired) or any capital
stock of any Subsidiary, or purchase, lease or otherwise acquire (in one
transaction or a series of transactions) all or any substantial part of the
assets of any other Person, except that:
(i) the Company and any Subsidiary may purchase and sell
inventory and other property and services in the ordinary course of
business;
(ii) the Company may sell (a) readily marketable
securities (A) in the ordinary course of business and (B) in connection
with Reverse Repurchase Agreements permitted pursuant to Section
6.4(vi) and (b) if at the time thereof and immediately after giving
effect thereto no Default or Event of Default shall have occurred and
be continuing, assets (other than readily marketable securities) to the
extent that the aggregate gross cash proceeds therefrom do not exceed
$25,000,000 for the period following the date hereof, provided that (x)
a Financial Officer of the Company certifies on behalf of the Company
that any such sale of assets is estimated by the Company in good faith
to be at a price equal to or greater than the then fair market value of
such asset and (y) in the case of sales of assets in respect of which
the book value is greater than $10,000,000, such sale shall have been
approved by the Board of Directors of the Company;
(iii) the Company may sell, transfer, dissolve, liquidate
or otherwise dispose of shares of stock or securities of any Designated
Subsidiary;
(iv) if at the time thereof and immediately after giving
effect thereto no Event of Default or Default shall have occurred and
be continuing (i) any Wholly Owned Subsidiary may merge into the
Company in a transaction in which the Company is the surviving
corporation and no Person other than the Company or a Wholly Owned
Subsidiary receives any consideration, (ii) any Subsidiary may merge
into or consolidate with any other Wholly Owned Subsidiary in a
transaction in which the surviving entity is a Wholly Owned
52
<PAGE> 58
Subsidiary and no Person other than the Company or a Wholly Owned
Subsidiary receives any consideration and (iii) the Company or any
Subsidiary may make any investment permitted by Section 6.4;
(v) the Company and any Subsidiary may lease and
sublease assets in the ordinary course of business;
(vi) any Subsidiary may sell, assign, pledge or otherwise
transfer any of its assets to the Company or any Subsidiary Guarantor;
and
(vii) any Joint Venture may sell or otherwise dispose of
any of its assets (other than in a sale of all or substantially all its
assets or in a complete liquidation of such Joint Venture).
6.6 Dividends and Distribution. Declare or pay, directly or
indirectly, any dividend or make any other distribution (by reduction of capital
or otherwise), whether in cash, property, securities or a combination thereof,
with respect to any shares of its capital stock or directly or indirectly
redeem, purchase, retire or otherwise acquire for value (or permit any
Subsidiary to purchase or acquire) any shares of any class of its capital stock
or set aside any amount for any such purpose; provided, however, that:
(i) Holdings may declare or distribute dividends payable
solely in its common stock;
(ii) any Subsidiary may declare and pay dividends or make
other distributions to (i) the Company and (ii) any Subsidiary
Guarantor;
(iii) so long as no Event of Default or Default shall have
occurred and be continuing, the Company may (i) declare and pay
dividends or make other distributions to Holdings in order to enable
Holdings to pay any taxes or expenses required to be paid by Holdings
in the ordinary course of business, so long as the aggregate amount of
such dividends or other distributions (other than any such dividends or
other distributions made for the purposes of paying taxes), together
with the aggregate principal amount of any loans made pursuant to
Section 6.1(vi)(c), does not exceed $2,000,000 in any fiscal year;
(iv) any Joint Venture may make distributions to its
owners, and
53
<PAGE> 59
(v) any prepayment, redemption or similar payment on or
in respect of the Notes.
6.7 Transactions with Affiliates. Sell or transfer any
property or assets to, or purchase or acquire any property or assets from, or
otherwise engage in any other transactions with, any of its Affiliates, except
that so long as no Default or Event of Default shall have occurred and be
continuing, the Company or any Subsidiary may engage in any of the foregoing
transactions in the ordinary course of business at prices and on terms and
conditions not less favorable to the Company or such subsidiary than could be
obtained on an arm's-length basis from unrelated third parties, as determined in
good faith by the Board of Directors of Holdings, the Company or such
Subsidiary, as the case may be; provided, however, that no determination of any
such Board of Directors shall be required with respect to (a) any such
transactions entered into in the ordinary course of business, (b) any such
transactions entered into with any Noteholder or any Affiliate of any Noteholder
or (c) transactions with directors, shareholders and employees pursuant to
agreements existing as of the Closing Date and other compensation arrangements
in the ordinary course of business, except that Holdings, the Company or any
Subsidiary may engage in any transaction described on Schedule 6.7.
6.8 Business of Company and Subsidiaries. Engage at any time
in any business or business activity other than (a) in the case of the Company
and the Subsidiaries, the businesses currently conducted by it or them or a
business substantially similar thereto and business activities reasonably
incidental thereto and (b) in the case of Holdings, the ownership of all the
outstanding common stock of the Company and business activities reasonably
incidentally hereto.
6.9 Fiscal Year. Change the end of its fiscal year from
December 31 to any other date.
6.10 Other Agreements. (i) Take or omit to take any action,
which act or omission would constitute a default or event of default under any
agreement, document or instrument to which it is a party.
(ii) Permit any Subsidiary Guarantor to enter into any
agreement or investment that by its terms restricts the payment of
dividends or the making of cash advances by such Subsidiary to the
Company or any Subsidiary that is a direct or indirect parent of such
Subsidiary.
54
<PAGE> 60
7. CONDITIONS PRECEDENT
7.1 Conditions Precedent. The obligation of the Noteholders to
exchange the Subordinated Rollover Notes and the Warrants for the New Notes and
the Deferred Warrant Consideration pursuant to Section 2.1 hereof, is subject to
the condition that each Noteholder shall have received, on the Closing Date, the
following, each dated the Closing Date unless otherwise indicated, in form and
substance satisfactory to Noteholders:
(a) (i) The Notes duly executed by the Company and payable to
and registered in the name of each Noteholder, respectively; and (ii) the
Holdings Guarantee and each Subsidiary Guarantee, duly executed by Holdings and
each Subsidiary Guarantor.
(b) Favorable opinion of Paul, Hastings, Janofsky & Walker
LLP, counsel to the Company, substantially in the form attached hereto as
Exhibit D, it being understood that to the extent that such opinion of counsel
to the Company shall rely upon any other opinion of counsel, each such other
opinion shall be in form and substance reasonably satisfactory to the
Noteholders and shall provide that the Noteholders may rely thereon.
(c) Resolutions of the board of directors of the each Coram
Party, certified by the Secretary or Assistant Secretary of the such Coram
Party, as of the Closing Date, to be duly adopted and in full force and effect
on such date, authorizing (i) the consummation of each of the transactions
contemplated by this Agreement and (ii) specific officers to execute and deliver
this Agreement and each other Note Document to which it is a party.
(d) Governmental certificates, dated the most recent
practicable date prior to the Closing Date, showing that each of Holdings, the
Company and the Significant Subsidiary is organized and existing in the
jurisdiction of its organization and is qualified as a foreign corporation and
in good standing in all other jurisdictions in which it is qualified to transact
business.
(e) A copy of the articles or certificate of incorporation and
all amendments thereto of each of Holdings, the Company and the Significant
Subsidiary, certified as of a recent date by the Secretary of State of such
Coram Party's jurisdiction of organization, and copies of the each Coram Party's
by-laws, certified by the Secretary or Assistant Secretary of each Coram Party
as true and correct as of the Closing Date.
55
<PAGE> 61
(f) The New Amaral Employment Agreement and the New Healthcare
Non-Compete Agreement, duly executed by Holdings, the Company and Donald Amaral
(the condition precedent in this paragraph being the "Employment Agreement
Condition").
(g) The Home Healthcare Non-Compete Agreement and the Initial
Healthcare Non-Compete Agreement, duly entered by Holdings, the Company and
Donald Amaral on or prior to May 31, 1998.
(h) The issuance of the Series B Notes shall have been
approved by the holders of the Common Stock (such approval being the
"Stockholder Approval" and the condition precedent in this paragraph, the
"Stockholder Approval Condition").
(i) Certificates of the Secretary or an Assistant Secretary of
each Coram Party, dated the Closing Date, as to the incumbency and signatures of
the officers of each Coram Party executing this Agreement, the Notes, each other
Note Document to which it is a party and any other certificate or other document
to be delivered pursuant hereto or thereto, together with evidence of the
incumbency of such Secretary or Assistant Secretary.
(j) Certificate of the Chief Financial Officer of the Company,
dated the Closing Date, stating that all of the representations and warranties
of the Company and Holdings contained herein or in the other Note Documents are
true and correct on and as of the Closing Date as if made on such date and that
no breach of any covenant contained in Article 6 and no Default or Event of
Default has occurred or would result from the Closing hereunder.
(k) Copies of all documentation evidencing all Indebtedness of
the Company existing on the Closing Date, including any documentation relating
to the Senior Debt, the terms of which shall be satisfactory to the Noteholders.
(l) All conditions to funding under the Senior Loan Agreement
shall have been satisfied and amounts shall be immediately available for drawing
thereunder (subject to any requirement for notices of borrowing).
7.2 Additional Conditions. The obligation of each Noteholder
to exchange its Notes and Warrants pursuant to Section 2.1 hereof is subject to
the additional conditions precedent that:
56
<PAGE> 62
(a) There shall not have occurred any event or condition since
December 31, 1997 which could have a Material Adverse Effect.
(b) All of the representations and warranties of Holdings and
the Company contained herein or in the other Note Documents shall be true and
correct on and as of the Closing Date as if made on such date and no breach of
any covenant contained in Article 6 or Default or Event of Default shall have
occurred or would result from the Closing hereunder.
(c) The Closing shall have occurred no later than June 30,
1998.
8. EVENTS OF DEFAULT; RIGHTS AND REMEDIES
8.1 Events of Default. The occurrence of any one or more of
the following events (regardless of the reason therefor) shall constitute an
"Event of Default" hereunder and under the Notes:
(a) any representation or warranty made or deemed made in or
in connection with any Note Document or the Notes, or any
representation, warranty, statement or information contained in any
report, certificate, financial statement or other instrument furnished
in connection with or pursuant to any Note Document, shall prove to
have been false or misleading in any material respect when so made,
deemed made or furnished;
(b) default shall be made in the payment of any principal of
any Note when and as the same shall become due and payable, whether at
the due date thereof or at a date fixed for prepayment thereof or by
acceleration thereof or otherwise;
(c) default shall be made in the payment of any interest or
premium on any Note or any fee or any other amount including, without
limitation, the Deferred Warrant Consideration, (other than an amount
referred to in (b) above) due under any Note Document, when and as the
same shall become due and payable, and such default shall continue
unremedied for a period of five days;
(d) default shall be made in the due observance or performance
by Holdings, the Company or any Subsidiary of any covenant, condition
or agreement contained in Sections 5.1(i), 5.5, 5.9 or in Article 6;
(e) default shall be made in the due observance or performance
by
57
<PAGE> 63
Holdings, the Company or any Subsidiary of any covenant, condition or
agreement contained in any Note Document (other than those specified in
(b), (c) or (d) above) and such default shall continue unremedied for a
period of 30 days after written notice thereof from the Noteholders or
any Noteholder to the Company;
(f) Holdings, the Company or any Subsidiary shall (i) fail to
pay any principal or interest, regardless of amount, due in respect of
any Indebtedness in a principal amount in excess of $1,000,000 when and
as the same shall become due and payable, or (ii) fail to observe or
perform any other term, covenant, condition or agreement contained in
any agreement or instrument evidencing or governing any such
Indebtedness if the effect of any failure referred to in this clause
(ii) is to cause, or to permit the holder or holders of such
Indebtedness or a trustee on its or their behalf (with or without the
giving of notice, the lapse of time or both) to cause, such
Indebtedness to become due prior to its stated maturity;
(g) an involuntary proceeding shall be commenced or an
involuntary petition shall be filed in a court of competent
jurisdiction seeking (i) relief in respect of Holdings, the Company or
any Subsidiary, or of a substantial part of the property or assets of
Holdings, the Company or a Subsidiary, under Title 11 of the United
States Code, as now constituted or hereafter amended, or any other
federal or state bankruptcy, insolvency, receivership or similar law,
(ii) the appointment of a receiver, trustee, custodian, sequestrator,
conservator or similar official for Holdings, the Company or any
Subsidiary or for a substantial part of the property or assets of
Holdings, the Company or a Subsidiary or (iii) the winding-up or
liquidation of Holdings, the Company or any Subsidiary; and such
proceeding or petition shall continue undismissed for 30 days or an
order or decree approving or ordering any of the foregoing shall be
entered;
(h) Holdings, the Company or any Subsidiary shall (i)
voluntarily commence any proceeding or file any petition seeking relief
under Title 11 of the United States Code, as now constituted or
hereafter amended, or any other federal or state bankruptcy,
insolvency, receivership or similar law, (ii) consent to the
institution of, or fail to contest in a timely and appropriate manner,
any proceeding or the filing of any petition described in (g) above,
(iii) apply for or consent to the appointment of a receiver, trustee,
custodian, sequestrator, conservator or similar official for Holdings,
the Company or any Subsidiary or for a substantial part of the property
or assets of Holdings, the Company or any Subsidiary, (iv) file an
answer admitting the material allegations of a petition
58
<PAGE> 64
filed against it in any such proceeding, (v) make a general assignment
for the benefit of creditors, (vi) become unable, admit in writing its
inability or fail generally to pay its debts as they become due or
(vii) take any action for the purpose of effecting any of the
foregoing;
(i) one or more judgments for the payment of money in an
aggregate amount that is not covered by insurance in excess of
$5,000,000 shall be rendered against Holdings, the Company, any
Subsidiary or any combination thereof and the same shall remain
undischarged for a period of 30 consecutive days during which execution
shall not be effectively stayed, or any action shall be legally taken
by a judgment creditor to levy upon assets or properties of Holdings,
the Company or any Subsidiary to enforce any such judgment;
(j) (i) a Reportable Event or Reportable Events, or a failure
to make a required installment or other payment (within the meaning of
Section 412(n)(1) of the Code), shall have occurred with respect to any
Plan or Plans that reasonably could be expected to result in liability
of Holdings or the Company to the PBGC or to a Plan in an aggregate
amount exceeding $5,000,000 and, within 30 days after the reporting of
any such Reportable Event to the Noteholders or after the receipt by
the Noteholders of a statement required pursuant to Section 5.6(ii)(c)
hereof, the Noteholders shall have notified the Company in writing that
(A) the Required Holders have made a reasonable determination that, on
the basis of such Reportable Event or Reportable Events or the failure
to make a required payment, there are reasonable grounds for the
termination of such Plan or Plans by the PBGC, the appointment by the
appropriate United States district court of a trustee to administer
such Plan or Plans or the imposition of a lien in favor of a Plan and
(B) as a result thereof an Event of Default exists hereunder; or (ii) a
trustee shall be appointed by a United States district court to
administer any such Plan or Plans; or (iii) the PBGC shall institute
proceedings (including giving notice of intent thereof) to terminate
any such Plan or Plans;
(k) (i) Holdings, the Company or any ERISA Affiliate shall
have been notified by the sponsor of a Multiemployer Plan that it has
incurred Withdrawal Liability to such Multiemployer Plan, (ii)
Holdings, the Company or such ERISA Affiliate does not have reasonable
grounds for contesting such Withdrawal Liability or is not contesting
such Withdrawal Liability in a timely and appropriate manner and (iii)
the amount of such Withdrawal Liability specified in such notice, when
aggregated with all other amounts required to be paid to Multiemployer
Plans in connection with Withdrawal Liabilities
59
<PAGE> 65
(determined as of the date or dates of such notification), either (A)
exceeds $5,000,000 or requires payments exceeding $1,000,000 in any
year or (B) is less than $5,000,000 but any Withdrawal Liability
payment remains unpaid 30 days after such payment is due;
(l) Holdings, the Company or any ERISA Affiliate shall have
been notified by the sponsor of a Multiemployer Plan that such
Multiemployer Plan is in reorganization or is being terminated, within
the meaning of Title IV of ERISA, if solely as a result of such
reorganization or termination the aggregate annual contributions of
Holdings, the Company and its ERISA Affiliates to all Multiemployer
Plans that are then in reorganization or have been or are being
terminated have been or will be increased over the amounts required to
be contributed to such Multiemployer Plans for their most recently
completed plan years by an amount exceeding $5,000,000;
(m) any Guarantee Agreement shall cease to be, or shall be
asserted by Holdings or by any Subsidiary Guarantor, as applicable, not
to be, in full force and effect; or
(n) the New Amaral Employment Agreement or the Non-Compete
Agreements delivered pursuant to Section 7.1(f) and (g) of this
Agreement shall be terminated or shall otherwise cease to be
enforceable or in full force and effect or Donald Amaral shall cease to
be the chief executive officer of the Company for any reason (other
than by reason of his incapacitation or death; or upon expiration of
the original term of such agreements; or upon his removal by majority
vote of the Board of Directors of the Company in which the Board member
appointed by the Noteholders pursuant to Section 10 hereof voted in
favor of such removal (or if no board member has been appointed
pursuant to Section 10, the Required Holders have approved such
removal));
then, and in every such event (other than an event with respect to the Company
described in paragraph (g) or (h) above), and at any time thereafter during the
continuance of such event, the Required Noteholders may, by notice to the
Company, declare the Notes then outstanding to be forthwith due and payable in
whole or in part, whereupon the principal of the Notes so declared to be due and
payable, together with accrued interest and premium, if any, thereon and any
unpaid accrued fees and all other liabilities of the Company accrued hereunder
and under any other Note Document, shall become forthwith due and payable,
without presentment, demand, protest or any other notice of any kind, all of
which are hereby expressly waived by the Company, anything contained herein or
in any other Note Document to the contrary notwithstanding.
60
<PAGE> 66
8.2 Waivers by the Company. Except as otherwise provided for
in this Agreement and applicable law, each of Holdings, the Company and the
Subsidiary Guarantors waives (i) presentment, demand and protest and notice of
presentment, dishonor, notice of intent to accelerate and notice of acceleration
and (ii) the benefit of all valuation, appraisal and exemption laws. Holdings
and the Company acknowledges that it has been advised by counsel of its choice
with respect to this Agreement, the other Note Documents and the transactions
evidenced by this Agreement and the other Note Documents.
8.3 Right of Set-Off. Upon the occurrence and during the
continuance of any Event of Default, each Noteholder is hereby authorized at any
time and from time to time, to the fullest extent permitted by law, to set off
and apply any and all deposits (general or special, time or demand, provisional
or final) at any time held and other indebtedness at any time owing by such
Noteholder to or for the credit or the account of any Coram Party against any
and all of the obligations of such Coram Party now or hereafter existing under
this Agreement, the Holdings Guaranty, the Subsidiary Guarantees and the Notes
held by such Noteholder irrespective of whether or not such Noteholder shall
have made any demand under this Agreement, the Holdings Guaranty, the Subsidiary
Guarantees or the Notes. Each Noteholder agrees promptly to notify the relevant
Coram Party after any such set-off and application made by such Noteholder;
provided, however, that the failure to give such notice shall not affect the
validity of such set-off and application. The rights of each Noteholder under
this Section are in addition to other rights and remedies (including, without
limitation, other rights of set-off) which such Noteholder may have.
61
<PAGE> 67
9. SUBORDINATION
9.1 Notes Subordinated to Senior Debt. The Company covenants
and agrees, and each Noteholder and any other holder of the Notes (each
Noteholder and such holders being hereinafter referred to collectively as
"Holders") by its acceptance thereof likewise covenants and agrees, that all
Obligations of the Company pursuant to this Agreement and all indebtedness
evidenced by the Notes (including without limitation principal thereof and
interest and premium, if any pursuant to Sections 2.6, thereon) (collectively
the "Subordinated Debt") shall be subordinated in accordance with the provisions
of this Section 9 to the prior payment in full of all Senior Debt of the
Company. For purposes of this Section 9, the term "Senior Debt" shall mean the
Senior Debt of the Company and shall include principal of and premium, if any,
and interest on all loans and other extensions of credit under, and all
expenses, fees, reimbursements, indemnities and other amounts owing pursuant to,
the terms of the Senior Debt, to the extent permitted to be incurred pursuant
hereto.
9.2 Priority and Payment Over of Proceeds in
Certain Events.
(a) Subordination on Dissolution, Liquidation or
Reorganization of the Company. Upon payment or distribution of assets or
securities of the Company of any kind or character, whether in cash, property or
securities, upon any dissolution or winding up or total or partial liquidation
or reorganization of the Company, whether voluntary or involuntary, or in
bankruptcy, insolvency, receivership or other proceedings or upon an assignment
for the benefit of creditors or any other marshalling of the assets and
liabilities of the Company, all Senior Debt shall first be paid in full in cash,
or payment provided for in cash or cash equivalents in a manner satisfactory to
the holders of Senior Debt, before any direct or indirect payments or
distributions, including, without limitation, by exercise of set-off, of any
cash, property or securities on account of principal of (or premium, if any) or
interest on the Notes and to that end the holders of Senior Debt shall be
entitled to receive (pro rata on the basis of the respective amounts of Senior
Debt held by them) directly, for application to the payment thereof (to the
extent necessary to pay all Senior Debt in full after giving effect to any
substantially concurrent payment or distribution to or provision for payment to
the holders of such Senior Debt), any payment or distribution of any kind or
character, whether in cash, property or securities, in respect of the
Subordinated Debt. The holders of Senior Debt are hereby authorized to file an
appropriate claim for and on behalf of the Holders if they or any of them do not
file, and there is not otherwise filed on behalf of the Holders, a proper claim
or proof of claim in the form required in any such proceeding prior to 15 days
before the expiration of the time to file such claim or claims.
62
<PAGE> 68
(b) Subordination on Default in Senior Debt. The Company shall
not make, and the Holders shall not accept, any direct or indirect payment (in
cash, property or securities, by set-off or otherwise) by or on behalf of the
Company of principal of on premium, if any, or interest on any Subordinated
Debt, or as a sinking fund for any Subordinated Debt, or in respect of any
redemption, retirement, prepayment, purchase or other acquisition of any
Subordinated Debt, whether pursuant to the terms of the Notes or any of the Note
Documents, if at the time of such payment there exists (i) a default in the
payment of all or any portion of principal of, interest on, fees or other
amounts owing in connection with any Senior Debt when the same becomes due and
payable, whether at maturity, at a date fixed for prepayment or by declaration
or otherwise or (ii) any other default under the terms of the Senior Debt that
with the giving of notice to the Company, the lapse of time, or both, would
entitle the holders of the Senior Debt to accelerate the maturity thereof
("Other Default") and the Noteholders have received notice of such Other Default
from a representative of the holders of the Senior Debt (the "Representative")
as provided below, and in either case such default shall not have been cured or
waived in writing; provided, however, that if within the period specified in the
next sentence with respect to an Other Default, the holders of the Senior Debt
have not declared the Senior Debt to be immediately due and payable (or have
declared such Senior Debt to be immediately due and payable and within such
period have rescinded such acceleration), then and in that event, payment of
principal of, and interest on, the Subordinated Debt shall be resumed upon
termination of such period, subject to the provisions of Sections 9 and 9.2
hereof. With respect to an Other Default the period referred to in the preceding
sentence shall commence upon receipt by the Noteholders of a written notice or
notices (which shall specify all Other Defaults existing on the date of such
notice and of which the Representative has actual knowledge at such time) of the
commencement of such period from the Representative, and shall end at the
completion of the 179th day after the beginning of such period. Only one such
179 day period may commence within any 360 consecutive days. Upon termination of
any such period, the Company shall resume payments on account of the principal
of, and interest on, the Subordinated Debt, subject to the provisions of
Sections 9.1 and 9.2 hereof.
63
<PAGE> 69
(c) Rights and Obligations of Holders.
(i) In the event that, notwithstanding the foregoing
provisions prohibiting such payment or distribution, including, without
limitation, Section 9.2(a) the Holders shall have received any payment on
account of the Subordinated Debt at a time when such payment is prohibited by
such provision before the Senior Debt is paid in full, then and in such event,
such payment or distribution shall be received and held in trust by the Holders
apart from their other assets and paid over or delivered to the holders of the
Senior Debt remaining unpaid to the extent necessary to pay in full in cash the
principal of, and interest on, such Senior Debt in accordance with its terms and
after giving effect to any concurrent payment or distribution to the holders of
such Senior Debt.
(ii) Nothing contained in this Section 9 will limit the
right of the Holders of Subordinated Debt to take any action to accelerate the
maturity of the Subordinated Debt pursuant to Section 8.1 hereof; provided,
however, that all Senior Debt then due or thereafter declared to be due shall
first be paid in full before the Holders are entitled to receive any payment
from the Company of principal of, or interest on, the Subordinated Debt.
(iii) Upon any payment or distribution of assets or
securities referred to in this Section 9, the Holders shall be entitled to rely
upon any order or decree of a court of competent jurisdiction in which such
dissolution, winding up, liquidation or reorganization proceedings are pending,
and upon a certificate of the receiver, trustee in bankruptcy, liquidating
trustee, agent or other Person making any such payment or distribution,
delivered to the Holders for the purpose of ascertaining the Persons entitled to
participate in such distribution, the holders of Senior Debt and other
Indebtedness of the Company, the amount thereof or payable thereon, the amount
or amounts paid or distributed thereon and all other facts pertinent thereto or
to this Section 9.
9.3 Rights of Holders of Senior Debt Not to Be Impaired. No
right of any present or future holder of any Senior Debt to enforce
subordination as herein provided shall at any time in any way be prejudiced or
impaired by any act or failure to act by any such holder, or by any
noncompliance by the Company with the terms and provisions and covenants herein
regardless of any knowledge thereof such holder may have or otherwise be charged
with.
The provisions of this Section 9 are intended to be for the
benefit of, and
64
<PAGE> 70
shall be enforceable directly by, the holders of the Senior Debt. The Company
and each Holder, by its acceptance thereof, acknowledges that the holders of the
Senior Debt are relying upon the provisions of this Section 9 in extending such
Senior Debt.
9.4 Subrogation. Upon the payment in full of all Senior Debt,
the Holders shall be subrogated to the extent of the payments or distributions
made to the holders of, or otherwise applied to payment of, the Senior Debt
pursuant to the provisions of this Section 9 and to the rights of the holders of
Senior Debt to receive payments or distributions of assets of the Company made
on the Senior Debt until the Notes shall be paid in full; and for the purposes
of such subrogation, no payments or distributions to holders of Senior Debt of
any cash, property or securities to which Holders of the Notes would be entitled
except for the provisions of this Section 9, and no payment over pursuant to the
provisions of this Section 9 to holders of Senior Debt by the Holders, shall, as
between the Company, its creditors other than holders of Senior Debt and the
Holders, be deemed to be payment by the Company to or on account of Senior Debt
it being understood that the provisions of this Section 9 are solely for the
purpose of defining the relative rights of the holders of Senior Debt, on the
one hand, and the Holders, on the other hand.
If any payment or distribution to which the Holders would
otherwise have been entitled but for the provisions of this Section 9 shall have
been applied, pursuant to the provisions of this Section 9, to the payment of
Senior Debt, then and in such case, the Holders shall be entitled to receive
from the holders of Senior Debt at the time outstanding any payments or
distributions received by such holders of Senior Debt in excess of the amount
sufficient to pay all Senior Debt in full.
9.5 Obligations of the Company Unconditional. Nothing
contained in this Section 9 or elsewhere in this Agreement or in the Notes is
intended to or shall impair, as between the Company and the Holders, the
obligations of the Company, which are absolute and unconditional, to pay to the
Holders the principal of (premium, if any), and interest on, the Notes as and
when the same shall become due and payable in accordance with their terms, or is
intended to or shall affect the relative rights of the Holders and creditors of
the Company other than the holders of the Senior Debt, nor shall anything herein
or therein shall prevent any Holder from exercising all remedies otherwise
permitted by applicable law upon the occurrence of a Default or Event of Default
under this Agreement, subject to the rights, if any, under this Section 9 of the
holders of Senior Debt in respect of cash, property or securities of the Company
received upon the exercise of any such remedy.
The failure to make a payment on account of principal of, or interest on, the
Notes by
65
<PAGE> 71
reason of any provision of this Section 9 shall not be construed as preventing
the occurrence of a Default or an Event of Default hereunder.
9.6 Notice to Holders. The Company shall give prompt written
notice to each Holder of any fact known to the Company which would prohibit the
making of any payment on or in respect of the Notes, but failure to give such
notice shall not affect the subordination of the Subordinated Debt to the Senior
Debt provided in this Section 9. Notwithstanding the provisions of this Section
9 or any other provision of this Agreement or the Notes, no Holder shall be
charged with knowledge of the existence of any facts which would prohibit the
making of any payment to or in respect of the Notes, unless and until the
Holders shall have received written notice thereof from the Company or
representative of or holder of Senior Debt, and, prior to the receipt of any
such written notice, subject to the provisions of this Section 9, the Holders
shall be entitled in all respects to assume no such facts exist. Nothing
contained in this Section 9.6 shall limit the right of the holders of Senior
Debt to recover payments as contemplated by Sections 9.1 and 9.2.
9.7 Right of Any Holder as Holder of Senior Debt. Any Holder
in its individual capacity shall be entitled to all the rights set forth in this
Section 9 with respect to any Senior Debt which may at any time be held by it,
to the same extent as any other holder of Senior Debt, and nothing in this
Agreement shall deprive such Holder of any of its rights as such holder.
9.8 Reinstatement. The provisions of this Section 9 shall
continue to be effective or be reinstated, and the Senior Debt shall not be
deemed to be paid in full, as the case may be, if at any time any payment of any
of the Senior Debt is rescinded or must otherwise be returned by the holder
thereof upon the insolvency, bankruptcy or reorganization of the Company or
otherwise, all as though such payment had not been made.
10. BOARD OF DIRECTORS
(_) The Company and Holdings hereby agree that at all times
after the date hereof and so long as any Original Holders or their Affiliate is
the beneficial holder of any Notes, the Noteholders (acting by the Required
Holders) shall be entitled to designate one member of the Board of Directors of
Holdings. Promptly after the date hereof, Holdings shall take all actions
necessary to elect, or to cause the Board of Directors to approve and appoint,
the designee of the Noteholders to the Board of Directors of Holdings. Such
designee shall also be a member of the Audit Committee and Compensation
Committee of the Board, if any.
66
<PAGE> 72
(_) In the event that a vacancy is created on the Board of
Directors at any time by the death, disability, retirement, resignation or
removal of the Noteholders' designee, Holdings hereby agrees to use its best
efforts to cause the directors designated by them to vote for the individual
designated by the Noteholders to fill such vacancy.
(_) If the Noteholders elect not to designate a member of the
Board of Directors, the Noteholders (acting by the Required Holders) may
designate one individual (an "Observer") to attend all meetings of the Board of
Directors (and any audit or compensation committees thereof) in a non-voting
observer capacity. The Observer shall be entitled to receive all reports,
presentations and materials as if such Observer were a member of the Board.
Holdings shall reimburse any director designated by the Noteholders for any
reasonable expenses incurred in connection with meetings of the Board of
Directors and committees thereof, and shall similarly reimburse the Observer for
all out-of-pocket expenses incurred in connection with the Observer's attendance
at any such meetings (including reasonable travel expenses).
(_) The Noteholders' right to designate a member of the Board
of Directors or an Observer shall continue so long as any Obligations are
outstanding.
11. MISCELLANEOUS
11.1 Complete Agreement; Modification of Agree- ment; Sale of
Interests. (a) The Note Documents constitute the complete agreement between the
parties with respect to the subject matter hereof and may not be modified,
altered or amended except as provided therein, or in the case of the Note
Documents by an agreement in writing signed by the applicable Coram Party and
those Noteholders party thereto in accordance with Section 11.1(d) hereof. No
Coram Party may sell, assign or transfer any of the Note Documents or any
portion thereof, including, without limitation, such Coram Party's rights,
title, interests, remedies, powers and duties hereunder or thereunder.
(b) Each Noteholder may sell, assign, transfer or negotiate to
one or more other lenders, commercial banks, insurance companies, other
financial institutions or any other Person acceptable to such Noteholder all or
a portion of its rights and obligations under the Notes held by such Noteholder
and this Agreement; provided, however, that acceptance of such assignment by any
assignee shall constitute the agreement of such assignee to be bound by the
terms of this Agreement applicable to such Noteholder. From and after the
effective date of such an assignment, (x) the assignees thereunder shall, in
addition to the rights and obligations hereunder held by it
67
<PAGE> 73
immediately prior to such effective date, have the rights and obligations
hereunder that have been assigned to it pursuant to such assignment and (y) the
assignor thereunder shall, to the extent that rights and obligations hereunder
have been assigned by it pursuant to such assignment, relinquish its rights and
be released from its obligations under this Agreement (and, in the case of an
assignment and acceptance covering all or the remaining portion of an assignor's
rights and obligations under this Agreement, such assignor shall cease to be a
party hereto). Each Noteholder may sell participations in the Notes at any time.
(c) The Company shall keep at its principal executive office a
register for the registration and registration of transfers of Notes. The name
and address of each holder of one or more Notes, each transfer thereof and the
name and address of each transferee of one or more Notes shall be registered in
such register. Prior to due presentment for registration of transfer, the Person
in whose name any Note shall be registered shall be deemed and treated as the
owner and holder thereof for all purposes hereof, and the Company shall not be
affected by any notice or knowledge to the contrary.
(d) Upon surrender of any Note at the principal executive
office of the Company for registration of transfer or exchange (and in the case
of a surrender for registration of transfer, duly endorsed or accompanied by a
written instrument of transfer duly executed by the registered holder of such
Note or his attorney duly authorized in writing and accompanied by the address
for notices of each transferee of such Note or part thereof), within five
Business Days thereafter the Company shall execute and deliver, at the Company's
expense (except as provided below), one or more new Notes (as requested by the
holder thereof) of the same series in exchange therefor, in an aggregate
principal amount equal to the unpaid principal amount of the surrendered Note.
Each such new Note shall be payable to such Person as such holder may request.
Each such new Note shall be dated and bear interest from the date to which
interest shall have been paid on the surrendered Note or dated the date of the
surrendered Note if no interest shall have been paid thereon. Notes shall not be
transferred in denominations of less than $1,000,000, provided that if necessary
to enable the registration of transfer by a holder of its entire holding of
Notes, one Note may be in a denomination of less than $1,000,000.
(e) Upon receipt by the Company of evidence reasonably
satisfactory to it of the ownership of and the loss, theft, destruction or
mutilation of any Note and (i) in the case of loss, theft or destruction, of
indemnity reasonably satisfactory to it, or (ii) in the case of mutilation, upon
surrender and cancellation thereof, within five Business Days thereafter the
Company at its own expense shall execute and deliver, in
68
<PAGE> 74
lieu thereof, a new Note of the same series, dated and bearing interest from the
date to which interest shall have been paid on such lost, stolen, destroyed or
mutilated Note or dated the date of such lost, stolen, destroyed or mutilated
Note if no interest shall have been paid thereon.
(f) No amendment or waiver of any provision of this Agreement
or the Notes or any other Note Document, nor consent to any departure by the
Company therefrom, shall in any event be effective unless the same shall be in
writing and signed by the Required Holders, and then such waiver or consent
shall be effective only in the specific instance and for the specific purpose
for which given; provided, however, that no amendment, waiver or consent shall,
unless in writing and signed by each holder of a Note affected thereby do any of
the following: (i) subject such holder to any additional obligations, (ii)
reduce the principal of, or interest on, the Notes or other amounts payable
hereunder or release or discharge the Company or any Guarantor from its
obligations to make such payments, (iii) postpone any date fixed for any payment
of principal of, or interest on, the Notes or other amounts payable hereunder,
(iv) change the aggregate unpaid principal amount of the Notes, or the number of
holders thereof, which shall be required for such holders or any of them to take
any action hereunder, or (v) amend this Section 11.1.
11.2 Fees and Expenses. The Company shall pay all reasonable
out-of-pocket expenses of the Required Holders in connection with the
preparation of the Note Documents and the transactions contemplated thereby and
any amendment, modification or waiver, or consent with respect to, any of the
Note Documents or its rights hereunder or thereunder, including all legal
expenses. In addition, if, at any time or times, any Noteholder shall employ
counsel or other advisors for advice or other representation or shall incur
reasonable legal or other costs and expenses in connection with:
(i) any litigation, contest, dispute, suit, proceeding or
action instituted by such Noteholder against the Company or any
Subsidiary of the Company as to which it is successful in obtaining a
judgment, or by the Company or any Subsidiary of the Company, in any
way relating to any of the Note Documents or any other agreements to be
executed or delivered in connection herewith (other than any such
action brought by Holdings, the Company or any Subsidiary of the
Company against any Noteholders or any Holder to enforce any provisions
of the Note Documents, and in which Holdings, the Company or such
Subsidiary is successful in obtaining a judgment against such
Noteholder or such Holder or, except as otherwise provided in any
settlement agreement, settles such action); or
69
<PAGE> 75
(ii) any attempt to enforce any rights of any Noteholder
against Holdings, the Company or any Subsidiary, that may be obligated
to such Noteholder by virtue of any of the Note Documents;
then, and in any such event, the attorneys' and other parties' fees arising from
such services, including those of any appellate proceedings, and all expenses,
costs, charges and other fees incurred by such counsel and others in any way or
respect arising in connection with or relating to any of the events or actions
described in this Section shall be payable, on demand, by the Company to such
Noteholder and shall be additional Obligations under this Agreement and the
other Note Documents. Without limiting the generality of the foregoing, such
expenses, costs, charges and fees may include: paralegal fees, costs and
expenses; accountants' and investment bankers' fees, costs and expenses; court
costs and expenses; photocopying and duplicating expenses; court reporter fees,
costs and expenses; long distance telephone charges; air express charges;
telegram charges; secretarial overtime charges; and expenses for travel, lodging
and food paid or incurred in connection with the performance of such legal
services.
11.3 No Waiver by Noteholders. A Noteholder's failure, at any
time or times, to require strict performance by any Coram Party of any provision
of this Agreement and any of the other Note Documents shall not waive, affect or
diminish any right of Noteholder thereafter to demand strict compliance and
performance therewith. Any suspension or waiver by any Noteholder of an Event of
Default by any Coram Party under the Note Documents shall not suspend, waive or
affect any other Event of Default by such Coram party under this Agreement and
any of the other Note Documents whether the same is prior or subsequent thereto
and whether of the same or of a different type. None of the undertakings,
agreements, warranties, covenants and representations of any Coram Party
contained in this Agreement or any of the other Note Documents and no Event of
Default by any Coram party under this Agreement and no defaults by any Coram
Party under any of the other Note Documents shall be deemed to have been
suspended or waived by Noteholders, unless such suspension or waiver is by an
instrument in writing signed by an officer of such Noteholder and the Required
Holders and directed to the Company specifying such suspension or waiver.
11.4 Remedies. Each Noteholder's rights and remedies under
this Agreement shall be cumulative and non-exclusive of any other rights and
remedies which such Noteholder may have under any other agreement, including
without limitation, the Note Documents, by operation of law or otherwise.
11.5 Waiver of Jury Trial. The parties hereto waive all right
to trial by jury in any action or proceeding to enforce or defend any rights
under the Note Documents.
70
<PAGE> 76
11.6 Severability. Wherever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under
applicable law, but if any provision of this Agreement shall be prohibited by or
invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such
provision or the remaining provisions of this Agreement.
11.7 Parties. This Agreement and the other Note Documents
shall be binding upon, and inure to the benefit of, the successors of the Coram
Parties and each Noteholder and the assigns, transferees and endorsees of such
Noteholder.
11.8 Conflict of Terms. Except as otherwise provided in this
Agreement or any of the other Note Documents by specific reference to the
applicable provisions of this Agreement, if any provision contained in this
Agreement is in conflict with, or inconsistent with, any provision in any of the
other Note Documents, the provision contained in this Agreement shall govern and
control.
11.9 Governing Law. Except as otherwise ex- pressly provided
in any of the Note Documents, in all respects, including all matters of
construction, validity and performance, this Agreement and the Obligations
arising hereunder shall be governed by, and construed and enforced in accordance
with, the laws of the State of New York applicable to contracts made and
performed in such state, without regard to the principles thereof regarding
conflict of laws, and any applicable laws of the United States of America. Each
Noteholder and the Coram Parties agree to submit to personal jurisdiction and to
waive any objection as to venue in the County of New York, State of New York.
Service of process on the Noteholder or the Coram Parties in any action arising
out of or relating to any of the Note Documents shall be effective if mailed to
such party at the address listed in Section 11.10 hereof. Nothing herein shall
preclude any Noteholder or any Coram Party from bringing suit or taking other
legal action in any other jurisdiction.
11.10 Notices. Except as otherwise provided herein, whenever
it is provided herein that any notice, demand, request, consent, approval,
declaration or other communication shall or may be given to or served upon any
of the parties by another, or whenever any of the parties desires to give or
serve upon another any communication with respect to this Agreement, each such
notice, demand, request, consent, approval, declaration or other communication
shall be in writing and either shall be delivered in person with receipt
acknowledged or by registered or certified
71
<PAGE> 77
mail, return receipt requested, postage prepaid, or telecopied and confirmed by
telecopy answerback addressed as follows:
(a) If to the Company or any other Coram Party at:
Coram Healthcare Corporation
1125 Seventeenth Street
Suite 2120
Denver, Colorado 80202
Attn: Wendy L. Simpson
Telecopy Number: (303) 672-8799
and
Paul J. Quiner, Esq.
Telecopy Number: (303) 298-0047
With a copy to:
Paul, Hastings, Janofsky & Walker LLP
555 South Flower Street
Los Angeles, California 90071
Attn: David L. Gersh
Telecopy Number: (213) 627-0705
(b) If to the Noteholders:
Cerberus Partners, L.P.
450 Park Ave.
28th Floor
New York, NY 10022
Attn: Steven Feinberg
Fax: (212) 421-2947
Goldman Sachs Credit Partners L.P.
c/o Goldman, Sachs & Co.
85 Broad Street, 6th Floor
New York, NY 10004
Attn: Jim Halka
Fax: (212) 357-4597
72
<PAGE> 78
Foothill Capital Corporation
11111 Santa Monica Blvd.
Suite 1500
Los Angeles, CA 90025
Attn: Ed Stearns
Fax: (310) 479-0461
With a copy to:
Weil, Gotshal & Manges LLP
767 Fifth Avenue
New York, New York 10153
Attn: Ted S. Waksman, Esq.
Telecopy Number: (212) 310-8007
or at such other address as may be substituted by notice given as herein
provided. The giving of any notice required hereunder may be waived in writing
by the party entitled to receive such notice. Every notice, demand, request,
consent, approval, declaration or other communication hereunder shall be deemed
to have been duly given or served on the date on which personally delivered,
with receipt acknowledged, telecopied and confirmed by telecopy answerback or
three (3) Business Days after the same shall have been deposited in the United
States mail. Failure or delay in delivering copies of any notice, demand,
request, consent, approval, declaration or other communication to the Persons
designated above to receive copies shall in no way adversely affect the
effectiveness of such notice, demand, request, consent, approval, declaration or
other communication.
11.11 Survival. The representations and warranties of Holdings
and the Company in this Agreement shall survive the execution, delivery and
acceptance hereof by the parties hereto and the closing of the transactions
described herein or related hereto.
11.12 Section Titles. The Section titles and Table of Contents
contained in this Agreement are and shall be without substantive meaning or
content of any kind whatsoever and are not a part of the agreement between the
parties hereto.
11.13 Counterparts. This Agreement may be executed in any
number of separate counterparts, each of which shall, collectively and
separately, constitute one agreement.
73
<PAGE> 79
11.14 Publicity. The Company shall not issue any press release
or make any public disclosure regarding the transactions contemplated hereby
unless such press release or public disclosure is approved by the Noteholders in
advance. Notwithstanding the foregoing, the Company may, in documents required
to be filed by it with the SEC or other regulatory bodies, make such statements
with respect to the transactions contemplated hereby as it may be advised by
counsel is legally necessary or advisable.
74
<PAGE> 80
IN WITNESS WHEREOF, Holdings, the Company and the Noteholders
have duly executed this Agreement as of the day and year first above written.
CORAM, INC.
By:
----------------------------------------
Name:
Title:
CORAM HEALTHCARE CORPORATION
By:
----------------------------------------
Name:
Title:
CERBERUS PARTNERS, L.P.
By:
----------------------------------------
Name:
Title:
GOLDMAN SACHS CREDIT PARTNERS L.P.
By:
----------------------------------------
Name:
Title:
FOOTHILL CAPITAL CORPORATION
By:
----------------------------------------
Name:
Title:
75
<PAGE> 1
EXHIBIT 10.2
[BANK OF MONTREAL LOGO]
OUR IRREVOCABLE STANDBY LETTER OF DATE OF ISSUE: ________, 1998
CREDIT NUMBER __________________ PAGE 1
BENEFICIARY: APPLICANT:
AETNA U.S. HEALTHCARE, INC. CORAM HEALTHCARE CORPORATION
151 FARMINGTON AVENUE 1125 SEVENTEENTH ST.
HARTFORD, CT 06156 SUITE 2100
ATTN: DAN MESSINA DENVER, CO 80202
AMOUNT AVAILABLE: USD ____________
_____________ AND 00/100'S US DOLLARS
EXPIRY DATE: _________________
GENTLEMAN:
WE HEREBY ESTABLISH OUR CLEAN IRREVOCABLE STANDBY LETTER OF CREDIT NO.
________________ IN YOUR FAVOR, AS BENEFICIARY FOR THE ACCOUNT OF CORAM
HEALTHCARE CORPORATION IN THE AGGREGATE AMOUNT AND USD ____________ (USD
____________), EFFECTIVE ______, 1998 AND EXPIRING AT OUR COUNTERS AT BANK OF
MONTREAL, LETTER OF CREDIT PROCESSING CENTER, 311 WEST MONROE STREET, 13TH
FLOOR, CHICAGO, IL, 60606 AT 5:00P.M. ON _________________.
THIS LETTER OF CREDIT IS AVAILABLE BY YOUR PRESENTATION OF THE FOLLOWING
DOCUMENTS:
1. THE BENEFICIARY'S DRAFT(S) DRAWN ON US AT SIGHT AND BEARING THE CLAUSE "DRAWN
UNDER BANK OF MONTREAL, CHICAGO, IL, STANDBY LETTER OF CREDIT NO.
________________".
2. A TYPEWRITTEN STATEMENT ON THE LETTERHEAD OF AETNA U.S. HEALTHCARE INC., AND
PURPORTEDLY SIGNED BY AN AUTHORIZED REPRESENTATIVE OF AETNA U.S. HEALTHCARE INC.
STATING THEREIN:
"I, (STATE NAME), BEING AN AUTHORIZED REPRESENTATIVE OF AETNA U.S. HEALTHCARE,
INC. DO HEREBY CERTIFY THAT THE FUNDS FROM CORAM HEALTHCARE CORPORATIONS'S
CAPITATION AMOUNTS PAID TO CORAM HEALTHCARE CORPORATION ("CORAM") ARE
INSUFFICIENT OR UNAVAILABLE TO PAY ITS NETWORK PROVIDERS, CORAM HAS PERSISTENTLY
ENGAGED IN A PATTERN OF FAILURE TO PAY ITS NETWORK PROVIDERS CLAIMS, WHEN DUE,
THAT ARE UNDISPUTED IN GOOD FAITH, THAT CORAM IS INSOLVENT OR THAT CORAM HAS
CEASED TO CONDUCT BUSINESS, THEREFORE WE, DEMAND PAYMENT OF US$ (AMOUNT) U.S.
DOLLARS UNDER BANK OF MONTREAL, CHICAGO, ILLINOIS, LETTER OF CREDIT NO.
________________."
3. THE ORIGINAL OF THIS LETTER OF CREDIT AND ALL AMENDMENTS, IF ANY FOR OUR
ENDORSEMENT, (IF YOUR DEMAND REPRESENTS A PARTIAL DRAWING HEREUNDER, WE WILL
ENDORSE THE ORIGINAL CREDIT AND RETURN SAME TO YOU FOR POSSIBLE FUTURE CLAIMS.
IF HOWEVER, YOUR DEMAND REPRESENTS A FULL DRAWING OR IF SUCH DRAWING IS
PRESENTED ON THE DAY OF THE RELEVANT EXPIRATION DATE HEREOF, WE WILL HOLD THE
<PAGE> 2
OUR IRREVOCABLE STANDBY LETTER OF DATE OF ISSUE: ______________
CREDIT NUMBER ________________ PAGE 2
ORIGINAL FOR OUR FILES AND REMOVE SAME FROM CIRCULATION.)
IT IS A CONDITION OF THIS CREDIT THAT IT SHALL BE DEEMED AUTOMATICALLY EXTENDED
WITHOUT AMENDMENT FOR ADDITIONAL PERIODS OF 18 MONTHS FROM THE CURRENT OR ANY
FUTURE EXPIRATION DATE, UNLESS WE NOTIFY YOU, BY CERTIFIED MAIL, AT LEAST FORTY
FIVE (45) DAYS PRIOR TO ANY EXPIRY DATE THAT WE ELECT NOT TO CONSIDER THIS
LETTER OF CREDIT RENEWED FOR ANY SUCH ADDITIONAL PERIOD.
WE ENGAGE WITH YOU THAT ALL DRAFTS DRAWN AND DOCUMENTS PRESENTED INCOMPLIANCE
WITH THE TERMS OF THIS LETTER OF CREDIT WILL BE DULY HONORED BY US IF PRESENTED
TO BANK OF MONTREAL, LETTER OF CREDIT PROCESSING CENTER, 311 WEST MONROE STREET,
13TH FLOOR, CHICAGO, ILLINOIS 60606 PRIOR TO 4PM EASTERN STANDARD TIME, ON OR
BEFORE THE EXPIRATION DATE HEREOF, OR ANY AUTOMATICALLY EXTENDED EXPIRATION
DATE.
ALL BANK CHARGES ARE FOR THE ACCOUNT OF THE APPLICANT.
EXCEPT AS STATED HEREIN, THIS UNDERTAKING IS NOT SUBJECT TO ANY CONDITION OR
QUALIFICATION. THIS CREDIT CANNOT BE MODIFIED OR REVOKED WITHOUT THE CONSENT OF
BOTH BANK OF MONTREAL, CHICAGO, ILLINOIS AND THE BENEFICIARY HERETO.
THIS LETTER OF CREDIT SETS FORTH IN FULL THE TERMS OF OUR UNDERSTANDING AND SUCH
UNDERTAKING SHALL NOT IN ANY WAY BE MODIFIED, AMENDED OR AMPLIFIED BY REFERENCE
TO ANY DOCUMENT OR INSTRUMENT REFERRED TO HEREIN OR IN WHICH THIS LETTER OF
CREDIT IS REFERRED TO OR TO WHICH THIS LETTER OF CREDIT RELATES AND ANY SUCH
REFERENCE SHALL NOT BE DEEMED TO INCORPORATE HEREIN BY REFERENCE ANY DOCUMENT OR
INSTRUMENT. THE OBLIGATION OF BANK OF MONTREAL, CHICAGO, ILLINOIS, UNDER THIS
LETTER OF CREDIT IS THE INDIVIDUAL OBLIGATION OF BANK OF MONTREAL, CHICAGO,
ILLINOIS AND IS IN NOW WAY CONTINGENT UPON REIMBURSEMENT WITH RESPECT THERETO OR
UPON OUR ABILITY TO PERFECT ANY LIEN, SECURITY INTEREST OR ANY OTHER
REIMBURSEMENT.
THIS LETTER OF CREDIT IS SUBJECT TO AND GOVERNED BY THE 1993 REVISION OF THE
UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS OF THE INTERNATIONAL
CHAMBER OF COMMERCE (PUBLICATION NO. 500). IF THIS CREDIT EXPIRES DURING AN
INTERRUPTION OF BUSINESS AS DESCRIBED IN ARTICLE 17 OF SAID PUBLICATION 500, THE
BANK HEREBY SPECIFICALLY AGREES TO EFFECT PAYMENT IF THIS CREDIT IS DRAWN
AGAINST WITHIN 30 DAYS AFTER RESUMPTION OF BUSINESS.
BANK OF MONTREAL
- --------------------------------
AUTHORIZED SIGNATURE
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
condensed consolidated financial statements of Coram Healthcare Corporation for
the quarter ended March 31, 1998 and is qualified in its entirety by reference
to such financial statements.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> MAR-31-1998
<CASH> 17,768
<SECURITIES> 0
<RECEIVABLES> 106,335
<ALLOWANCES> 17,839
<INVENTORY> 16,839
<CURRENT-ASSETS> 135,831
<PP&E> 48,413
<DEPRECIATION> 28,966
<TOTAL-ASSETS> 419,447
<CURRENT-LIABILITIES> 152,280
<BONDS> 150,305
0
0
<COMMON> 49
<OTHER-SE> 108,037
<TOTAL-LIABILITY-AND-EQUITY> 419,447
<SALES> 107,689
<TOTAL-REVENUES> 107,689
<CGS> 80,500
<TOTAL-COSTS> 80,500
<OTHER-EXPENSES> 24,249
<LOSS-PROVISION> 3,666
<INTEREST-EXPENSE> 14,175
<INCOME-PRETAX> (13,713)
<INCOME-TAX> 1,000
<INCOME-CONTINUING> (15,124)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (15,124)
<EPS-PRIMARY> (0.31)
<EPS-DILUTED> (0.31)
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
condensed consolidated financial statements of Coram Healthcare Corporation for
the quarter ended March 31, 1997 and is qualified in its entirety by reference
to such financial statements.
</LEGEND>
<RESTATED>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1997
<PERIOD-START> JAN-01-1997
<PERIOD-END> MAR-31-1997
<CASH> 18,562
<SECURITIES> 0
<RECEIVABLES> 139,732
<ALLOWANCES> 37,992
<INVENTORY> 14,375
<CURRENT-ASSETS> 152,910
<PP&E> 72,011
<DEPRECIATION> 55,992
<TOTAL-ASSETS> 530,329
<CURRENT-LIABILITIES> 283,017
<BONDS> 268,683
0
0
<COMMON> 44
<OTHER-SE> (30,582)
<TOTAL-LIABILITY-AND-EQUITY> 530,329
<SALES> 123,915
<TOTAL-REVENUES> 123,915
<CGS> 83,925
<TOTAL-COSTS> 83,925
<OTHER-EXPENSES> 29,392
<LOSS-PROVISION> 4,288
<INTEREST-EXPENSE> 21,496
<INCOME-PRETAX> (12,411)
<INCOME-TAX> 49
<INCOME-CONTINUING> (14,588)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (14,588)
<EPS-PRIMARY> (0.31)
<EPS-DILUTED> (0.31)
</TABLE>
